Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000623

International filing date: 18 February 2005 (18.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0424080.0
Filing date: 29 October 2004 (29.10.2004)

Date of receipt at the International Bureau: 01 April 2005 (01.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

PCT/GB2005/000623

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed William Morell

Dated 8 March 2005

Patents Form 1/77

Patents Act 1977
(Rule 16)

01NOV04 E937672-1 000192
P01/7700 0.00-0424080.0 NONE

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference — P.90919A

2. Patent application number
(The Patent Office will fill this part in) — 0424080.0

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

F2G LTD
Lankro Way, Eccles, Manchester
Greater Manchester, M30 0BH
United Kingdom

Patents ADP number *(if you know it)* — 8837056001

If the applicant is a corporate body, give the country/state of its incorporation — GB

4. Title of the invention — 2031 OXIDOREDUCTASE

5. Name of your agent *(if you have one)* — J.A. KEMP & CO.

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*

14 South Square
Gray's Inn
London
WC1R 5JJ

Patents ADP number *(if you know it)* — 26001

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application	Date of filing *(day / month / year)*

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request? — Yes

Answer YES if:

a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form	
Description	86
Claim(s)	4
Abstract	0
Drawing(s)	17 + (2)

10. If you are also filing any of the following, state how many against each item.

Priority documents	
Translations of priority documents	
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	
Request for a preliminary examination and search (Patents Form 9/77)	
Request for a substantive examination (Patents Form 10/77)	
Any other documents (please specify)	

11. I/We request the grant of a patent on the basis of this application.

Signature(s) J.A. Kemp & Co. J.A. KEMP & CO. Date 29 October 2004

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

WOODS, Geoffrey Corlett
020 7405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

2031 OXIDOREDUCTASE

Field of the invention

The present invention relates to a method of screening for an anti-fungal agent, to fungal 2031 oxidoreductase (2031 OR) enzymes and to diagnosis and therapy of fungal infections.

Background of the invention

Oxidoreductases are a major class of enzymes (EC 1) that catalyse oxidation-reduction (redox) reactions. Redox reactions involve the transfer of reducing equivalents, in the form of electrons or hydrogen atoms, between molecules, i.e., from an electron donor (or reductant) to an electron acceptor (or oxidant). There are many different types of oxidoreductase important for many cellular processes from respiration to protein folding.

The NADH:flavin oxidoreductase /NADH oxidase family of enzymes (InterPro reference IPR001155) contains approximately 263 members mostly of bacterial or yeast origin but with some plant and nematode members. Members of this family use flavin mononucleotide (FMN) or flavin adenine dinucleotide (FAD) as a tightly bound prosthetic group. The flavin prosthetic group can exist in an oxidised (FMN or FAD) or a reduced form ($FMNH_2$ or $FADH_2$). These oxidoreductases use the reduced form of nicotinamide adenine dinucleotide (NADH) or nicotinamide adenine dinucleotide phosphate (NADPH) as the reductant. A variety of substrates can act as oxidants in the redox reaction.

Old Yellow Enzyme (OYE) is the oldest known member of this family of oxidoreductases (reviewed in Williams and Bruce, 2002, Microbiology 148, 1607-1614). OYE1 (EC 1.6.99.1) was isolated from brewer's bottom yeast by Warburg & Christian (1932, Naturwissenschaften 20, 688) and was the first enzyme for which a cofactor was shown to be required (Theorell, 1935, Biochem. Z. 275, 344-346). This yellow cofactor was found to be riboflavin 5'-phosphate (also known as flavin mononucleotide, FMN). There are 2 OYEs known in *Saccharomyces cerevisiae* (OYE2 & OYE3) and 2 in *Schizosaccharomyces pombe*. A great deal is known about

the biochemical mechanism and structure of the enzyme, however, the precise physiological role of the enzyme remains to be elucidated.

OYE has NADPH dehydrogenase activity (see reaction 1 below). The reduced enzyme catalyses the reduction of α/β-unsaturated carbonyl compounds including cyclohexenone (see reaction 2), duroquinone, menadione and N-ethylmaleimide.

(1) $Enz\text{-}FMN + 2NADPH \Leftrightarrow Enz\text{-}FMNH_2 + 2NADP^+$

(2) $Enz\text{-}FMNH_2 + 2\text{-cyclohexenone} \Leftrightarrow Enz\text{-}FMN + \text{cyclohexanone}$

It has been speculated that OYE may be involved in sterol metabolism (Stott et al, 1993, J. Biol. Chem. 268: 6097-6106) or may be part of the antioxidant defence machinery involved in detoxification of, for example, lipid peroxidation breakdown products (Kohli & Massey, 1998, J. Biol. Chem. 273, 32763-32770). Neither OYE2 nor OYE3 are essential for *S. cerevisiae*. (http://genome-www4.stanford.edu/cgi-bin/SGD/locus.pl?locus=S0001222; http://db.yeastgenome.org/cgibin/SGD/locus.pl?locus=YPL171C)

Bacterial members of the NADH:flavin oxidoreductase family include *Escherichia coli* N-ethylmaleimide reductase, *Pseudomonas putida* M10 morphinone reductase, *Enterobacter cloacae* PB2 penterythritol tetranitrate reductase and *Azoarcus evansii* 2-aminobenzoyl-CoA monooxygenase/reductase (Schühle et al., 2001, J. Bacteriol. 183, 5268-5278).

Summary of the invention

The inventors have found a gene for an oxidoreductase of the NADH:flavin oxidoreductase type to be essential for the viability of fungal cells. This finding allows the identification of anti-fungal agents based on their ability to target the oxidoreductase.

The invention provides a new group of oxidoreductases which are herein referred to as 2031 oxidoreductases (2031 ORs) which can be used to screen for anti-fungal

agents. In particular 2031 oxidoreductases from *Aspergillus fumigatus*, *Aspergillus nidulans*, *Candida albicans*, *Colletotrichium trifolii*, *Fusarium graminearum (anamorph Gibberella zeae) Fusarium sporotrichoides*, *Magnaporthe grisea*, *Neurospora crassa*, *Schizosaccharomyces pombe* and *Ustilago maydis* (see Table I) are provided. 2031 OR defines a novel set of oxidoreductases, related to but distinct from OYE and its close relatives, which are essential for the viability of fungal cells.

Accordingly the invention provides the following:

- a method of identifying an anti-fungal agent which targets an essential protein or gene of a fungus comprising contacting a candidate substance with

(i) a NADH:flavin oxidoreductase protein which comprises the sequence shown by SEQ ID NO:3,

(ii) a NADH:flavin oxidoreductase protein which is a homologue of (i) and which comprises the sequence shown by SEQ ID NO: 8, 12, 14, 19, 24, 42, 44, 83 or 85,

(iii) a protein which has 50% identity with (i) or (ii),

(iv) a protein comprising a fragment of (i), (ii) or (iii) which fragment has a length of at least 50 amino acids,

(v) a polynucleotide that comprises sequence which encodes (i), (ii), (iii) or (iv),

(vi) a polynucleotide comprising sequence which has at least 70% identity with the coding sequence of (v),

and determining whether the candidate substance binds or modulates (i), (ii), (iii), (iv), (v) or (vi), wherein binding or modulation of (i), (ii), (iii), (iv), (v) or (vi) indicates that the candidate substance is an anti-fungal agent,

- use of (i), (ii), (iii), (iv), (v) or (vi) as defined above to identify or obtain an anti-fungal agent,

- use of an anti-fungal agent identified by the method of the invention in the manufacture of a medicament for prevention or treatment of fungal infection,

- a method of detecting the presence of a fungus in a sample comprising detecting the presence in the said sample of a protein or polynucleotide of the invention,

- an isolated protein or polynucleotide of the invention,

- an organism which is transgenic for a polynucleotide of the invention,

- an organism which has been genetically engineered to render a polynucleotide or protein of the invention non-functional or inhibited.

- an antibody which is specific for a protein of the invention,

- a method for preventing or treating a fungal infection comprising administering an anti-fungal agent identified by the screening method of the invention, and

- a fungus which has been killed, or whose growth has been impaired, by inhibition of the expression or activity of a protein or polynucleotide of the invention.

Detailed description of the invention

As mentioned above the invention relates to use of particular protein and polynucleotide sequences (termed "proteins of the invention" and "polynucleotides of the invention" herein) which are of, or derived from, fungal oxidoreductase proteins and polynucleotides (including homologues and/or fragments of the fungal oxidoreductase proteins and polynucleotides) to identify anti-fungal agents.

As used herein, the term "oxidoreductase" ("OR") may be defined as an enzyme or which is capable of catalysing an oxidation or reduction reaction. The protein of the invention may have an oxidation or reduction activity, such any such activity mentioned herein. The ORs of the invention generally fall within classification EC1 of the enzyme commission.

An essential fungal gene may be defined as one which, when disrupted genetically (for example when not expressed) in a fungus, prevents survival or significantly retards growth of the cell on minimal or defined medium, or in guinnea pigs, mice, rabbits or rats infected with the fungus. In one embodiment the protein of the invention is able to complement such an effect of the genetic disruption. Thus the protein may cause survival (viability) of a fungal cell which does not express its native 2031 oxidoreductase.

A protein or polynucleotide of the invention (or a fungal "2031 OR" gene, nucleic acid or protein) may be defined by similarity in sequence to a another member of the family. As mentioned above this similarity may be based on percentage identity (for example to the sequences shown in the sequence listing).

A protein or polynucleotide of the invention may comprise one or more of the motifs defined by regions 1 - 11 of Figures 1 and 2 (marked at the top of the Figures)

of any of the sequences shown. Thus a protein of the invention may comprise one or more of motifs 1 – 11 as shown for SEQ ID NO:3 and a polynucleotide of the invention may comprise one or more of motifs 1 – 11 as shown for SEQ ID NO:1.

Typically the motif is present in substantially the same location as the equivalent location shown in Figure 1 or 2. The equivalent location can be deduced, for example, using any suitable algorithm mentioned herein. In one embodiment the protein or polynucleotide also comprises sequence flanking the motif as shown in Figures 1 or 2 such as sequences of length at least 10, 20 or 30 amino acids/nucleotides flanking the N terminal side and/or C terminal side, or 5' and/or 3' side, of the motif; or sequence which has percentage identity with the flanking sequence.

The protein of the invention typically comprises at least 2, 3, 5, 8 or 11 of the motifs shown in Figures 1 and 2. The protein preferably comprises at least motif no.6 and/or motif no.9.

The protein or polynucleotide of the invention may align with other 2031 OR polynucleotides or proteins (as shown in SEQ ID Nos. 1-44 and 82-85) showing a greater identity to these than to Old Yellow Enzyme family polynucleotides or proteins

The protein or polynucleotide of the invention typically clusters with other 2031 OR polynucleotides or proteins (as shown in SEQ ID Nos. 1-44 and 82-85) rather than Old Yellow Enzyme family polynucleotides or proteins after phylogenetic analysis, for example with a bootstrap value of greater than 60%.

In one embodiment the protein of the invention has a sequence which matches PFAM profile "oxidored FMN", or INTERPRO profile IPR001155 (for example with an Evalue of e-50 or less) and is closer to a 2031 OR shown in any one of SEQ ID Nos.1-44 and 82-85 than to Old Yellow Enzyme family proteins.

The protein or polynucleotide of the invention may be in isolated form (such as non-cellular form), for example when used in the method of the invention. Preferably, the isolated polynucleotide comprises a 2031 OR gene. Preferably, the isolated protein comprises a 2031 OR. The polynucleotide may comprise native, synthetic or recombinant polynucleotide, and the protein may comprise native, synthetic or recombinant protein. The polynucleotide or protein may comprise combinations of native, synthetic or recombinant polynucleotide or protein, respectively. The polynucleotides and proteins of the invention may have a sequence which is the same

as, or different from, naturally occurring 2031 OR polynucleotides and proteins.

It is to be understood that the term "isolated from" may be read as "of" herein. Therefore references to polynucleotides and proteins being "isolated from" a particular organism include polynucleotides and proteins which were prepared by means other than obtaining them from the organism, such as synthetically or recombinantly.

Preferably, the polynucleotide or protein, is isolated from a fungus, more preferably a filamentous fungus, even more preferably an Ascomycete.

Preferably, the polynucleotide or protein, is isolated from an organism selected from *Aspergillus; Blumeria; Candida; Colletotrichium; Cryptococcus; Encephalitozoon*; *Fusarium; Leptosphaeria; Magnaporthe*; *Mycosphaerella; Neurospora, Phytophthora; Plasmopara; Pneumocystis*; *Pyricularia; Pythium; Puccinia; Rhizoctonia; Schizosaccharomyces, Trichophyton; and Ustilago.*

Preferably, the polynucleotide or protein, is isolated from an organism independently selected from a group of genera consisting of *Aspergillus, Candida, Colletotrichium, Fusarium, Magnaporthe, Mycosphaerella, Neurospora, Schizosaccharomyces* and *Ustilago.*

Preferably, the polynucleotide or protein, is isolated from an organism selected from the species *Aspergillus flavus; Aspergillus fumigatus; Aspergillus nidulans; Aspergillus niger; Aspergillus parasiticus*; *Aspergillus terreus; Blumeria graminis; Candida albicans; Candida cruzei; Candida glabrata; Candida parapsilosis; Candida tropicalis; Colletotrichium trifolii; Cryptococcus neoformans; Encephalitozoon cuniculi*; *Fusarium graminarium; Fusarium solani; Fusarium sporotrichoides; Leptosphaeria nodorum; Magnaporthe grisea; Mycosphaerella graminicola; Neurospora crassa; Phytophthora capsici; Phytophthora infestans; Plasmopara viticola; Pneumocystis jiroveci; Puccinia coronata; Puccinia graminis; Pyricularia oryzae; Pythium ultimum; Rhizoctonia solani*; *Schizzosaccharomyces pombe; Trichophyton interdigitale; Trichophyton rubrum;* and *Ustilago maydis.*

Preferably, the polynucleotide or protein, is isolated from an organism selected from *Aspergillus fumigatus*; *Aspergillus nidulans, Candida albicans, Colletotrichium trifolii, Fusarium graminearum, Fusarium sporotrichoides, Magnaporthe grisea, Mycosphaerella graminicola, Neurospora crassa, Schizosaccharomyces pombe* and *Ustilago maydis.*

The polynucleotide, and preferably the protein, may be isolated from *A. fumigatus* AF293.

Table I. 2031 OR sequences claimed and their relationship to sequences given in the sequence listing.

	gDNA/EST[1]	Coding sequence(cDNA/mRNA) w/o UTRs[2]	Protein
A. fumigatus Oxidoreductase 2031	SEQ ID No. 1: 299-469, 520-1618	SEQ ID No. 2: 115-1384	SEQ ID. No. 3
A. fumigatus Oxidoreductase 4929	SEQ ID No. 4: 1-180, 267-1352	SEQ ID No. 5: 1-1266	SEQ ID No. 6
A. fumigatus Oxidoreductase 1495	SEQ ID No. 7: 1-1329	SEQ ID No. 7: 1-1329	SEQ ID No. 8
A. nidulans 1_112	SEQ ID No. 9: 1-1269	SEQ ID No. 9: 1-1269	SEQ ID No. 10
C. albicans 2431	SEQ ID No. 11: 1-1299	SEQ ID No. 11 1-1299	SEQ ID No. 12
C. albicans 2464	SEQ ID No. 13: 1-1110	SEQ ID No. 13: 1-1110	SEQ ID No. 14
N. crassa NCU07452.1	SEQ ID No. 15: 1-1305	SEQ ID No. 15: 1-1305	SEQ ID No. 16
N. crassa Oxidoreductase NCU08900	SEQ ID No. 17: 1-924,1015-1362,1435-1476	SEQ ID No. 18: 1-1314	SEQ ID No. 19
M. grisea MG04569.3 (pred gene)	SEQ ID No. 20: 1-726, 810-1412	SEQ ID No. 21: 1-1329	SEQ ID No.22
S. pombe T39956	SEQ ID No. 23: 1-1188	SEQ ID No. 23: 1-1188	SEQ ID No. 24
C. trifolii (EST assembly)	SEQ ID No. 25: 130-777	SEQ ID No. 26: 1-645 [3]	SEQ ID No. 27
F. sporotrichoides FsCon[0063] (ESTs)	SEQ ID No. 28: 103-803	SEQ ID No. 29: 1-701	SEQ ID No. 30
F. sporotrichoides FsCon[0237] (ESTs)	SEQ ID No. 31: 76-631 (rev comp)	SEQ ID No. 32: 1-556	SEQ ID No.33
F. sporotrichoides FsCon[0458] (ESTs)	SEQ ID No. 34: 174-657	SEQ ID No. 34: 174-657	SEQ ID No.35

F. graminearum 15771741 (EST)	SEQ ID No. 36: 1-744	SEQ ID No. 37: 1-742[4]	SEQ ID No.38
F. graminearum FG00074.1	SEQ ID No. 82: 1-1326	SEQ ID No. 82: 1-1326	SEQ ID No. 83
M. graminicola mg[0281] (EST)	SEQ ID No. 39: 1-647	SEQ ID No. 39: 1-647	SEQ ID No.40
M. graminicola mga0328f (EST)	SEQ ID No. 41: 1-560	SEQ ID No. 41: 1-560	SEQ ID No.42
M. grisea MG03823.3	SEQ ID No. 43: 1-1254	SEQ ID No. 43: 1-1254	SEQ ID No.44
Ustilago maydis Contig 1.2	SEQ ID No. 84: 1-1350	SEQ ID No. 84: 1-1350	SEQ ID No. 85

[1]Numbers after SEQ ID Nos. correspond to bases of genomic DNA encoding the protein.

[2]RNA sequences are given in the sequence listing with Thymidine (T), although it is understood that *in vivo* Uridine (U) would be present.

[3]NA one-base deletion at position 690 of the EST (SEQ ID No. 22) is required to give the best predicted cDNA/protein.

[4]Two single base deletions are required to optimise translation.

Bioinformatics analysis was carried out to identify functionally important regions within the fungal 2031 ORs. The 2031 ORs are related to but distinct from the "Old Yellow Enzyme" (OYE) group of yeast enzymes, which also includes ergosterol-binding protein of *Candida albicans*. Comparison of the 2031 ORs with crystal structures of OYE family proteins identified highly conserved residues responsible for the catalytic function of these enzymes. However, the comparisons also identified seven clusters of residues conserved in 2031 enzymes but not OYE enzymes which flanked the substrate binding site and were therefore implicated in determining substrate specificity (regions 2, 4, 6, 7, 8, 10, and 11 in Figures 1 and 2, and Example 4 hereinafter). Four further conserved clusters of residues were identified which, while not predicted to be involved in catalysis, were conserved in 2031 but not OYE and so also distinguish 2031 ORs from OYEs (regions 1, 3, 5, and 9 in Figures 1 and 2, and Example 4 hereinafter).

Variants of the above mentioned polynucleotides and proteins are also provided, and

are discussed below.

In one embodiment, the protein of the invention may comprise an amino acid sequence substantially as set out and independently selected from regions 1 - 11 of any of SEQ ID Nos 3, 6, 8, 10, 12, 14, 16, 19, 22, 24, 27, 30, 33, 35, 38, 40, 42, 44, 83 or 85 as given in Figure 1, or variants thereof. At least one region or motif may be functional.

The polynucleotide of the invention may comprise DNA, such as genomic DNA. The polynucleotide may comprise a sequence substantially as set out and independently selected from regions 1 - 11 of any of SEQ ID Nos. 1, 4, 7, 9, 11, 13, 15, 17, 20, 23, 25, 28, 31, 34, 36, 39 41, 43, 82 or 84 as given in Figure 2, or complements, or variants thereof.

Preferably, the polynucleotide encodes a fungal 2031 OR protein which comprises substantially the amino acid sequences SEQ ID Nos 3, 6, 8, 10, 12, 14, 16, 19, 22, 24, 27, 30, 33, 35, 38, 40, 42, 83 or 85 or a variant thereof.

The polynucleotide may comprise RNA, preferably mRNA, preferably spliced mRNA. Preferably, the polynucleotide comprises substantially the sequence shown as SEQ ID Nos 2, 5, 7, 9, 11, 13, 15, 18, 21, 23, 26, 29, 32, 34, 36, 37, 39, 41, 43, 82 or 84 or a complement, or a variant thereof.

Preferably, the protein comprises substantially the sequences SEQ ID Nos. 3, 6, 8, 10, 12, 14, 16, 19, 22, 24, 27, 30, 33, 35, 38, 40, 42, 44, 83 or 85 or a variant thereof.

Preferably, the protein is encoded by the regions of sequences SEQ ID Nos. 1, 4, 7, 9, 11, 13, 15, 17, 20, 23, 25, 26, 28, 29, 31, 34, 36, 39, 41, 43, 82 or 84 as described in Figure 1. in the column "gDNA/EST" in Table I, or a complement, or a variant thereof.

The polynucleotide may comprise substantially a nucleotide sequence region or motif independently selected from at least one of regions 1-11 from at least one of the sequences SEQ ID Nos. 1, 2, 4, 5, 7, 9, 11, 13, 15, 17, 18, 20, 21, 23, 25, 26, 28, 29, 31, 32, 34, 36, 37, 39, 41, 43, 82 or 84, as given in Figure 2, or a complement, or a variant thereof.

Preferably, the isolated polynucleotide comprises substantially a nucleotide sequence independently selected from the regions and sequences given in the column "gDNA/EST" in Table I.

Preferably, the protein is encoded by a polynucleotide which polynucleotide comprises substantially a sequence independently selected from at least one of the the regions and sequences given in the column "gDNA/EST" in Table I, or a complement or, a variant thereof.

By the term "native amino acid/polynucleotide/protein", is meant an amino acid, polynucleotide or protein produced naturally from biological sources either *in vivo* or *in vitro*.

By the term "synthetic amino acid/polynucleotide/protein", is meant an amino acid, polynucleotide or protein which has been produced artificially or *de novo* using a DNA or protein synthesis machine known in the art.

By the term "recombinant amino acid/polynucleotide /protein", is meant an amino acid, polynucleotide or protein which has been produced using recombinant DNA or protein technology or methodologies which are known to the skilled technician.

The term "variant", and the terms "substantially the amino acid/polynucleotide/protein sequence" are used herein to refer to related sequences. As discussed below such related sequences are typically homologous to (share percentage identity with) a given sequence, for example over the entire length of the sequence or over a portion of a given length. The related sequence may also be a fragment of the sequence or of a homologous sequence. A variant protein may be encoded by a variant polynucleotide.

By the term "variant", and the terms "substantially the amino acid/polynucleotide/protein sequence", we mean that the sequence has at least 30%, preferably 40%, more preferably 50%, and even more preferably, 60% sequence identity with the amino acid/polynucleotide/protein sequences of any one of the sequences referred to. A sequence which is "substantially the amino acid/polynucleotide/peptide sequence" may be the same as the relevant sequence.

Calculation of percentage identities between different amino acid/polynucleotide/protein sequences may be carried out as follows. A multiple

alignment is first generated by the ClustalX program (pairwise parameters: gap opeining 10.0, gap extension 0.1, protein matrix Gonnet 250, DNA matrix IUB; multiple parameters: gap opening 10.0, gap extension 0.2, delay divergent sequences 30%, DNA transition weight 0.5, negative matrix off, protein matrix gonnet series, DNA weight IUB; Protein gap parameters, residue-specific penalties on, hydrophilic penalties on, hydrophilic residues GPSNDQERK, gap separation distance 4, end gap separation off). The percentage identity is then calcluated from the multiple alignment as (N/T)*100, where N is the number of positions at which the two sequences share an identical residue, and T is the total number of positions compared. Alternatively, percentage identity can be calculated as (N/S)*100 where S is the length of the shorter sequence being compared. The amino acid/polynucleotide/protein seqences may be synthesised *de novo*, or may be native amino acid/polynucleotide/protein sequence, or a derivative thereof.

An amino acid/polynucleotide/protein sequence with a greater identity than 65% to any of the sequences referred to is also envisaged. An amino acid/polynucleotide/protein sequence with a greater identity than 70% to any of the sequences referred to is also envisaged. An amino acid/polynucleotide/protein sequence with a greater identity than 75% to any of the sequences referred to is also envisaged. An amino acid/polynucleotide/protein sequence with a greater identity than 80% to any of the sequences referred to is also envisaged. Preferably, the amino acid/polynucleotide/protein sequence has 85% identity with any of the sequences referred to, more preferably 90% identity, even more preferably 92% identity, even more preferably 95% identity, even more preferably 97% identity, even more preferably 98% identity and, most preferably, 99% identity with any of the referred to sequences.

The above mentioned percentage identities may be measured over the entire length of the original sequence or over a region of 15, 20, 50 or 100 amino acids/bases of the original sequence. In a preferred embodiment percentage identity is measured with reference to SEQ ID No. 3. Preferably the variant protein has at least 40% identity, such as at least 60% or at least 80% identity with SEQ ID No. 3 or a portion of SEQ ID No. 3.

Alternatively, a substantially similar nucleotide sequence will be encoded by a

sequence which hybridizes to the sequences shown in SEQ ID Nos. 1, 2, 4, 5, 7, 8, 9, 11, 13, 15, 17, 18, 20, 21, 23, 25, 26, 28, 29, 31, 32, 34, 36, 37, 39, 41, 43, 82 or 84 or their complements under stringent conditions. By stringent conditions, we mean the nucleotide hybridises to filter-bound DNA or RNA in 6x sodium chloride/sodium citrate (SSC) at approxmiately 45°C followed by at least one wash in 0.2x SSC/0.1% SDS at approximately 5-65°C. Alternatively, a substantially similar protein may differ by at least 1, but less than 5, 10, 20, 50 or 100 amino acids from the sequences shown in SEQ ID Nos. 3, 6, 8, 10, 12, 14, 16, 19, 22, 24, 27, 30, 33, 35, 38, 40, 42, 44, 83 or 85. Such differences may each be additions, deletions or substitutions.

Due to the degeneracy of the genetic code, it is clear that any nucleic acid sequence could be varied or changed without substantially affecting the sequence of the protein encoded thereby, to provide a functional variant thereof. Suitable nucleotide variants are those having a sequence altered by the substitution of different codons that encode the same amino acid within the sequence, thus producing a silent change.

Other suitable variants are those having homologous nucleotide sequences but comprising all, or portions of, sequence which are altered by the substitution of different codons that encode an amino acid with a side chain of similar biophysical properties to the amino acid it substitutes, to produce a conservative change. For example small non-polar, hydrophobic amino acids include glycine, alanine, leucine, isoleucine, valine, proline, and methionine. Large non-polar, hydrophobic amino acids include phenylalanine, tryptophan and tyrosine. The polar neutral amino acids include serine, threonine, cysteine, asparagine and glutamine. The positively charged (basic) amino acids include lysine, arginine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Certain organisms, including *Candida* are known to use non-standard codons compared to those used in the majority of eukaryotes. Any comparisons of polynucleotides and proteins from such organisms with the sequences given here should take these differences into account.

In accurate alignment of protein or DNA sequences the trade-off between optimal matching of sequences and the introduction of gaps to obtain such a match is important. In the case of proteins, the means by which matches are scored is also of significance. The family of PAM matrices (e.g., Dayhoff, M. et al., 1978, Atlas of

protein sequence and structure, Natl. Biomed. Res. Found.) and BLOSUM matrices quantitate the nature and likelihood of conservative substitutions and are used in multiple alignment algorithms, although other, equally applicable matrices will be known to those skilled in the art. The popular multiple alignment program ClustalW, and its windows version ClustalX (Thompson et al., 1994, Nucleic Acids Research, 22, 4673-4680; Thompson et al., 1997, Nucleic Acids Research, 24, 4876-4882) are efficient ways to generate multiple alignments of proteins and DNA.

Use of the Align program is also preferred (Hepperle, D., 2001: Multicolor Sequence Alignment Editor. Institute of Freshwater Ecology and Inland Fisheries, 16775 Stechlin, Germany), although others, such as JalView or Cinema are also suitable.

Calculation of percentage identities between proteins occurs during the generation of multiple alignments by Clustal. However, these values need to be recalculated if the alignment has been manually improved, or for the deliberate comparison of two sequences. Programs that calculate this value for pairs of protein sequences within an alignment include PROTDIST within the PHYLIP phylogeny package (Felsenstein; http://evolution.gs.washington.edu/ phylip.html) using the "Similarity Table" option as the model for amino acid substitution (P). For DNA/RNA, an identical option exists within the DNADIST program of PHYLIP.

Other modifications in protein sequences are also envisaged and within the scope of the claimed invention, i.e. those which occur during or after translation, e.g. by acetylation, amidation, carboxylation, phosphorylation, proteolytic cleavage or linkage to a ligand.

The term "variant", and the terms "substantially the amino acid/polynucleotide/protein sequence" also include a fragment of the relevant polynucleotide or protein sequences, including a fragment of the homologous sequences (which have percentage identity to a specified sequence) referred to above. A polynucleotide fragment will typically comprise at least 10 bases, such as at least 20, 30, 50, 100, 200, 500 or 1000 bases. A protein fragment will typically comprise at least 10 amino acids, such as at least 20, 30, 50, 80, 100, 150, 200, 300, 400 or 500 amino acids. The fragments may lack at least 3 amino acids, such as at least 10, 20 or 30 amino acids of the amino acids from either end of the protein.

The invention provides a method of screening which may be used to identify modulators of 2031 OR proteins or polynucleotides, such as inhibitors of expression or activity of the proteins or polynucleotides of the invention. In one embodiment of the method a candidate substance is contacted with a protein or polynucleotide of the invention and whether or not the candidate substance binds or modulates the protein or polynucleotide is determined.

The modulator may promote (agonise) or inhibit (antagonise) the activity of the protein. A therapeutic modulator (against fungal infection) will inhibit the expression or activity of protein or polynucleotide of the invention.

The method may be carried out *in vitro* (inside or outside a cell) or *in vivo*. In one embodiment the method is carried out on a cell, or cell culture cell extract. The cell may or may not be a cell in which the polynucleotide or protein is naturally present. The cell may or may not be a fungal cell, or may or may not be a cell of any of the fungi mentioned herein. The protein or polynucleotide may be present in a non-cellular form in the method, thus the protein may be in the form of a recombinant protein purified from a cell.

Any suitable binding or activity assay may be used. Methods which determine whether a candidate substance is able to bind the protein or polynucleotide may comprise providing the protein or polynucleotide to a candidate substance and determining whether binding occurs, for example by measuring the amount of the candidate substance which binds the protein or polynucleotide. The binding may be determined by measuring a characteristic of the protein or polynucleotide that changes upon binding, such as spectroscopic changes. The binding may be determined by measuring reaction substrate or product levels in the presence and absence of the candidate and comparing the levels.

The assay format may be a 'band shift' system. This involves determining whether a test candidate advances or retards the protein or polynucleotide on gel electrophoresis relative to the absence of the compound.

The method may be a competitive binding method. This determines whether the candidate is able to inhibit the binding of the protein or polynucleotide to an agent which is known to bind to the protein or polynucleotide, such as an antibody specific for the protein, or a substrate of the protein.

Whether or not a candidate substance modulates the activity of the protein may be determined by providing the candidate substance to the protein under conditions that permit activity of the protein, and determining whether the candidate substance is able to modulate the activity of the product.

The activity which is measured may be any of the activities of the protein of the invention mentioned herein, such as oxidoreductase activity. In one embodiment the screening method comprising carrying out a redox reaction in the presence and absence of the candidate substance to determine whether the candidate substance inhibits the oxidoreductase activity of the protein of the invention, wherein the redox reaction is carried out by contacting said protein with NADH or NADPH; and an electron acceptor, under conditions in which in the absence of the candidate substance the protein catalyses reduction of the electron acceptor.

In a preferred embodiment the inhibition of the redox reaction is measured by detecting the amount of NADH or NADPH oxidation, for example by measuring the generation of the oxidised forms of NADH and NADPH spectroscopically. This can be done by measurement at 340nm (see Example 7).

Alternatively, a suitable colourimetric oxidoreductase substrate may be used to measure inhibition, such as methylene blue, phenazine methosulphate or 2, 6-dichlorophenolindophenol.

Suitable candidate substances which can tested in the above methods include antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and CDR-grafted antibodies). Furthermore, combinatorial libraries, defined chemical identities, peptide and peptide mimetics, oligonucleotides and natural product libraries, such as display libraries (e.g. phage display libraries) may also be tested. The candidate substances may be chemical compounds. Batches of the candidate substances may be used in an initial screen of, for example, ten substances per reaction, and the substances from batches which show inhibition tested individually.

According to a further aspect of the present invention, there is provided a polynucleotide or protein of the invention for use as a medicament or in diagnosis.

The polynucleotide or protein may be modified prior to use, preferably to produce a derivative or variant thereof. The polynucleotide or protein may be

derivatised. The protein may be modified by epitope tagging, addition of fusion partners or purification tags such as glutathione *S*-transferase, multiple histidines or maltose binding protein, addition of green fluorescent protein, covalent attachment of molecules including biotin or fluorescent tags, incorporation of selenomethionine, inclusion or attachment of radioisotopes or fluorescent/non-fluorescent lanthanide chelates. The polynucleotide may be modified by methylation or attachment of digoxygenin (DIG) or by addition of sequence encoding the above tags, proteins or epitopes.

Preferably, the medicament is adapted to retard or prevent a fungal infection. The fungal infection may be in human, animal or plant. The polynucleotide or protein may be used for the development of a drug. The polynucleotide or protein may be used in, or for the generation of, a molecular model of said polynucleotide or said protein.

According to a further aspect of the present invention, there is provided use of a polynucleotide or protein of the invention for the preparation of a medicament for the treatment of a fungal infection.

The polynucleotide or protein may be modified prior to use, preferably to produce a derivative or variant thereof. The polynucleotide or protein may be derivatised. The polynucleotide or protein may not be modified or derivatised.

Preferably, the medicament is adapted to retard or prevent a fungal infection. The treatment may comprise retarding or preventing fungal infection. Preferably, the drug and/or medicament comprises an inhibitor, preferably a 2031 OR inhibitor. Preferably, the drug or medicament is adapted to inhibit expression and/or activity of the polynucleotide or a fragment thereof, and/or the function of the protein or a fragment thereof.

Preferably, the fungal infection comprises an infection by a fungus, more preferably an Ascomycete, and even more preferably, an organism selected from the genera *Aspergillus; Blumeria; Candida; Colletotrichium; Cryptococcus; Encephalitozoon*; *Fusarium; Leptosphaeria; Magnaporthe*; *Mycosphaerella; Neurospora, Phytophthora; Plasmopara; Pneumocystis*; *Pyricularia; Pythium; Puccinia; Rhizoctonia; Schizosaccharomyces, Trichophyton; and Ustilago.*

Preferably, the fungal infection comprises an infection by an organism selected from the genera *Aspergillus, Candida, Colletotrichium, Fusarium, Magnaporthe,*

Mycosphaerella and *Ustilago*.

Preferably, the fungal infection comprises an infection by an organism selected from the species *Aspergillus flavus; Aspergillus fumigatus; Aspergillus nidulans; Aspergillus niger; Aspergillus parasiticus*; *Aspergillus terreus; Blumeria graminis; Candida albicans; Candida cruzei; Candida glabrata; Candida parapsilosis; Candida tropicalis; Colletotrichium trifolii; Cryptococcus neoformans; Encephalitozoon cuniculi*; *Fusarium graminarium; Fusarium solani; Fusarium sporotrichoides; Leptosphaeria nodorum; Magnaporthe grisea; Mycosphaerella graminicola; Phytophthora capsici; Phytophthora infestans; Plasmopara viticola; Pneumocystis jiroveci; Puccinia coronata; Puccinia graminis; Pyricularia oryzae; Pythium ultimum; Rhizoctonia solani*; *Trichophyton interdigitale; Trichophyton rubrum;* and *Ustilago maydis*.

Preferably, the fungal infection comprises an infection by an organism selected from the species *Aspergillus fumigatus*; *Aspergillus nidulans, Candida albicans, Colletotrichium trifolii, Fusarium graminearum, Fusarium sporotrichoides, Magnaporthe grisea, Mycosphaerella graminicola* and *Ustilago maydis*.

According to another aspect of the present invention, there is provided a method of detecting the presence of a fungal infection in an individual, said method comprising:-

(i) obtaining a sample from an organism; and

(ii) detecting in the said sample the presence of a polynucleotide or protein of the invention.

The individual may be a person (human) or animal (such as a mammal or bird) or a plant. The fungal infection may arise from infection with an organism selected from the genera *Aspergillus; Blumeria; Candida; Colletotrichium; Cryptococcus; Encephalitozoon*; *Fusarium; Leptosphaeria; Magnaporthe*; *Mycosphaerella; Phytophthora; Plasmopara; Pneumocystis*; *Pyricularia; Pythium; Puccinia; Rhizoctonia; Trichophyton; and Ustilago*

The fungal infection may arise from infection with an organism selected from the species *Aspergillus flavus; Aspergillus fumigatus; Aspergillus nidulans; Aspergillus niger; Aspergillus parasiticus*; *Aspergillus terreus; Blumeria graminis; Candida albicans; Candida cruzei; Candida glabrata; Candida parapsilosis; Candida*

tropicalis; Colletotrichium trifolii; Cryptococcus neoformans; Encephalitozoon cuniculi; *Fusarium graminarium; Fusarium solani; Fusarium sporotrichoides; Leptosphaeria nodorum; Magnaporthe grisea; Mycosphaerella graminicola; Phytophthora capsici; Phytophthora infestans; Plasmopara viticola; Pneumocystis jiroveci; Puccinia coronata; Puccinia graminis; Pyricularia oryzae; Pythium ultimum; Rhizoctonia solani*; *Trichophyton interdigitale; Trichophyton rubrum;* and *Ustilago maydis*.

Preferably, the sample comprises a biological sample which, preferably, comprises nucleic acid and/or protein. In one embodiment of the method the nucleic acid or protein is purified (at least partially) from the sample before the detection is performed.

Where the organism is *Aspergillus fumigatus, Aspergillus nidulans* or *Aspergillus niger*, the sample may comprise sputum, bronchoalveloar lavage, urine, respiratory specimens, endotracheal aspirates, sterile specimens obtained by an invasive procedure such as vitreous tap, tympanocentesis, brain biopsy or aspiration, nasal or sinus specimens, blood, tissue or autopsy.

Where the organism is *Magnaporthe grisea* the sample may comprise rice leaf or rice stem.

Preferably, said detecting of the presence in the said sample of a polynucleotide as defined by the first or third aspect comprises use of at least one oligonucleotide pair adapted to be used for amplification of DNA, preferably genomic, more preferably, fungal genomic DNA. The amplification may be PCR amplification.

Preferably, the PCR amplification employs at least one primer pair comprising a polynucleotide selected from the group consisting of:

Aspergillus fumigatus; SEQ ID Nos 67 and 68 for SEQ ID No. 1; SEQ ID Nos 69 and 70 for SEQ ID No. 4; and SEQ ID Nos 71 and 72 for SEQ ID No. 7.
Candida albicans; SEQ ID Nos 73 and 74 for SEQ ID No. 11.
Magnaporthe grisea; SEQ ID Nos 75 and 76 for SEQ ID No. 20.

Preferably, said detecting comprises subjecting the amplified DNA to size analysis, preferably, electrophoresis and, preferably, comparing the results to a positive control and, preferably, a negative control. Said detecting may also comprise sequencing of the amplified DNA to demonstrate the correct sequence.

Preferably, said detecting of the presence in the said sample of a protein comprises use of a monoclonal or polyclonal antibody directed to part or all of the protein of the invention.

According to a further aspect of the present invention, there is provided a recombinant DNA molecule or vector comprising a polynucleotide of the invention.

The recombinant DNA molecule or vector may comprise an expression cassette. Preferably, the recombinant DNA molecule or vector comprises an expression vector. Preferably, the polynucleotide sequence is operatively linked to an expression control sequence. A suitable control sequence may comprise a promoter, an enhancer etc.

According to another aspect of the present invention, there is provided a cell containing a polynucleotide, recombinant DNA molecule or vector of the invention.

The cell may be transformed or transfected with the polynucleotide, recombinant DNA molecule or vector by suitable means. Preferably, the cell produces a recombinant protein of the invention.

The invention also provides an organism which is transgenic for the polynucleotide of the invention (whose cells may be the same as the cells of the invention mentioned herein). Such an organism is typically a fungus, such as any genera or species of fungus mentioned herein. The organism may be microorganism, such as a bacterium, virus or yeast. The organism may be a plant, animal (including birds and mammals), such as any of the animals mentioned herein.

The organism may be produced by introduction of the polynucleotide of the invention into a cell of the organism, and in the case of a multicellular organism allowing the cell to grow into a whole organism.

According to a further aspect of the present invention, there is provided a cell in which a native polynucleotide or protein of the invention protein is non-functional and/or inhibited. The cell may be of, or present in, a multicellular organism.

The cell may be a mutant cell. The cell is typically a fungal cell, such as of any genera or species of fungus mentioned herein. A preferred means of generating the cell is to modify the polynucleotide of the invention, such that the polynucleotide is non-functional. This modification may be to cause a mutation, which disrupts the expression or function of a gene product. Such mutations may be to the nucleic acid sequences that act as 5' or 3' regulatory sequences for the polynucleotide, or may be a mutation introduced into

the coding sequence of the polynucleotide. Functional deletion of the polynucleotide may be, for example, by mutation of the polynucleotide in the form of nucleotide substitution, addition or, preferably, nucleotide deletion.

The polynucleotide may be made non-functional and/or inhibited by:

(i) shifting the reading frame of the coding sequence of the polynucleotide;

(ii) adding, substituting or deleting amino acids in the protein encoded by the polynucleotide; or

(iii) partially or entirely deleting the DNA coding for the polynucleotide and/or the upstream and downstream regulatory sequences associated with the polynucleotide.

(iv) inserting DNA into the coding or non-coding regions.

A preferred means of introducing a mutation into a polynucleotide is to utilize molecular biology techniques specifically to target the polynucleotide which is to be mutated. Mutations may be induced using a DNA molecule. A most preferred means of introducing a mutation is to use a DNA molecule that has been especially prepared such that homologous recombination occurs between the target polynucleotide and the DNA molecule. When this is the case, the DNA molecule, which may be double stranded, may contain base sequences similar or identical to the target polynucleotide to allow the DNA molecule to hybridize to (and subsequently recombine with) the target.

It is also possible to provide a cell in which the polynucleotide is non-functional and/or inhibited without introducing a mutation into the gene or its regulatory regions. This may be done by using specific inhibitors. Examples of such inhibitors include agents that prevent transcription of the polynucleotide, or prevent translation, expression or disrupt post-translational modification. Alternatively, the inhibitor may be an agent that increases degradation of the gene product (e.g. a specific proteolytic enzyme). Equally, the inhibitor may be an agent which prevents the polynucleotide product from functioning, such as neutralizing antibodies (for instance an anti-2031 OR antibody). The inhibitor may also be an antisense oligonucleotide, or any synthetic chemical capable of inhibiting expression of the gene or the stability and/or function of the protein. The inhibitor may also be a protein which interacts with the 2031 OR to prevent its function. The inhibitor may also be an RNA molecule which causes inhibition by RNA interference. In one

embodiment the antisense polynucleotide or RNA molecule which causes RNA interference are examples of polynucleotides of the invention.

According to a further aspect, there is provided an antibody exhibiting immunospecificity for a protein of the invention. The antibody may be used as a diagnostic reagent.

The antibody may be monoclonal or polyclonal, and may be raised in mouse, rat, rabbit, chicken, turkey, horse, goat or donkey. The antibody may be raised against one or all of the proteins together, or may be raised against proteolytic or recombinant fragments.

For the purposes of this invention, the term "antibody", unless specified to the contrary, includes fragments which bind a protein of the invention. Such fragments include Fv, F(ab') and $F(ab')_2$ fragments, as well as single chain antibodies. Furthermore, the antibodies and fragment thereof may be chimeric antibodies, CDR-grafted antibodies or humanised antibodies.

Administration

The formulation of any of the therapeutic substances (e.g. proteins, polynucleotides or modulators) mentioned herein will depend upon factors such as the nature of the substance and the condition to be treated. Any such substance may be administered in a variety of dosage forms. It may be administered orally (e.g. as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules), parenterally, subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The substance may also be administered as suppositories. A physician will be able to determine the required route of administration for each particular patient.

Typically the substance is formulated for use with a pharmaceutically acceptable carrier or diluent. The pharmaceutical carrier or diluent may be, for example, an isotonic solution. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating

agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film coating processes.

Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol. Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

Solutions for intravenous or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

A therapeutically effective non-toxic amount of substance is administered. The dose may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular patient. A typical daily dose is from about 0.1 to 50 mg per kg, preferably from about 0.1mg/kg to 10mg/kg of body weight, according to the activity of the specific inhibitor, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g.

Agricultural use

Modulators identified by the method of the invention may be administered to plants in order to prevent or treat fungal infections. The modulators are normally applied in the form of compositions together with one or more agriculturally acceptable carriers or

diluents and can be applied to the crop area or plant to be treated, simultaneously or in succession with further compounds.

The modulators of the invention can be applied together with carriers, surfactants or application-promoting adjuvants customarily employed in the art of formulation. Suitable carriers and diluents correspond to substances ordinarily employed in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, binders or fertilizers.

A preferred method of applying the modulators of the present invention or an agrochemical composition which contains them is leaf application. The number of applications and the rate of application depend on the intensity of infection by the fungus. However, the active ingredients can also penetrate the plant through the roots via the soil (systemic action) by impregnating the locus of the plant with a liquid composition, or by applying the compounds in solid form to the soil, e.g. in granular form (soil application). The active ingredients may also be applied to seeds (coating) by impregnating the seeds either with a liquid formulation containing active ingredients, or coating them with a solid formulation. In special cases, further types of application are also possible, for example, selective treatment of the plant stems or buds.

The active ingredients are used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation, and are therefore formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations, for example, in polymer substances. Like the nature of the compositions, the methods of application, such as spraying, atomizing, dusting, scattering or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances. Advantageous rates of application are normally from 50g to 5kg of active ingredient (a.i.) per hectare ("ha", approximately 2.471 acres), preferably from 100g to 2kg a.i./ha, most preferably from 200g to 500g a.i./ha.

The formulations, compositions or preparations containing the active ingredients and, where appropriate, a solid or liquid adjuvant, are prepared in known manner, for example by homogeneously mixing and/or grinding active ingredients with extenders,

for example solvents, solid carriers and, where appropriate, surface-active compounds (surfactants).

Suitable solvents include aromatic hydrocarbons, preferably the fractions having 8 to 12 carbon atoms, for example, xylene mixtures or substituted naphthalenes, phthalates such as dibutyl phthalate or dioctyl phthalate, aliphatic hydrocarbons such as cyclohexane or paraffins, alcohols and glycols and their ethers and esters, such as ethanol, ethylene glycol, monomethyl or monoethyl ether, ketones such as cyclohexanone, strongly polar solvents such as N-methyl-2-pyrrolidone, dimethyl sulfoxide or dimethyl formamide, as well as epoxidized vegetable oils such as epoxidized coconut oil or soybean oil; or water.

The solid carriers used e.g. for dusts and dispersible powders, are normally natural mineral fillers such as calcite, talcum, kaolin, montmorillonite or attapulgite. In order to improve the physical properties it is also possible to add highly dispersed silicic acid or highly dispersed absorbent polymers. Suitable granulated adsorptive carriers are porous types, for example pumice, broken brick, sepiolite or bentonite; and suitable nonsorbent carriers are materials such as calcite or sand. In addition, a great number of pregranulated materials of inorganic or organic nature can be used, e.g. especially dolomite or pulverized plant residues.

Depending on the nature of the active ingredient to be used in the formulation, suitable surface-active compounds are nonionic, cationic and/or anionic surfactants having good emulsifying, dispersing and wetting properties. The term "surfactants" will also be understood as comprising mixtures of surfactants.

Suitable anionic surfactants can be both water-soluble soaps and water-soluble synthetic surface-active compounds. Suitable soaps are the alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammonium salts of higher fatty acids (chains of 10 to 22 carbon atoms), for example the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures which can be obtained for example from coconut oil or tallow oil. The fatty acid methyltaurin salts may also be used.

More frequently, however, so-called synthetic surfactants are used, especially fatty sulfonates, fatty sulfates, sulfonated benzimidazole derivatives or alkylarylsulfonates. The fatty sulfonates or sulfates are usually in the form of alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammoniums salts

and have a 8 to 22 carbon alkyl radical which also includes the alkyl moiety of alkyl radicals, for example, the sodium or calcium salt of lignonsulfonic acid, of dodecylsulfate or of a mixture of fatty alcohol sulfates obtained from natural fatty acids. These compounds also comprise the salts of sulfuric acid esters and sulfonic acids of fatty alcohol/ethylene oxide adducts. The sulfonated benzimidazole derivatives preferably contain 2 sulfonic acid groups and one fatty acid radical containing 8 to 22 carbon atoms. Examples of alkylarylsulfonates are the sodium, calcium or triethanolamine salts of dodecylbenzenesulfonic acid, dibutylnaphthalenesulfonic acid, or of a naphthalenesulfonic acid/formaldehyde condensation product. Also suitable are corresponding phosphates, e.g. salts of the phosphoric acid ester of an adduct of p-nonylphenol with 4 to 14 moles of ethylene oxide.

Non-ionic surfactants are preferably polyglycol ether derivatives of aliphatic or cycloaliphatic alcohols, or saturated or unsaturated fatty acids and alkylphenols, said derivatives containing 3 to 30 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenols.

Further suitable non-ionic surfactants are the water-soluble adducts of polyethylene oxide with polypropylene glycol, ethylenediamine propylene glycol and alkylpolypropylene glycol containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethylene glycol ether groups and 10 to 100 propylene glycol ether groups. These compounds usually contain 1 to 5 ethylene glycol units per propylene glycol unit.

Representative examples of non-ionic surfactants are nonylphenolpolyethoxyethanols, castor oil polyglycol ethers, polypropylene/polyethylene oxide adducts, tributylphenoxypolyethoxyethanol, polyethylene glycol and octylphenoxyethoxyethanol. Fatty acid esters of polyoxyethylene sorbitan and polyoxyethylene sorbitan trioleate are also suitable non-ionic surfactants.

Cationic surfactants are preferably quaternary ammonium salts which have, as N-substituent, at least one C_8-C_{22} alkyl radical and, as further substituents, lower unsubstituted or halogenated alkyl, benzyl or lower hydroxyalkyl radicals. The salts

are preferably in the form of halides, methylsulfates or ethylsulfates, e.g. stearyltrimethylammonium chloride or benzyldi(2-chloroethyl)ethylammonium bromide.

The surfactants customarily employed in the art of formulation are described, for example, in "McCutcheon's Detergents and Emulsifiers Annual", MC Publishing Corp. Ringwood, New Jersey, 1979, and Sisely and Wood, "Encyclopaedia of Surface Active Agents," Chemical Publishing Co., Inc. New York, 1980.

The agrochemical compositions usually contain from about 0.1 to about 99% preferably about 0.1 to about 95%, and most preferably from about 3 to about 90% of the active ingredient, from about 1 to about 99.9%, preferably from about 1 to 99%, and most preferably from about 5 to about 95% of a solid or liquid adjuvant, and from about 0 to about 25%, preferably about 0.1 to about 25%, and most preferably from about 0.1 to about 20% of a surfactant. Whereas commercial products are preferably formulated as concentrates, the end user will normally employ dilute formulations.

All of the features described herein may be combined with any of the above aspects, in any combination.

Embodiments of the invention will now be described by way of example, with reference to the accompanying drawings in which:-

Figure 1 illustrates a multiple sequence alignment of amino acid sequences corresponding to fungal and bacterial 2031 and OYE family oxidoreductases;

Figure 2 illustrates a multiple sequence alignment of nucleic acid sequences corresponding to fungal 2031 and family oxidoreductases;

Figure 3A illustrates the expression of recombinant 2031 OR; B shows purified recombinant 2031 OR.

Figure 4. Phylogenetic tree showing relationships between *A. fumigatus* 2031 OR and similar proteins. This demonstrates a 2031 OR clade, which can be distinguished from the OYE proteins;

Figure 5 illustrates reduction of a range of substrates by recombinant 2031 OR.

Figure 6 illustrates the inhibition of 2031 OR by two compounds identified from a screen.

EXAMPLES

Example 1. Identification of an essential gene in *Aspergillus fumigatus*

An essential region of the *A. fumigatus* genome was identified using the mycobank technology as described in patent WO00177295A1 with the following modifications:

Re-haploidisation (section 1.6):

P24 lines 11-18: Conidia (*A. fumigatus)* were collected from a stable diploid transformant colony and approximately $3x10^4$ spores were used to inoculate 1 ml of SAB broth containing 1mg/ml FPA. This culture was incubated with shaking (200 rpm) at 37°C for 20 hours. 100µl of the culture was spread onto complete media containing 0.2 mg/ml FPA and incubated at 37 °C for 3 days or until rapidly growing sectors emerged. Conidia were collected from each sector and plated onto nitrate, nitrite and hypoxanthine media and the nitrogen utilisation profiles of the resulting conidia assessed. Colonies with the nitrogen utilisation profiles of the parental strains indicated breakdown of the diploid to a haploid. 44 haploid sectors were isolated from transformant 2031. None of the haploids isolated were hygromycin resistant indicating the insertion of the *hph* gene into a portion of the genome required for function.

Transformation (section 1.7):

P25 line 9: Plasmid pAN7-1 linearised with HindIII was used as the transforming vector. PAN7-1 carries the *hph* gene which confers hygromycin resistance.

P25 lines 17-20: 1 ml of cold YED was added to the cuvette and incubated at 37 °C for 1 h. Aliquots were spread on selective agar (complete media with 250 µg/ml hygromycin). Colonies growing on selective media were deemed putative transformants.

The point of insertion was identified using the plasmid rescue method outlined on page 31 lines 5-17. The insertion site was confirmed by employing PCR: Using the sequence obtained from plasmid rescue data a primer was designed within the

sequence of pAN7-1 and a complementary primer was designed within the predicted sequence near the point of insertion. Genomic DNA isolated from the diploid 2031 was used as a template.

The resulting DNA sequence (experiment 2031, with 175 bases of upstream pAN7.1 sequence removed) corresponds to the gDNA sequence immediately downstream of the insertion site and is given as SEQ ID No. 45.

Example 2. Characterisation of the essential gene

2.1 Genome analysis

The TIGR *A. fumigatus* database (www.TIGR.org) was searched (blastn) with the sequence SEQ ID No. 45, identified in Example 1 above, and a match to contig 4798 (Eval 4.6e-148) was identified. The appropriate region of the contig sequence was down-loaded from www.tigr.org and gene predictions carried out using Genscan (genes.mit.edu/GENSCAN.html; Settings; organism = vertebrate; Suboptimal exon cutoff = 1.00).

The *ab initio* prediction of genes from genomes is known to be an inaccurate process (Burset, M. and Guigó, 1996, Genomics, 34, 353-367) and this is particularly so when the programs used have not been specifically trained for the genome under examination (as is the case here). It is therefore necessary to carefully examine the predictions, to compare any predicted genes with any homologous proteins, and to exploit the operative's knowledge of fungal gene structure, and thus to arrive at an informed prediction. The predicted genes were therefore compared with similar sequences using blastp (http:// blast.genome.ad.jp/), the multiple alignment program ClustalX (Thompson et al., 1997, Nucleic Acids Research, 24:4876-4882), and the alignment editor/ viewer Align (Hepperle, D., 2001: Multicolor Sequence Alignment Editor. Institute of Freshwater Ecology and Inland Fisheries, 16775 Stechlin, Germany). Gene structures were visualised and modified using Artemis (http://www.sanger.ac.uk/Software/Artemis/; Rutherford et al., 2000, Bioinformatics 16, 944-945).

The gene adjacent to the insertion site corresponded to bases 299-469 (exon 1) and bases 520-1618 (exon 2) of the genomic sequence given as SEQ ID No. 1. The protein sequence for the gene is given as SEQ ID No. 3. The insertion site was 735 bases upstream of the 5' ATG start of the gene.

Searches of the protein databases at http://blast.genome.ad.jp/ showed that protein SEQ ID No. 3 is a member of the NADH-dependent flavin oxidoreductase family. This protein is henceforth referred to as 2031 oxidoreductase (2031 OR; having come from mycobank experiment 2031). Other 2031 OR-like proteins were also identified (see Example 4.1). The NADH-dependent flavin oxidoreductase family also includes Old Yellow Enzyme (OYE), from *S. cerevisiae* and other fungi, although 2031 ORs can be distinguished from OYEs.

Referring to Figures 1, there is shown a multiple alignment of the 2031 OR amino acid sequence from *A. fumigatus* along with related ORs from other fungi and bacteria (see also Example 4). Regions 1-11 refer to amino acids conserved between ORs.

Fungal 2031 ORs are given by: SEQ ID Nos. 3, 6 and 8, *A. fumigatus*; SEQ ID No. 10, *A.nidulans*; SEQ ID Nos. 12 and 14, *C. albicans*; SEQ ID Nos. 16 and 19, *N. crassa*; SEQ ID Nos 22 and 44, *M. grisea*; SEQ ID No. 24, (NP_595868), *S. pombe*; SEQ ID No. 27, *C. trifolii*; SEQ ID Nos. 30, 33 and 35, *F. sporotrichioides*; SEQ ID Nos. 38 and 83, *F. graminearum*SEQ ID Nos. 40 and 42, *M. graminicola*; SEQ ID No. 85, *U. maydis*.

Bacterial ORs resembling 2031 are: T44612 (*Pseudomonas putida*), SEQ ID No. 86; NP_625402 (*Streptomyces coelicolor*), SEQ ID No. 87; NP_295913 (*Deinococcus radiodurans*), SEQ ID No. 88; AF320254 (*Azoarcus evansii*, SEQ ID No. 89.

Fungal ORs similar to the Old Yellow Enzyme family (originally identified in *S. cerevisiae*):*A. fumigatus,* Af4875 and Af4961, SEQ ID Nos. 90 and 91 respectively; *C. albicans,* Ca2460 and A36990, SEQ ID Nos. 92 and 93 respectively; *N. crassa,* Nc4452, SEQ ID No. 94; *S. cerevisiae,* OYE1, OYE2 and OYE3, SEQ ID Nos. 95-97 respectively.

Details of the sequence searches that identified the ORs other than SEQ ID No. 3, and methods for the construction of multiple alignments are given in Example 4 hereinafter.

Referring to Figure 2, there is shown a multiple alignment of the nucleotide sequence of 2031 OR from *A. fumigatus* along with related 2031 ORs from other fungi and bacteria (see also Example 4). Regions 1-11 refer to amino acids conserved between 2031 ORs at the amino acid level. Fungal 2031 ORs are given by SEQ ID No.: SEQ ID Nos. 1, 2, 4, 5, and 7, *A. fumigatus*; SEQ ID No. 9, *A.nidulans*; SEQ ID Nos. 11 and 13, *C. albicans*; SEQ ID Nos. 15, 17 and 18, *N. crassa*; SEQ ID Nos. 20, 21 and 43, *M. grisea*; SEQ ID No. 23 (NP_595868), *S. pombe*; SEQ ID Nos. 25 and 26, *C. trifolii*; SEQ ID Nos. 28, 29, 31, 32 and 34, *F. sporotrichioides*; SEQ ID Nos. 36, 37 and 82, *F. graminearum*; SEQ ID Nos. 39 and 41, *M. graminicola;* SEQ ID No. 84, *U. maydis*.

Details of the sequence searches that identified the ORs, and methods for the construction of multiple alignments are given in Example 4 hereinafter.

2.2 Genomic Sequencing of Genes

Following the above bioinformatic analyses, the genomic sequences of 2031 OR was experimentally determined.

2.2.1 Bacterial and Fungal Strains

For bacterial cloning, *E. coli* strains Top10 (Invitrogen) and select96 (Promega) were used in accordance with manufacturers' instructions.

A. fumigatus clinical isolate AF293 (ref. No. NCPF7367; available to the public from the NCPF repository; Bristol, U.K.); the CBS repository (Belgium) or from Dr. David Denning's clinical isolate culture collection, Hope Hospital, Salford. U.K.) is the preferred strain according to the present invention. AF293 was isolated in 1993 from the lung biopsy of a patient with invasive aspergillosis and aplastic anaemia. It was donated by Shrewsbury PHLS.

2.2.2 Purification of A. fumigatus genomic DNA

To obtain mycelial material for genomic DNA isolation, approximately 10^7 *A. fumigatus* conidia were inoculated in 50 ml of Vogel's minimal medium and incubated with shaking at 200 rpm until late exponential phase (18-24 h) at 37°C. Mycelium was

dried down onto Whatmann 54 paper using a Buckner funnel and a side-arm flask attached to a vacuum pump and washed with PBS/Tween. At this point, the mycelium could be freeze-dried for extraction at a later date.

The mycelium (fresh or freeze dried) was ground to a powder using liquid nitrogen in a –20°C cooled mortar. The ground biomass was transferred to 50 ml tubes on ice up to the 10 ml mark. An equal volume of extraction buffer (0.7 M NaCl; 0.1 M Na_2SO_3; 0.1 M Tris-HCl pH 7.5; 0.05 M EDTA; 1%(w/v) SDS; pre-warmed to 65°C) was then added to each tube, mixed thoroughly with a pipette tip and incubated at 65°C for 20 minutes in a water bath. A volume of chloroform/isoamyl alcohol (24:1) equivalent to the volume of the original biomass was then added to each tube, tubes were mixed thoroughly and incubated on ice for 30 min. Tubes were then centrifuged at 3,500 x g for 30 min and the aqueous phase carefully transferred to fresh 50 ml tubes without disturbing the interface.

An equal volume of chloroform/isoamyl alcohol (24:1) was added, the tubes vortexed and incubated on ice for 15 minutes. Tubes were then spun at 3,500 x g for 15 minutes. After this spin, if large amounts of precipitate were still present, the supernatant was removed and the chloroform:isoamyl alcohol step repeated. The supernatant was removed and placed in clean sterile Oak Ridge tubes. An equal volume of isopropanol was added and mixed gently. Tubes were incubated at room temperature for at least 15 minutes. Tubes were then centrifuged at 3,030 x g for 10 minutes at 4°C to pellet the DNA. The supernatant was removed and the pellet allowed to air dry for 10-25 minutes. The pellet was suspended in 2 ml sterile water. 1 ml of 7.5 M ammonium acetate was added, mixed and incubated on ice for 1 hour. Tubes were centrifuged at 12,000 x g for 30 min, the supernatants transferred to a fresh tube and 0.54 volumes of isopropanol were added, mixed and incubated at room temperature for at least 15 minutes. Tubes were then centrifuged at 5,930 x g for 10 min, the supernatant was removed and the pellet washed in 1 ml of 70% ethanol. Tubes were centrifuged at 5,930 x g for 10 min and all the ethanol was removed. The pellet was air dried for 20-30 minutes at room temperature and suspended in 0.5-1.0 ml of TE (10 mM Tris-HCl pH 7.5; 1mM EDTA) Finally, the DNA was treated with RNase A (5 µl of 1mg/ml stock).

2.2.3 PCR Reactions

Primers were designed to the upstream and downstream regions of the *A. fumigatus* AF293 2031 OR; cloning primer pair SEQ ID Nos. 46 (Ox9_for) and 47 (Ox10_rev). The following reagents and conditions were used:

PCR Master Mix

10x high fidelity PCR buffer	5 µl
dNTP (clontech: 10mM)	1 µl
nH_2O	39 µl
Pfu Ultra Polmerase (2.5U/µl)	1 µl
Forward primer (Ox9_for: 10 pmol/µl stock)	1 µl
Reverse primer (Ox10_rev: 10 pmol/µl stock)	1 µl
gDNA (1:30 dilution of stock)	2 µl

PCR Cycle

1) 95° C 2 min
2) 95° C 30 sec
3) 54° C 30 sec
4) 72° C 2 min
5) 72° C 10 min
6) 8° C Hold

40 cycles of steps 2-4 were carried out and the PCR products were run on a gel. The product band (1.9kb) was excised from the gel and purified using Qiagen's QIAquick Gel Extraction Kit (Qiagen Ltd, Boundary Court, Gatwick Road, Crawley, West Sussex, RH10 9AX, UK) according to the manufacturers instructions and eluted into 30 µl of sterile water (BDH molecular biology grade/filter sterile).

2.2.4 Genomic DNA Cloning and Sequencing

Since the gDNA was amplified using Pfu ultra polymerase which produces blunt ends it was necessary to add 'A' overhangs before ligating in to pGEM Teasy. 12.5 µl of purified PCR product was incubated with 12.5 µl 2x PCR Reddy Mix (ABGene) at 70°

C for 30 minutes. The sample was then purified using Qigen Qiaquick gel extraction kit and eluted in 30 µl of molecular biology grade water.

The PCR product was then ligated into pGEM-Teasy (Promega) using the following ligation mixture:

2x Buffer	5 µl
pGEM Teasy	1 µl
PCR product	3 µl
T4 DNA Ligase	1 µl

The reaction was incubated over-night at 4° C.

2 µl of the ligation mix were then added to Select 96 cells (Promega) and incubated for 20 min on ice. Cells were then heat shocked at 42° C for 45 secs and placed back on ice. 250 µl of room temp. SOC medium was then added and the cells incubated for 1 hour at 37° C, with shaking at 220 rpm. 50 and 200 µl amounts were then plated on to LB agar plates containing ampicillin (100 µg/ml), 50 µl X-gal (4%) and 10 µl IPTG (100 mM) and incubated over night at 37° C.

Individual white colonies were picked from each transformation inoculated into LB with ampicillin (100 µg/ml) and incubated over-night at 37° C, with shaking at 220 rpm. Plasmid DNA was extracted using Qiagen miniprep kit according to the manufacturers instructions. 1 µl of plasmid DNA was digested with EcoRI for 1 hour at 37° C. Fragment sizes were calculated to be 3Kb and 1.6Kb for gDNA and 3Kb and 1.2 Kb for cDNA. Clones showing the correct restriction digest pattern were sequenced at MWG Biotech UK Ltd, Waterside House, Peartree Bridge, Milton Keynes, MK6 3BY. The experimentally determined sequence of 2031 OR was identical in the coding regions to that identified by bioinformatic analyses (Example 2).

Example 3. cDNA sequencing and RACE for 2031 OR

The internal sequence of the 2031 OR message was experimentally determined by cloning and sequencing cDNA, and the 5' and 3' ends of the gene were determined by RACE (Rapid Amplification of cDNA Ends).

3.1 cDNA cloning and sequencing

3.1.1 Preparation of A. fumigatus RNA and cDNA

Fungal cultures were prepared as described in Example 2.2.2. Cultures were harvested by filtration, then washed twice with DEPC-treated water and transferred to a 50ml Falcon tube. Samples were frozen in liquid nitrogen and stored at -80°C until required.

To prepare RNA, fungal samples were ground to a fine powder under liquid nitrogen. RNA was then extracted using the Qiagen RNeasy Plant Mini Kit following the protocol for isolation of total RNA from filamentous fungi in the RNeasy Mini Handbook (06/2001, Pages 75-78, http://www.qiagen.com/literature/handbooks/rna/rnamini/1016272HBRNY_062001WW.pdf). The following modifications were used: At step 3, RLC was used as the lysis buffer of choice; At step 7, the Rneasy column was incubated for 5 min at room temperature after addition of RW1; The optional step 9a was carried out; At step 10, 30µl RNase-free water was added, the samples incubated for 10 min at room temperature, and then centrifuged; At step 11, the elution step was repeated to give a total volume of 60 µl RNA.

DNA contamination was removed from the RNA by the addition of Dnase, using 2 µl DNase per µg RNA, in the presence of 10X DNase buffer and incubating at 37°C for 2h. DNase-treated RNA was cleaned up using the RNeasy Plant Mini Kit following the RNeasy Mini Protocol for RNA Cleanup (RNeasy Mini Handbook 06/2001, pages 79-81).

To synthesise cDNA from the above RNA the following reaction mixture was prepared: 100ng-1µg of DNA-free RNA, 3µl oligo (dT) (100 ng/µl), and DEPC-treated water to a total volume of 42 µl. Samples were incubated in a heat block at 65°C for 5 min after which they were allowed to cool slowly to room temperature. Then 2µl Ultrapure dNTPs, 1µl reverse transcriptase (Stratascript) and 5µl 10X reverse transcriptase reaction buffer (Stratascript) were added. Samples were incubated at 42°C for 1h, denatured at 90°C for 5 min and then cooled on ice.

3.1.2 Production of cDNA constructs

PCR was carried out using the cDNA above to generate cDNA fragments using the primer pair SEQ ID No. 48 (Ox1_for) and SEQ ID No. 49 (Ox3_rev). PCR reactions were carried out using the following reagents and conditions:

PCR Master Mix

10x high fidelity PCR buffer	5 µl
dNTP (clontech: 10mM)	1 µl
$MgSO_4$ (50 mM)	2 µl
nH_2O	37.8µl
Platinum TAQ Polmerase (5U/µl)	0.2µl
Forward primer (Ox1_for: 10 pmol/µl stock)	1µl
Reverse primer (Ox3_rev: 10 pmol/µl stock)	1µl
cDNA	2 µl

PCR Cycle

1) 94° C 5 min
2) 94° C 30 sec
3) 53° C 30 sec
4) 68° C 90 sec
5) 68° C 10 min
6) 8° C Pause

Cycles 2-4 were run 40 times in total. The amplicon was 1269 bp. The PCR products were purified using Qiagen's QIAquick PCR Purification Kit (Qiagen Ltd, Boundary Court, Gatwick Road, Crawley, West Sussex, RH10 9AX, UK) according to the manufacturers instructions. The purified PCR products were examined on agarose gels.

PCR products were ligated into pGEM-Teasy, used to transform Select 96 cells, and sequenced as described in 2.2.4 above. The cDNA sequence obtained is given as bases 115 – 1385 of SEQ ID No. 2.

3.2 RACE

To determine the 5' and 3' ends of the genes, RACE (Rapid Amplification of cDNA Ends) was carried out, using the GeneRacer™ Kit (Invitrogen; cat. No. L1502-01), essentially as per manufacturers instructions.

3.2.1 Preparation of RNA

A. fumigatus biomass was prepared as described in 2.2.2. RNA was prepared using the FastRNA kit (QBIOgene) following the manufacturer's instructions (Revision 6030-999-1J05) with the following amendments: At step 1 40 mg of biomass was used per extraction; At step 2, samples were processed for 20 seconds at speed 5, incubated on ice for 3 minutes, and processed again for 20 seconds at speed 5; At step 3 samples were centrifuged for 5 minutes; At step 5, 500 µl DIPS were added, mixed, and incubated at room temperature for 2 minutes. Samples were mixed again and incubated for a further 2 minutes; At step 6 two washes in 250 µl SEWS were carried out; At step 7, the pellet was disolved in 50 µl SAFE buffer.

3.2.2 RACE

1 µg total RNA prepared as described above was de-phosphorylated in a 10 µl reaction using 10 units of calf intestinal phosphate (CIP), 1 µl 10X CIP buffer and 40U RNaseOut™ (made up to 10 µl in DEPC water) at 50°C for 1 hour. Samples were then made up to 100 µl with DEPC water and the RNA extracted with 100 µl (25:24:1) phenol:chloroform: isoamyl alcohol. RNA was then precipitated by the addition of 2 µl mussel glycogen (10mg/ml), 10 µl 3M sodium acetate, pH 5.2 and 220 µl 95% ethanol and the sample frozen on dry ice for 10 minutes. RNA was pelleted by centrifugation at 14,500 rpm for 20 minutes at 4°C, washed with 70% ethanol, air dried and re-suspended in 8 µl DEPC water.

De-phosphorylated RNA (7 µl) was de-capped in a 10 µl reaction with 0.5 U tobacco acid pyrophosphatase (TAP), 1 µl 10x TAP buffer and 40U RnaseOut™ for 1 hour at 37°C. RNA was extracted with phenol:chloroform and precipitated as above, and then re-suspended in 7 µl DEPC-treated water.

De-phosphorylated, de-capped RNA (7 µl) was added to the pre-aliquoted GeneRacer™ RNA Oligo (0.25 µg) and incubated at 65°C for 5 minutes. A 10 µl ligation reaction was then set up by the addition of 1 µl 10x ligase buffer, 1 µl 10mM

ATP, 40U RnaseOut™ and 5U T4 RNA ligase and incubated at 37°C for 1 hour. RNA was extracted and precipitated as described previously and re-suspended in 11 µl DEPC-treated water.

First-strand cDNA was prepared by the addition of 1 µl GeneRacer™ Oligo dT primer and 1 µl dNTP mix (10mM each) to 10 µl ligated RNA and incubated at 65°C for 5 minutes. The following reagents were added to the 12 µl ligated RNA and primer mix; 4 µl 5x first strand buffer, 2 µl 0.1M DTT, 1 µl RNaseOut™ and 1 µl SuperScript™ II RT (200U/µl) and incubated first at 42°C for 50 minutes and then, to stop the reaction, at 70°C for 15 minutes. 2U RNase H was added to the reaction mix and incubated at 37°C for 20 minutes.

To amplify the 5'cDNA ends a 50 µl PCR reaction was set up using 1 µl of the RACE-ready cDNA prepared above, 1 µl GeneRacer™ 5' primer, 1 µl reverse gene-specific primer (SEQ ID No. 50; Ox6race_rev: 5 pmol/µl stock), 1 µl dNTP solution (10mM each), 2 µl 50 mM $MgSO_4$, 5 µl High Fidelity PCR buffer, 0.5 µl Platinum® *Taq* DNA Polymerase High Fidelity (5 U/µl) and 38.5 µl sterile water. Cycling parameters are given in Table II below.

A second, nested PCR stage was then set up using 1 µl of the RACE cDNA from the first stage above, 1 µl Nested 5' primer (supplied with kit), 1 µl reverse gene-specific primer (SEQ ID No. 50; Ox6race_rev: 5 pmol/µl stock), 1 µl dNTP solution (10 mM each), 2 µl 50 mM $MgSO_4$, 5 µl High Fidelity PCR buffer, 0.5 µl Platinum® *Taq* DNA Polymerase High Fidelity (5 U/µl) and 38.5 µl sterile water. Cycling parameters are given in Table II below.

To amplify 3' ends a 50 µl PCR reaction was set up using 1 µl of the RACE-ready cDNA prepared above, 1 µl GeneRacer™ 3' primer (10 µM), 1 µl forward gene-specific primer (SEQ ID No. 51; Ox7race_for: 5 pmol/µl stock), 1 µl dNTP solution (10 mM each), 2 µl 50 mM $MgSO_4$, 5 µl High Fidelity PCR buffer, 0.5 µl Platinum® *Taq* DNA Polymerase High Fidelity (5 U/µl) and 38.5 µl sterile water. Cycling parameters are given in Table II below:

A second, nested PCR stage was then set up using 1 µl of the 3' RACE cDNA from the first stage above, 1 µl Nested 3' primer (supplied with kit), 1 µl reverse gene-specific primer (SEQ ID No. 52; Ox8race_for: 5 pmol/µl stock), 1 µl dNTP solution (10mM each), 2 µl 50 mM $MgSO_4$, 5 µl High Fidelity PCR buffer, 0.5 µl Platinum®

Taq DNA Polymerase High Fidelity (5U/μl) and 38.5 μl sterile water. Cycling parameters are given in Table II below.

Table II. Cycling parameters for 5' and 3'RACE

5' and 3' RACE			Nested PCR		
94 °C	2min	1 cycle	94° C	2 min	1 cycle
94 °C	30s	5 cycles	94° C	30 sec	25 cycles
72 °C	1min		67° C	30 sec	
			68° C	1 min	
94 °C	30s	5 cycles			
70 °C	1min				
			68° C	10 min	1 cycle
94 °C	30s	25 cycles	8° C	Hold	
64 °C	30s				
68 °C	1min				
68 °C	10min	1 cycle			
8 °C	Hold				

5' and 3' RACE confirmed the predicted 5' ATG and 3' stop codon as well as giving the 5' and 3' untranslated regions shown as bases 1-114 and 1385 – 1921 of SEQ ID No. 2. The coding sequence for 2031 OR thus determined was identical to that given as bases 299-469 and 520-1618 of the gDNA gien as SEQ ID No. 1.

Example 4. Identification of other fungal 2031 ORs and related genes

Homologs of *A. fumigatus* 2031 OR were identified in other fungi and bacteria by means of bioinformatics analysis. Sequences identified by bioinformatics can be used to design primers which in turn can be used in PCR to generate DNA coding for the 2031 OR homolog.

Alternatively, degenerate PCR can be used to obtain sequence for novel genes, which can then be used to generate probes for screening cDNA or genomic libraries of the organism of interest to identify clones containing the 2031 OR homolog. As a further alternative, Southern blots using fragments of genes from one species as probes can be used to identify the presence of a homolog in the genome of a second species. The same probe can then be used to screen cDNA or genomic DNA libraries. Once clones corresponding to the novel genes have been identified they can be expressed for functional characterisation of the protein.

4.1 Identification of homologs by bioinformatics

Analysis of the 2031 OR protein sequence with PFAM (http://www.sanger.ac.uk/Software/Pfam/) identified this as a member of the Oxidored FMN family (PF00724), E-value 3.6e-57. This includes the well-characterised "Old Yellow Enzyme" proteins of *S. cerevisiae* and other fungi.

Homologs of *A. fumigatus* 2031 OR sequence were identified by database searches (see Table III). Where necessary, matching contigs were down-loaded and genes predicted from genomic DNA by Genscan analysis, blast searches, alignment and visualisation with Artemis as described in Example 2. Protein and nucleotide multiple alignments were generated for 2031 OR and related genes (Figures 1 and 2).

Protein and nucleic acid multiple alignments are generated by means of programs such as ClustalX (Thompson et al., 1994, Nucleic Acids Research, 22, 4673-4680; Thompson et al., 1997, Nucleic Acids Research, 24, 4876-4882;) and/or using manual alignment editors such as Align (Hepperle, D., 2001: Multicolor Sequence Alignment Editor. Institute of Freshwater Ecology and Inland Fisheries, 16775 Stechlin, Germany).

Table III: 2031 homologs identified by database searches

Contig/EST/ predicted gene	E-value[1]	SEQ ID No.			Species (details of search given in footnotes)
		EST/gDNA	CDNA[2]	Protein	
4929	6.6e-81	4	5	6	*Aspergillus fumigatus*[3]
4951	1.1e-68	7	-	8	*Aspergillus fumigatus*[3]
4875	5.7e-13	-	-	-	*Aspergillus fumigatus*[3]
4961	3.2e-10	-	-	-	*Aspergillus fumigatus*[3]
1.112	3e-33	9	-	10	*Aspergillus nidulans*[4]
6-2431	2.6e-77	11	-	12	*Candida albicans*[5]
6-2464	5.9e-50	13	-	14	*Candida albicans*[5]
6-2460	5.8e-19	-	-	-	*Candida albicans*[5]
A36990	1e-15	-	-	-	*Candida albicans*[6]
NCU07452.1	7e-94	15	-	16	*Neurospora crassa*[7]
NCU08900.1	2e-19	17	18	19	*Neurospora crassa*[7]
NCU04452.1	2e-23	-	-	-	*Neurospora crassa*[7]
MG04569.3	1e-106	20	21	22	*Magnaporthe grisea*[8]
MG03823.3	8e-19	43	-	44	*Magnaporthe grisea*[8]
NP_595868	1e-05	23	-	24	*Schizosaccharomyces pombe*[6]
OYE1	1e-15	-	-	-	*Saccharomyces cerevisiae*[6]
OYE2	4.5e-19	-	-	-	*Saccharomyces cerevisiae*[9]
OYE3	1.0e-16	-	-	-	*Saccharomyces cerevisiae*[9]
FsCon[0063] (EST contig)	1e-82	28	29	30	*Fusarium sporotrichioides*[10]
Gz15771741	5e-76	36	*37*	*38*	*Fusarium graminearum*[10] 0
Mg[0281] (EST contig)	2e-67	39		*40*	*Mycosphaerella graminicola*[10]
CtCon[0249] (EST contig)	1e-55	25	26	*27*	*Colletotrichium trifolii*[10]
FsCon[0458]	1e-42	34		35	*Fusarium*

(EST contig)					*sporotrichioides*[10]
FsCon[0237] (EST contig)	1e-40	31	32	33	*Fusarium sporotrichioides*[10]
Mga0328f	3e-35	41		*42*	*Mycosphaerella graminicola*[10]
T44612	1e-52	-	-	-	*Pseudomonas putida*[11]
NP_625402	1e-79	-	-	-	*Streptomyces coelicolor*[11]
NP_295913	1e-78	-	-	-	*Deinococcus radiodurans*[11]
AF320254	5e-55	-	-	-	*Deinococcus radiodurans*[11]
FG00074.1		82	*82*	*83*	*Fusarium graminearum*[12]
Contig 1.2	1e-71	84	*84*	*85*	*Ustilago maydis*[13]

[1]E-values for blast scores refer to searches with 2031 OR protein unlesss pecified otherwise in footnotes.

[2]A cDNA was generated in cases where either the gene contains multiple exons, or there are probable frame-shift errors from sequencing of the EST, or the EST given is the non-coding strand.

[3]Search of the *A. fumigatus* genome at http://www.TIGR.org (tblastn) with NP_595868.

[4]Search of *A. nidulans* genome held on local machine (tblastn).

[5]Search of the *C. albicans* genome at http://www-sequence.stanford.edu/group/candida/ (blastp).

[6]Search of the non-redundant protein sequence database (nr) at http://blast.genome.ad.jp (blastp).

[7]Search of the N. crassa predicted proteins at http://www.broad.mit.edu/annotation/fungi/neurospora/ (blastp).

[8]Search of the *M. grisea* predicted proteins at http://www.broad.mit.edu/annotation/fungi/magnaporthe/ (blastp).

[9]Search of *S. cerevisiae* orf proteins (http://mips.gsf.de/cgi-bin/blast/blast_page?genus=yeast)

[10]Search of COGEME pathogenic fungal EST database at http://cogeme.ex.ac.uk/blast.html (tblastn, max E-val=0.1).

[11]Search of NCBI non-redundant protein database on local machine with SEQ ID No. 1 (blastx). Only a selected set of hits against bacterial proteins are shown.

[12]Search of *F. graminearum* predicted proteins held on local machine (blastp).

[13]Search of *U. maydis* contigs held on local machine (tblastn).

To clarify the relationships between the 2031 OR, OYE and the hits identified from blast searches, phylogenetic analysis was carried out. The PHYLIP suite of programs was used (Felsenstein, Felsenstein, J., 2002. PHYLIP (Phylogeny Inference Package) version 3.6a3. Distributed by the author. Department of Genome Sciences, University of Washington, Seattle). The multiple alignment used for the analyses was essentially that given in Figure 1 with partial sequences, gapped regions and unreliably aligned sections excluded. A distance matrix was generated using PROTDIST with the Jones-Taylor-Thornton model and the tree inferred using FITCH with global rearrangements and 10 jumbles of input order. 100 bootstrap replicates were generated using SEQBOOT, distance matrices generated using PROTDIST as above, trees inferred using NEIGHBOUR, and then bootstrap values and the consensus tree were calculated using CONSENSE. Trees were viewed using TREEVIEW (Page, 1996 Page, R. D. M., 1996. TREEVIEW: An application to display phylogenetic trees on personal computers. *Computer Applications in the Biosciences* 12, 357-358.)

Phylogenetic analysis identified a clade supported by good bootstrap values, which included *A. fumigatus* 2031 OR and other enzymes. This could be distinguished from a clade containing OYE enzymes which was also supported by good bootstrap values. Bacterial homologs of both 2031 OR and OYE (not shown) were also identified. We have therefore identified a set of 2031 OR homologs which, surprisingly, is distinct from the well-characterised OYE family, and which, by virtue of the essentiality demonstrated for *A. fumigatus* 2031 OR, represents a set of potential targets for anti-fungal drugs

4.2 Identification of homologs by degenerate PCR

4.2.1. Preparation of genomic DNA from organism of interest

Fungal cultures are prepared using methods suitable for particular species. For example, Aspergillus and Candida species, *Cryptococcus neoformans, Fusarium solani* and *Trichophyton* species are maintained on Sabouraud dextrose agar at 30-35°C; *Leptosphaeria nodorum* on Malt agar medium (30 g/L malt extract; 15 g/L Bacto-agar, pH 5.5), 24.0°C; *Magnaporthe grisea* on Oatmeal agar (6.7 g/L agar, 53.3 g/L instant oatmeal) 25.0°C, or Cornmeal agar (Difco 0386), 26.0 C; *Phytophthora capsici* cultures were maintained on on V-8 agar at 24°C; *Pyricularia oryzae* cultures were maintained on rice polish agar at 24°C under white fluorescent lights (12hr artificial day), and were subcultured every 7 - 14 days by the transfer of mycelial plugs to fresh plates; *Pythium ultimum* cultures were maintained on PDA at 24°C, and subcultured every 7 days by the transfer of aerial mycelium to fresh plates with an inoculating needle; *Rhizoctonia solani* cultures were maintained on PDA at 24°C under fluorescent lights (12 h artificial day), and subcultured every 7 days by the transfer of mycelial plugs to fresh plates; *Ustilago maydis* cultures were maintained on PDY agar at 30°C in the dark, and subcultured by re-streaking.

Genomic DNA was prepared from cultures using standard methodologies, e.g. using the Qiagen DNeasy Plant Kit, or using methods described in Example 2.2.

4.2.2 PCR

Primers (SEQ ID Nos. 53 and 54) were designed on the 2031 OR-specific regions given as regions 2 and 6 in Figure 2. However, those skilled in the art will appreciate that it may be necessary to try alternative primers. PCR reactions using the above primer pair are set up as follows:

12.5 µl 2x ReddyMix PCR mastermix (ABIgene)
1 µl primer SEQ ID No. 53 (5 pmol)
1 µl primer SEQ ID No. 54 (5 pmol)
template gDNA (1.5-4 µg/ml)
nuclease-free water to give a final volume of 25 µl

The reactions are run using the following conditions on a Biometra personal PCR cycler (Thistle Scientific Ltd, DFDS House, Goldie Road, Uddington, Glasgow, G71 6NZ):-

Step1	95°C	5min
Step2	95°C	1min
Step3	53°C	1min 30sec
Step4	68°C	2min 30sec
Step5	72°C	10min
Step6	4°C	Hold

30 cycles of steps 2-4 are carried out. The PCR products are purified (to remove residual enzymes and nucleotides) using Qiagen's QIAquick PCR Purification Kit (Qiagen Ltd, Boundary Court, Gatwick Road, Crawley, West Sussex, RH10 9AX, UK) according to the manufacturers instructions and eluted into 40µl of sterile water (BDH molecular biology grade/filter sterile). The purified PCR products are examined on 1% agarose gels.

Those skilled in the art will appreciate that degenerate PCR may require variations in a number of parameters in the attempts to generate a product. These include primer concentration, template concentration, concentration of Mg^{2+} ions, elongation and annealing times, and annealing temperature. Variations in temperature can be accomodated by the use of a gradient PCR machine.

The purified PCR products are cloned into pPEM-Teasy (Promega) and then transformed into XL10-Gold® Kan ultracompetent *E. coli* cells according to the manufacturer's instructions. The transformation reactions are then plated onto LB agar plates containing ampicillin (100 µg/ml), 50 µl X-gal (4%) and 10 µl IPTG (100 mM). Following overnight incubation at 37°C, individual white colonies from each transformation are sub-cultured into LB broth containing ampicillin (100 µg/ml). After overnight incubation at 37°C with shaking, plasmids are extracted using Qiagen spin mini plasmid extraction kits according to the manufacturers instructions and sent away for full-length sequencing.

4.3 Identification of homologs by Southern Blotting

4.3.1 Digestion of genomic DNA and transfer to nylon membranes

Genomic DNA from the fungi of interest are digested with the appropriate restriction enzyme and run on 0.8 % agarose gel. The gel is then submerged in 250 mM HCl for no more than 10 mins, with shaking, at room temperature, after which the gel is rinsed with sterilised RO water.

Transfer of the DNA onto nylon membrane is carried out using 0.4 M NaOH. Transfer protocols and apparatus are well known and are described in e.g. Sambrook et al., (1989), Molecular Cloning, 2nd Edition., Cold Spring Harbor Laboratory Press. After transfer, the DNA is fixed to the membrane by baking at 120°C for 30 min. The membrane can then be used immediately, or stored dry for future use.

4.3.2. Preparation of probe

Probes are generated either by restriction digests of DNA or by PCR of an appropriate region. A suitable probe can be generated by PCR using the primer pair SEQ ID Nos. 53 and 54, *A. fumigatus* genomic DNA, and the methods give in 4.2.2.

1 µg DNA template is diluted in molecular biology water to a total volume of 16 µl, denatured in a boiling water bath for 10 mins, and quickly chilled on ice. 4 µl DIG-High Prime (1 mM dATP, 1mM dCTP, 1mM dGTP, 0.65 mM dTTP, 0.35 mM alkali-labile-digoxygenin-11-dUTP, 1 U/µl labelling grade Klenow enzyme, 5 x reaction buffer, in 50% (v/v) glycerol) is then added and the reaction incubated at 37°C for 20 hours, after which 2 µl of 200 mM EDTA pH 8.0 is added to terminate the labelling reaction. The labelling efficiency is estimated by comparison with DIG-labelled control DNA.

4.3.3.Prehybridisation and Hybridisation

The membrane is placed in a hybridisation tube containing 20 ml of prehybridisation solution (DIG Easy Hyb, Roche) per 100cm² of membrane surface area and prehybridised at 42°C for 2 hours in a hybridisation oven. The DIG- labelled probe is denatured by heating in a boiling water bath for 10 min and then chilled directly on

ice. The probe is then diluted to ~200 ng/mL in hybridisation solution (Easy Hyb, Roche; at least 5 mL of hybridisation solution is required per hybridisation). The prehybridisation solution is discarded from the hybridization tube and the hybridisation solution containing the DIG-labelled probe added quickly. The hybridisation then proceeds overnight at a 42°C in the hybridisation oven. The optimum temperature is dependant on probe size and homology with target sequence and was determined empirically.

After hybridisation, the membrane is washed twice at 42°C, 5 mins per wash, with 50 mL of stringency wash solution (3 x SSC, 0.1% SDS; where 20 x SSC buffer is 3 M NaCL, 300mM sodium citrate, pH 7.0), followed by two washes at RT, 15 min per wash, in 50 mL stringency wash solution. The stringency of these washes can be decreased by increasing the SSC concentration to 6 x SSC, 0.1% SDS and/or decreasing the wash temperatures.

4.3.4. Detection

The membrane is washed in 20 mL washing buffer (100mM Maleic acid, 150 mM NaCl; pH 7.5; 0.3% v/v Tween 20), and then incubated successively with the following; 20 mL blocking solution (1 % w/v blocking reagent for nucleic acid hybridisation, Roche, dissolved in 100mM maleic acid, 150 mM NaCl, pH 7), for 30 min at room temperature; Anti-DIG-alkaline phosphatase (Roche) diluted 1:5,000 in blocking buffer, 30 min at room temperature; Washing buffer, two washes each of 15 min at room temperature; Detection buffer (100 mM Tris-Hcl, 100 mM NaCl; pH 9.5), 2 min at room temperature. The membrane is then removed, placed on top of an acetate sheet, and ~ 0.5 ml (per 100cm²) of CSPD or CDP-star added to the top of the membrane. A second sheet of acetate is then placed over the surface of the membrane, the assembly incubated for 5 min at room temperature and then sealed in a plastic bag. The assembly is then exposed to X-ray film for between 15 min and 1 hour. Optimal exposure time is determined empirically by increasing exposure time up to 24 hours.

The presence of a band on the gel is evidence of a gene in the genomic DNA of interest. The molecular weight of the band depends on the size of the restriction fragment that contains the gene.

Example 5. Expression during infection of wax moth larvae (*Galleria melonella*) and mice with *A. fumigatus*

5.1 Preparation of cDNA from infected wax-moth larvae

Wax moth larvae have been shown to be good model systems in which to study *Candida* infection (Cotter et al., 2000, FEMS Immunol Med Microbiol 27, 163-9; Brennan et al., 2002, FEMS Immunol Med Microbiol 34, 153-7). We have found that this insect system is also a good system in which to study Aspergillus infection (D. Law and J. Rooke, manuscript in preparation).

5.1.1 Growth and infection of wax-moth larvae

Spores of *A. fumigatus* (AF293), grown on Sabaraud Dextrose agar, were harvested and re-suspended in PBS/Tween 80. Spores were washed and the concentration adjusted such that a 10 µl inoculum will cause death in 90% of the test group 3-4 days after infection (for AF293 this is 5.0-7.0x10^8 cfu/ml). Inoculum concentration was estimated using an improved Neubauer haemocytometer counting chamber and confirmed by TVC enumeration.

Wax moth larvae were purchased from Livefood UK, Somerset, UK (www.livefood.co.uk), and were maintained in the dark at room temperature in wood shavings prior to infection. Healthy larvae (250 mg +/- 50 mg) were selected and incubated at 4°C for 10 minutes immediately prior to infection to immobilise them. Larvae were then injected through the cuticle of the left last pro-leg with 10 µl spore suspension (100x stock), using a sterile Hamilton syringe. Larvae were then transferred to a sterile Petri dish. The following controls were also established: Larvae injected with 10 µl PBS/Tween only; larvae injected with 10 µl heat killed spores (killed by incubation for 20 min 100°C); larvae pierced but not injected; and untouched larvae. Larvae were incubated at 30°C and monitored at least twice daily. All treatments and controls were carried out on batches of 10 larvae. Larval deaths and general health condition was recorded every 24 hrs and dead or moribund larvae were removed from the test group.

5.1.2 Preparation of DNA-free RNA from Aspergillus fumigatus-infected wax moth larvae (Galleria melonella).

cDNA was prepared from the following sources: Uninfected larvae; larvae after 48h infection with *A. fumigatus* (early infection); larvae after 72h infection with *A. fumigatus* (late infection); larvae infected with heat-killed *A. fumigatus* spores; and *A. fumigatus* grown in Sabaraud Dextrose agar broth for 16hr.

Frozen larvae were ground to a fine powder under liquid nitrogen in a mortar and pestle previously baked at 22°C overnight, treated with RNaseZAP, rinsed with DEPC-treated water (0.1% (v/v) DEPC, stirred for 1h and autoclaved for 1h) and cooled with liquid nitrogen. Ground sample was transferred to Eppendorf tubes (no more than 50 mg per tube) and total RNA extracted using the Qiagen RNeasy Plant Mini Kit following the protocol for isolation of total RNA from filamentous fungi in the RNeasy Mini Handbook (06/2001, Pages 75-78, http://www.qiagen.com/literature/handbooks/rna/rnamini/1016272HBRNY_062001WW.pdf).

The following modifications were used: At step 3, 600 µl RLT was added to each 50 mg tissue and vortexed; At step 4, samples were centrifuged for 3 min at maximum speed; At step 6, all samples from the same tissues were applied to the same RNeasy column; At step 7, RNeasy column was incubated for 5 min at room temperature after addition of RW1; Optional step 9a was carried out twice; At step 10, 30 µl RNase-free water was added, samples incubated for 10 min at room temperature, and then centrifuged for 1 min at 14,000 RPM; At step 11, the elution step was repeated to give a total volume of 60 µl RNA. A sample of the RNA was run on a 1.5% agarose gel and the amount of RNA quantified using the molecular marker. RNA was then stored at -80°C.

A portion of the RNA was Dnase treated using 2 µl RNase-free DNase (Promega) per µg RNA, in the presence of 10X DNase buffer (Promega) at 37°C for 4h. The RNA was then cleaned up using the Qiagen RNeasy Plant Mini Kit following the RNeasy Mini Protocol for RNA Cleanup (RNeasy Mini Handbook 06/2001, pages 79-81), but including a further DNase treatment step during clean-up as in the Rneasy handbook.

The following modifications were made: Optional step 5a was carried out; At step 6, 30µl RNase-free water was added, samples incubated for 10 min at room temperature and then centrifuged for 1 min at 14,000 RPM; At step 7, the eluate from step 6 was transferred onto the RNeasy column, incubated for 10 min at room temperature, and then centrifuged for 1 min at 14,000 RPM. A sample of the DNase-treated RNA was run on an agarose gel, quantified and stored at -80°C.

5.1.3 Checking RNA samples for DNA contamination

To verify the absence of genomic DNA from the RNA samples, PCR was carried out using primers that amplify the β-tubulin gene (SEQ ID Nos. 77 and 78). In the absence of a reverse-transcription step, only gDNA will be detected and thus any gDNA contamination will be revealed. The following reaction mixture was set up:

12.5 µl 2x ReddyMix PCR mastermix (ABIgene)
1 µl each primer (5 pmol)
template gDNA (1.5-4 µg /ml)
nuclease-free water to give a final volume of 25 µl

The reactions were run using the following conditions on a Biometra personal PCR cycler (Thistle Scientific Ltd, DFDS House, Goldie Road, Uddington, Glasgow, G71 6NZ):-

Step1	95°C	5min
Step2	90°C	1min
Step3	51°C	1min
Step4	68°C	1min
Step5	68°C	10min
Step6	4°C	Hold

40 cycles steps 2-4

If a PCR product was observed, genomic DNA was present and the sample was DNase-treated again. If the PCR was negative, no DNA was present in the sample.

5.1.4 Preparation of cDNA

300 µg DNA-free RNA and 3 µl oligo (dT) (100 ng/µl) were added to an RNase-free 0.5 ml microcentrifuge tube, and made up a total volume of 42 µl with DEPC-treated water. Samples were mixed and incubated in a heat block at 65°C for 5 min and then slowly cooled to room temperature. 2 µl Ultrapure dNTPs (10 mM each, Clontech), 1 µl stratascript reverse transcriptase (Stratagene) and 5 µl 10X reverse transcriptase reaction buffer were then added. The samples were incubated at 42°C for 1h, denatured at 90°C for 5 min and then cooled on ice. Samples were dispensed in 5-10 µl aliquots and stored at -20°C.

5.2. Preparation of cDNA from infected mice

5.1.1 Infection of mice with A. fumigatus and extraction of tissues.

Mice were infected with *Aspergillus fumigatus* and organs harvested as follows. Thirteen male CD1 mice were injected with the immunosuppressant cyclophosphamide (0.025 g/ml; 200 mg/kg) IV via the tail vein. After 72 hours, twelve mice were injected with 0.15 ml *Aspergillus fumigatus* AF293 conidia (7.5×10^5/ml). 11 hours after infection, four mice were sacrificed with an overdose of inhaled halothane. The brain, lungs, liver and kidney were removed, frozen by immersion in liquid nitrogen, and stored at –70°C. A further four mice were also sacrificed at 24 and 48 hours after infection.

RNA was prepared from mouse tissues as described for wax moth larvae above (5.1.2 and 5.1.3).

5.2.2 Preparation of cDNA from DNA-free RNA.

cDNA was prepared from DNA-free RNA using the Promega Reverse Transcription kit, following the protocol as supplied with the product (Technical Bulletin No. 099, http://www.promega.com /tbs/tb099/tb099.pdf). In a modification to the protocol, the cDNA synthesis reaction was incubated for 60 min at 42°C rather than for the suggested 15 min. Samples were stored in 5-10µl aliquots at -20°C.

5.3 Design and optimisation of primers

Primers were designed against the 2031 OR cDNA sequence using Beacon Designer 2.1 (Premier Biosoft, http://www.premierbiosoft.com) with the following parameters;

Target Tm = 58 ± 8°C; Length of primers = 16-24; Amplicon length = 75-150 bp. All other settings were default. Care was taken to choose primers that would not form dimers or other secondary structures. Secondary structures of amplicons were calculated using mfold (http://www.bioinfo.rpi.edu/applications/mfold/old/dna/form1.cgi) and primer sets giving an amplicon with little or no secondary structure were chosen. The resulting primers are given as SEQ ID Nos. 79 and 80.

To determine optimum annealing temp for the primer set, a gradient PCR was run on an Icycler PCR machine (Biorad), using *A. fumigatus* AF293 genomic DNA as a template and the following reaction mixture:

112.5 µl Abgene PCR Reddymix
9 µl SEQ ID No. 79; OXRED 2031F6 (5 pm/µl)
9 µl SEQ ID No. 80; OXRED 2031R5 (5 pm/µl)
85.5 µl H_2O
9 µl AF293 gDNA (10 ng/ul)

For the negative control, the gDNA was omitted and the amount of water increased correspondingly.

For each mix, 25 µl was pipetted into 8 wells on a multiwell plate, and each well run at a different temp (between 50 and 65°C) with the following conditions:

Step1. 95°C – 5 min
Step2. 95°C – 1 min
Step3. Gradient 50-65°C – 1.5 min
Step4. 72°C – 1 min
Step5. 72°C – 10 min
Step6. 8°C – hold

Steps 2-4 were run for 30 cycles

The PCR products were run on a 2% agarose gel. A single band of the correct size of 148 bp was seen on the gel for all the temperatures, and the optimum was found to be 63°C.

5.4 Testing species-specificity of primers

The real-time primers designed above were further tested to ensure that mouse nucleic acid was not amplified using these primers. Four reactions were set up, each containing the following:

12.5 µl Abgene Reddymix
1 µl primer SEQ ID No. 79
1 µl primer SEQ ID No. 80
9.5 µl H2O
and either; 1 µl infected mouse kidney cDNA (50 ngµl; experimental); 1 µl uninfected mouse kidney cDNA (50 ng/µl; uninfected control); 1 µl AF293 gDNA (10 ng/µl; positive control); 1 µl water (negative control).

The following PCR settings were used:
Step1 95°C – 5 min
Step2 95°C – 1 min
Step3 63°C – 1.5 min
Step4 72°C – 1 min
Step5 72° C – 10 min
Step6 8°C – hold
Steps 2-4 were run 40 times

The PCR products were run on a 2% agarose gel. *A. fumigatus* genomic DNA gave a band of 148 bp, the expected size, but no bands were seen in uninfected or infected mouse cDNA. These primers therefore appeared to be specific.

5.5 Real-time PCR to detect expression in infected larvae

PCR reactions were set up using the Biorad iQ SYBR green supermix as follows:

14 µl Primer SEQ ID No. 79
14 µl Primer SEQ ID No. 80
175 µl SYBR mix
133 µl H_2O

Four reactions were set up containing 72 µl of the above mix and either; 3 µl H_2O; 3 µl uninfected larvae cDNA (50 ng/µl); 3 µl AF293 gDNA (5 ng/µl); or 3 µl infected larvae cDNA (50 ng/µl) were added. 3 x 25 µl aliquots of each reaction were aliquoted into an Abgene multiwell plate, the plate sealed with optical sealing tape (Biorad), then placed in a Biorad Icycler real-time PCR machine. Reactions were run with the following conditions:

Step1.	95.0°C	3 min
Step2.	95.0°C	30 sec
Step3.	63.0°C	30 sec
Data collection and real-time analysis enabled.		
Step4.	72.0°C	15 sec
60 cycles of steps 2-4.		
Step5.	95.0°C	30 sec
Step6.	50.0°C	30 sec
Step7.	50.0°C	10 sec

90 cycles of step 7 with setpoint temperature increased by 0.5°C after each cycle starting with cycle 2. Melt curve data collection and analysis enabled.

Results are shown in Tables IV and V. Expression of 2031 OR was demonstrated in both Af293 cDNA (Ct = 25.8) and in infected larvae (Ct = 32.3). Therefore, the message is expressed both in *A. fumigatus* cultures and in *A. fumigatus* from infected

larvae. The negative and uninfected larvae controls give only primer dimers and non-specific products.

Table IV. PCR Quantification Spreadsheet Data for SYBR-490

Well	Identifier	Ct
C08	infected larvae (50ng)	33
C09	infected larvae (50ng)	32.4
C10	infected larvae (50ng)	31.4
D03	Negative	51.3
D04	Negative	N/A
D05	Negative	55.6
H03	uninfected larvae	36.4
H04	uninfected larvae	N/A
H05	uninfected larvae	N/A
H08	*A. fumigatus* gDNA (5ng)	25.8
H09	*A. fumigatus* gDNA (5ng)	26
H10	*A. fumigatus* gDNA (5ng)	25.8

Data Analysis Parameters: Calculated threshold was replaced by the user selected threshold 7.4.; User selected baseline cycles were 2 to 10.

Table V. Melt Curve Analysis Spreadsheet Data for SYBR-490

Well	Well Identifier	Peak ID	Melt Temp
C8	infected larvae (50ng)	C8.1	88.5
C9	infected larvae (50ng)	C9.1	88.5
C10	infected larvae (50ng)	C10.1	88.5
D3	Negative	D3.1	78
D5	Negative	D5.1	81.5
		D5.2	77.5

H3	uninfected larvae	H3.1	81.0
H5	uninfected larvae	H5.1	78.0
H8	*A. fumigatus* gDNA (5ng)	H8.1	89.0
H9	*A. fumigatus* gDNA (5ng)	H9.1	89.0
H10	*A. fumigatus* gDNA (5ng)	H10.1	89.0

Melt Curve Analysis Parameters; Threshold for automatic peak detection was set at 2.64.

5.6 Real-time PCR to detect expression in infected mouse kidney cDNA.

Real-time experiments similar to those described in 5.5 using 1 µl of infected mouse cDNA showed no amplification (data not shown). The experiment was therefore carried out using an increased amount of infected mouse cDNA with the following conditions:

18 µl Primer SEQ ID No. 79
18 µl Primer SEQ ID No. 80
225 µl SYBR mix
99 µl H_2O

Four reactions were set up containing 60 µl of the above mix and either; 15 µl H_2O; 3 µl uninfected mouse kidney (50 ng/µl) + 12 µl H_2O; 15 µl infected mouse kidney – 48h post-infection (50ng/ µl); or 3 µl AF293 cDNA (5ng/µl) + 12 µl H_2O were added. 3 x 25 µl aliquots of each reaction were aliquoted into an Abgene multiwell plate, the plate sealed with optical sealing tape (Biorad), then placed in a Biorad Icycler real-time PCR machine. Reactions were run with the following conditions:

Step1.	95.0°C	3 min
Step2.	95.0°C	for 30 sec
Step3.	63.0°C	for 30 sec

Data collection and real-time analysis enabled.

Step4.	72.0°C	for 15 sec

60 cycles of steps 2-4.

Step5.	95.0°C	for 30 sec
Step6.	50.0°C	for 30 sec
Step7.	50.0°C	for 10 sec

90 cycles of step 7 with setpoint temperature increased by 0.5°C after each cycle starting with cycle 2. Melt curve data collection and analysis enabled.

Expression of *A. fumigatus* AF293 2031 OR was seen in cDNA (Ct = 28.8) but only in 2 of the 3 infected mouse kidney reactions (Ct values = 34.4, 41.2) (Tables VI and VII). The product in the other infected kidney cDNA reaction (well A12) was a primer dimer or a non-specific product (Tm = 81°C on the melt curve), whereas the correct 2031 OR product has a Tm of 88.5°C (Tables VI and VII). The negative and uninfected kidney controls gave only primer dimers and non-specific products.

Table VI: PCR Quantification Data for SYBR-490

Well	Identifier	Ct
A10	infected kidney (250ng)	34.4
A11	infected kidney (250ng)	41.2
A12	infected kidney (250ng)	38
D02	Negative	50.3
D03	Negative	54.6
D04	Negative	46.2
H02	uninfected kidney	52.8
H03	uninfected kidney	54
H04	uninfected kidney	51.8
H10	AF293 (5ng)	28.7
H11	AF293 (5ng)	28.7
H12	AF293 (5ng)	30

Calculated threshold was replaced by the user selected threshold 5.4. User selected baseline cycles were 2 to 10.

Table VII. Melt Curve Analysis Spreadsheet Data for SYBR-490

Well	Well Identifier	Peak ID	Melt Temp
A10	infected kidney (250 ng)	A10.1	88.5
A11	infected kidney (250 ng)	A11.1	88.5
A12	infected kidney (250 ng)	A12.1	81.0
D2	Negative	D2.1	79.0
D3	Negative	D3.1	78.0
D4	Negative	D4.1	78.0
H2	uninfected kidney	H2.1	78.5
H3	uninfected kidney	H3.1	77.5
H4	uninfected kidney	H4.1	90.5
H10	AF293 (5ng)	H10.1	88.5
H11	AF293 (5ng)	H11.1	88.5
H12	AF293 (5ng)	H12.1	88.5

Threshold for automatic peak detection was set at 2.09.

A. fumigatus 2031 OR is therefore clearly expressed during infection of wax moth larvae. 2031 OR is only expressed at a very low level during infection of mouse kidney, since increased amounts of template had to be used to give a signal. The expression during infection suggests that the gene product may be a suitable target for an anti-fungal drug.

Example 6. Expression of recombinant 2031 OR and/or fragments

Recombinant proteins or fragments were expressed to enable detailed study of function and as the starting point for the development of a high-throughput screen for inhibitory compounds.

6.1 Production of cDNA constructs

PCR was carried out using cDNA prepared as described above to generate polynucleotides encoding 2031 OR sequence essentially corresponding to SEQ ID No. 3. PCR reactions were carried out using the following reaction mixture and conditions. All Reagents were present in the KOD kit (Novagen).

2.5 µl 10x PCR Buffer
5 µl dNTPs (2mM)
2 µl $MgSO_4$ (25mM)
1 µl primer A (5 pmol) (SEQ ID No. 55; SL_OxXa30F5)
1 µl primer B (5 pmol) (SEQ ID No. 56; SL-OxXa30R7)
1 µl template cDNA
11.5 µl nuclease-free water
1 µl KOD Polymerase

PCR reactions were run using the following conditions:-

Step1	94°C	5 min
Step2	94°C	1 min
Step3	59.3°C	1 min
Step4	68°C	1 min 30sec
Step5	68°C	10 min
Step6	10°C	Hold

40 cycles of steps 2-4 were carried out and the PCR products were purified using Qiagen's QIAquick PCR Purification Kit (Qiagen Ltd, Boundary Court, Gatwick Road, Crawley, West Sussex, RH10 9AX, UK) according to the manufacturers instructions. The purified PCR products were examined on agarose gels.

cDNA fragments were then cloned in to the pET30 Xa/LIC vector (Novagen), transformed into Nova Blue chemically competent *E. coli* cells, and plated on to a prewarmed kanamycin (+) selection plate. After an overnight incubation at 37° C,

kanamycin-resistant colonies were selected and grown up in kanamycin containing LB medium. Plasmid DNA was isolated using the Plasmid Mini Kit (Qiagen). Confirmation of the presence and correct orientation of the inserts was determined by restriction analysis and sequencing of the construct.

Purified plasmid DNA, which had been confirmed to be of the correct sequence and orientation, was transformed into chemically competent BL21 Star (DE3) One Shot *E. coli* cells and grown overnight at 37° C. 2 ml of an over-night culture were used to innoculate 100 ml of LB, 30 μg/ml kanamycin, and the cultures incubated at 37° C, 220 rpm until the cell density reached an optical density of 0.6 (approximately 3 hours). Expression of the recombinant protein was then induced with IPTG (1mM) for 5 hours.

Bacteria were harvested by centrifugation at 4500 rpm for 10 minutes and the pellets lysed in lysis buffer (10 ml Bugbuster (Novagen), 10 μl Benzonase (Novagen), 0.4 μl lysozyme (Novagen) and 100 μl 1M imadazole for 20 minutes at room temperature. Cells were then spun down at 16000g for 20' at 4° C and the supernatant, containing soluble recombinant protein, removed to a clean tube.

Supernatant was added to prewashed Ni-Nta resin at a concentration of 5-10 mg protein per ml of resin and allowed to bind for 1 hour at 4° C. Protein-resin mix was then poured into a column, washed twice in 4 ml of wash buffer (2.5 ml 1M phosphate buffer pH8 , 6.25 ml 4M NaCl, 1 ml 1M Imidazole pH8, 0.5 ml 10% Tween 20; made up to 50 mls in n.H_2O) and then eluted in 4x 0.5 ml fractions with elution buffer (250 μl 1M Phosphate Buffer pH8, 625 μl 4M NaCl, 1.25 ml 1M Imidazole pH8, 50 μl 10% Tween 20, Made up to 5 mls in n.H_2O). Fractions containing purified protein were detected by SDS-Page and Western blotting using an S-tag HRP conjugate (Novagen). Fractions containing purified recombinant protein were concentrated using YM10 columns (Millipore)

Figure 3A shows the induction of recombinant 2031 OR expression by IPTG over 24 hours. Protein samples were taken at time points, run on an SDS-PAGE gel and stained with coomassie. By 1 hr a band of the correct size was clearly induced compared to the uninduced samples. The amount of protein increased with longer induction times. Figure 3B shows a coomassie stained gel of the purified recombinant 2031 OR. Alternative expression systems can be used for expression in bacteria, such as the glutathione S-transferase or mannose-binding fusion-protein system.

Recombinant fragments of other 2031 ORs can be generated using the primer pairs and templates described in Table VIII, or similar primers and other 2031 OR listed in Table III.

Table VIII. Primer pairs for the recombinant expression of 2031 OR family proteins

Species	Template	Primer A	Primer B
A. fumigatus	SEQ ID No. 2	SEQ ID No. 55	SEQ ID No. 56
A. fumigatus	SEQ ID No. 5	SEQ ID No. 57	SEQ ID No. 58
A. fumigatus	SEQ ID No. 7	SEQ ID No. 59	SEQ ID No. 60
A. nidulans	SEQ ID No. 9	SEQ ID No. 61	SEQ ID No. 62
C. ablicans	SEQ ID No. 11	SEQ ID No. 63	SEQ ID No. 64
M. grisea	SEQ ID No. 21	SEQ ID No. 65	SEQ ID No. 66

Example 7. Oxidoreductase assay and inhibitor screening

7.1 Oxidoreductase assay

The assay for 2031 OR is based on methods described by Abramovitz & Massey (1976, J. Biol. Chem. 251: 5321-5326) and Stott et al. (1993, J. Biol. Chem. 268: 6097-6106) and is based upon the ability of this enzyme to oxidise the pyridine nucleotides NADH and/or NADPH. The peak of absorbance for the reduced form of these cofactors (i.e. NADH and NADPH) is at a wavelength of 340 nm whereas the oxidised forms of the cofactors (i.e. NAD^+ and $NADP^+$) do not absorb at this wavelength. Conversion of NAD(P)H to $NAD(P)^+$ can therefore be monitored spectrophotometrically at a wavelength of 340 nm. A similar assay can be employed for all oxidoreductases that use NADH or NADPH as a cofactor.

Assays were carried out in 96-well plates. To each well was added the following; Recombinant 2031 OR (10-1000 ng); 40 µl of 125-2500 µM NADPH; 1 µL 100 mM cyclohexeneone or other substrate, and the volume made up to 200 µL with 0.1 M potassium phosphate pH 7.0. Samples were incubated at room temperature and absorbance measurements were taken at 340 nm every 30 seconds for 10 min. The change in absorbance was expressed as nmoles NADPH oxidised, using the molar

extinction coefficient of NADPH and NADH at 340nm of 6270 (i.e., a 1M solution has an optical density of 6270 at this wavelength).

Initial experiments with a variety of potential substrates for recombinant 2031 OR showed that the protein had a functional dehydrogenase activity and determined that cyclohexenone was a better substrate than menadione, duroquinone or N-ethylmaleimide. This is illustrated in figure 5. Final concentrations in the assay were as follows: 500 μM substrate, 1 μg/200 μL 2031 OR, 120 μM NADPH .

Although the physiological substrates of 2031 OR remain to be determined, generic oxidoreductase substrates such as ferricyanide, methylene blue, phenazine methosulphate and 2,6-dichlorophenolindophenol may also be used to assay for oxidoreductase activity.

Screens for inhibitors of 2031 OR can be carried out using the assay described above modified by the addition of putative inhibitor substances to the reactions and decreasing the amount of potassium phosphate buffer. Assays can be carried out in 384- or 1536-well plates to increase throughput of the screen.

7.2 High-throughput screen for the identification of 2031 OR inhibitors

2031 OR inhibitors were identified by means of a high-throughput screen. The following reagents were prepared:

Assay plates: Compounds to be tested were dissolved in 100% DMSO (polypropylene vessels), diluted in water and loaded into 384 square well polystyrene plates (10μl/well). The final DMSO concentration in all assay wells was 5%v/v.

ßNADPH (tetrasodium salt)/2-cyclohexen-1-one reagent; Solutions of NADPH (1.2917 mM in 100 mM potassium phosphate buffer, pH7.0) and 2-cyclohexen-1-one (10 mM in 100 mM potassium phosphate buffer, pH7.0) were prepared on the day of the assay and combined in a ratio of 1 part of 2-cyclohexen-1-one solution to 9 parts NADPH solution. Final assay well concentrations for NADPH and 2-cyclohexen-1-one were 465 μM and 400 μM respectively.

2031 OR enzyme: Recombinant enzyme was prepared as described in Example 6 and desalted as follows: 2.5 ml of eluted protein was loaded onto on to a PD10 column (Amersham) equilibrated with 25 ml of 0.1 M KPO_4 pH7. The protein was then eluted with 3.5 ml of 0.1 M KPO_4 pH7. Aliquots of the protein were stored at –80°C. For the

iscreen, protein was typically diluted to 5 to 11.25 µg/ml in 100 mM potassium phosphate buffer, pH7.0.

Stop reagent: 0.4 M NaOH in water.

The Km for 2-cyclohexen-1-one, the substrate for 2031 OR in the screening assay, was determined to be 100 µM. To give an increased signal, the screen was carried out using 2-cyclohexen-1-one at 4 times Km. The kinetics of the screen over the prescribed incubation time were such that reaction progress curves were both linear with time and protein concentration. The Z' value for the screen was equal to 0.77 and thus fully acceptable (Zhang et al., 1999, J. Biomolecular Screening, 4, 67-73). Consistency of signal between wells on plates, plate to plate and screen run to screen run were also acceptable for an HTS regime.

Assays were carried out using Tecan Freedom, Tecan TeMo and PerkinElmer Minitrak robots together with a ThermoLabsystems multidrop 384 and a Tecan Safire automated plate reader. 20 µl of enzyme followed by 20 µl NADPH/2-cyclohexen-1-one solution were added to wells of the microtitre plates containing test compounds. 20 µl of 100 mM potassium phosphate buffer, pH7.0 was used for a duplicate set of plates for background no-enzyme controls; DMSO (diluted in the same way as solubilised compound stocks) was used for no-compound controls. Plates were incubated at room temperature for 30 minutes after which 25 µl of 0.4 M NaOH stop reagent was added. Plates were read at 340 nm on a Tecan Safire plate reader and data processed using 'in-house' created Excel spreadsheets to convert raw data into percent inhibiton data. Secondary screens were carried out to measure dose response data for selected compounds, using essentially the same protocol as the pimary screen. The secondary screen used the Excelfit version 3 software (IDBS), with sigmoidal model 606, to graph appropriate inhibition values and determine IC50 data for compounds tested. Figure 6 shows typical results for 2 inhibitory compounds (A and B) identified by the primary screen and then assayed in the secondary screen.

Identification of the correct stop reagent for the HTS assay was not trivial. Initially, a chemical inhibitor of the system was sought to terminate the reactions in a pH independant manner, but it was found that NaOH offered more benefits than originally anticipated, in that it not only overcame the buffering in the reaction to fully

terminate the reaction, but also afforded a much greater protection for un-reacted NADPH. It is known that high levels of NaOH convert NADP, a product of the reaction which does not absorb at 340 nm, to a fluorescent product, which would interfere with the 340 nm readings taken (Passonneau and Lowry, 1993, Enzymatic analysis, a practical guide, pp.3-21 and p381. 1993 The Humana Press Inc. NJ USA.). Therefore, the NaOH level used in the HTS assay was chosen such that the amount of fluorescence from NADP conversion was reduced to an insignificant level, whilst fully terminating the reaction. The greater stability of the NADPH afforded by the use of NaOH meant that instead of immediate plate readings, plates could be read up to at least 20 hours post reaction termination (no further extended time points were investigated). This was an obvious advantage in that larger screens could be run. Plates stored for spectrophotmetric reading were sealed with self adhesive film and stored in the dark.

Example 8. Method for detecting fungal infection

The sequences described in the invention were exploited to diagnose fungal infections. Samples from patients potentially carrying an infection with *A. fumigatus*, *A. nidulans,* or *C. albicans* or rice leaves or stem potentially infected with *M. grisea,* or of alfalfa infected with *C. trifolii*, or wheat infected with *F. graminearum, F. sporotrichioides*, or *M. graminicola*, or other organisms, are processed to extract DNA using the DNAeasy Tissue kit or QIAamp DNA Blood Mini kit (Quiagen, Crawley, UK), although other DNA preparation methods are available and suitable.

Once DNA has been prepared, PCR reactions are set up as follows:

Reaction mix:

12.5 µl 2x ReddyMix PCR mastermix (ABgene)

1 µl primer A (5 pmol)

1 µl primer B (5 pmol)

5 µl template DNA

5.5 µl nuclease-free water

Suiable primer pairs are given in the table IX below:

Table IX. Primer pairs for PCRs to diagnose fungal infection.

Species	Template	Primer A[1]	Primer B[1]
A. fumigatus	SEQ ID No. 1	SEQ ID No. 67 (94)	SEQ ID No. 68 (286)
A. fumigatus	SEQ ID No. 4	SEQ ID No. 69 (239)	SEQ ID No. 70 (450)
A. fumigatus	SEQ ID No. 7	SEQ ID No. 71 (1097)	SEQ ID No. 72 (1271)
C. ablicans	SEQ ID No. 11	SEQ ID No. 73 (103)	SEQ ID No. 74 (277)
M. grisea	SEQ ID No. 20	SEQ ID No. 75 (385)	SEQ ID No. 76 (620)

Figures in brackets after SEQ ID No. indicate the base in the template at which the primer starts.

Appropriate controls include; (i) template DNA but no primers; primers but no template (negative controls); (ii) cDNA encoding fungal 2031 OR or DNA from cultured fungi instead of patient DNA (positive control).

PCR reactions are run as follows:

Step1	95°C	5 min
Step2	95°C	1 min
Step3	53°C	1 min 30sec
Step4	72°C	1 min 30sec
Step5	72°C	10 min
Step6	4°C	Hold

30 cycles of steps 2-4 are carried out and the PCR products examined on agarose gels. The production of a band of the correct molecular weight is diagnostic of the presence of the particular fungus. It may be additionally necessary to carry out diagnostic restriction digests of the PCR products. If necessary, PCR products are subcloned into a vector, such as pGEM-Teasy (Promega), and sequenced to verify that the PCR products are from the appropriate fungus.

Alternatively, the presence of an infection with *A. fumigatus*, *A. nidulans*, *C. albicans* or *M. grisea*, *C. trifolii*, *F. graminearum*, *F. sporotrichioides* or *M. graminicola*, or other organisms is detected by means of antibodies raised against the

fungal protein. One suitable means is the use of a capture ELISA. Here, microtitre plates are coated with a monoclonal antibody raised against the fungal protein. Then the plates are incubated with diluted patient samples, or appropriate protein extracts of samples (particularly if the samples are biopsies or plant tissues). Plates are then incubated with a polyclonal antibody (again against the fungal protein). Finally, binding of the second antibody was detected by means of an enzyme-coupled or fluorescently-labelled antibody directed against the polyclonal. In practise, two monoclonal or polyclonal antibodies or various combinations may be used.

Example 9. Production of an antibody

Antibodies against the fungal 2031 ORs will be of considerable use as diagnostic reagents (see example 8 above). As an immunogen, recombinant domains are used (as described in Example 6). Alternatively, synthetic proteins encoding regions either unique to the individual 2031 ORs, or likely to provide cross-reactivity within a set of ORs, a set of species, or a range of genera are used. Peptides may need to be conjugated to carrier proteins before immunization.

Preimmune sera from animals to be immunised are screened against the immunogen to ensure that there is no endogenous cross reactivity. Animals (typically sheep, rabbits or mice) are then immunised. For polyclonal antibody production, the resulting sera is affinity purified using the immunogen cross-linked to a chromatography matrix. Alternatively, purification of the antibody fraction from the serum, e.g. using protein G or protein A cross-linked to a matrix, may be sufficient. Monoclonal antibody production proceeded by methods familiar to those skilled in the art.

The specificities of the resulting polyclonal and/or monoclonal antibodies are checked by ELISA and/or western blotting using the immunogen, related constructs or whole cell lysates and extracts as targets. Negative controls, such as other ORs, different constructs or different species are also employed to test specificity and/or to determine the range of species and/or genus cross-reactivity.

Example 10. Production of fungi with 2031 OR genes functionally disabled.

A BAC (bacterial artificial chromosome) clone library containing the *A. fumigatus* genome, partially digested with Bam*HI* and inserted into the vector pBACe3.6 was purchased from the Sanger Centre, Cambridge, UK. The BAC clone containing the gene to be inactivated is identified by bioinformatics (BLAST searching of Sanger BAC and related databases) and the glycerol stock of the clone grown up in 50 ml LB, 20 μg/ml chloramphenicol at 37°C overnight. The overnight culture is centrifuged at 4,500 rpm for 15 min. The bacterial pellet is resuspended in 4 ml of Buffer P1 (Qiagen plasmid miniprep kit) and then 4 ml of buffer P2 (Qiagen plasmid miniprep kit, lysis buffer) is added and mixed gently by inverting 3-6 times. Proteins and genomic DNA are precipitated by adding 4 ml of buffer P3 (Qiagen plasmid miniprep kit, neutralizing buffer) and incubating on ice for 10 minutes. Following the centrifugation of the mixture at 4500 rpm for 30 min, the supernatant is transferred into a 50 ml falcon tube, an equal volume of phenol/chlorophorm (1:1) mixture is added, and the mixture centrifuged for 15 min at 4500 rpm. The supernatant is then transferred into an Oakridge tube and 0.7 volumes isopropanol are added. After mixing, the tube is centrifuged at 10,000 rpm (Beckman centrifuge, rotor JA-17) for 30 min at 4°C. The resulting pellet is washed with 2 ml 70% ethanol at the same speed. The resulting BAC DNA is resuspended in 100 μl buffer EB.

The transposition reaction is carried out as follows. 7 μl purified BAC, 1 μl transposon pZVK2 (an engineered plasmid the sequence of which is given as SEQ ID No. 81), containing the mosaic ends of pMOD2 (Epicenter), a kanamycin resistance gene and a Zeocin resistance gene under the control of fungal promoter) and 1 μl EZ:TN transposase (Epicenter) are incubated at 37°C for two hrs after which 1 μl stop solution (1% SDS) is added and the mixture heated to 70°C for 10 minutes. Electrocompetent GeneHogs *E. coli* cells (Invitrogen) are then transformed with the transposed BAC, the cells plated onto LB agar, 25 μg/ml kanamycin, 20 μg/ml chloramphenicol, and plates incubated overnight at 37°C.

At least 96 colonies are picked and grown up in 96-well plates in 2xLB (double concentrated LB), 20 μg/ml chloramphenicol, at 37°C overnight. BAC DNA is then purified using the Millipore montage 96 BAC KIT using a MWG ROBOSEQ 4200 robot. BACs containing the transposon inserted into the gene of interest are identified

by PCRs both spanning the gene of interest and extending from the transposon into the BAC. Insertion into the gene of interest is manifested as an increase in product size. Southern blots are also carried out to ensure that the transposon has only inserted once into the BAC.

The BAC is then linearised using a restriction enzyme determined to cut in the vector backbone but not the BAC DNA, and used to transform *A. fumigatus* strain Af293. *A. fumigatus* (haploid) protoplasts are prepared using 5% Glucanex (Novo Nordisk A/S) solution (in 0.6 M KCl) and shaking for 2 h at 80 rpm in 30^{o}C . The protoplasts are washed with 0.6 M KCl and then with STC (Sorbitol, Tris, $CaCl_2$). The washed protoplasts are diluted in STC to 10^5/ml and 100 µl transferred into 14 ml falcon tubes. 7 µl of linearised BAC are added to the tube and the whole mixture incubated on ice for 20 min. Transformation is carried out by adding 200 µl of PEG 8000 solution (60%w/v, pH 7.5) drop-wise over 2 min and then adding 800 µl PEG. The mixture is left at room temperature for 20 min. Transformed protoplasts are washed with STC, resuspended in 1 ml STC, spread onto CM-sorbitol- Zeocin (250 µg/ml) plates and incubated at 37 ^{o} C.

After 4-10 days of incubation, zeocin resistant colonies are picked and checked for presence of the knocked-out gene by PCR using primers which specifically amplify the whole gene of interest. Usually 10-20 transformants are checked. The ectopic integration of the BAC gives two bands by PCR, one for the endogenous gene and one for the BAC/transposon construct, which has a higher molecular weight. Replacement of the endogenous gene with the transposon-modified gene results in a single band of higher molecular weigh by PCR. If none of the transformants show the disrupted endogenous gene, the gene of interest may be essential, with the knock-out cells having died and only cells where replacement is unsuccessful surviving. In this case, the transformation is carried out on diploids using the same method of transformation. Essentiality of the gene is then tested by rehaploidisation, and examining the segregation pattern in haploids.

Example 11. Rescue of MycoBank transformant with the 2031 oxidoreductase gene.

11.1 Preparation of the 2031 OR construct

The 2031 OR gene with NheI overhangs was prepared by PCR using the primer pair; SEQ ID No 98 and SEQ ID No. 99.

PCR Reaction: 2.5 µl 10x PCR buffer
0.5 µl dNTPs
2 µl $MgSO_4$
1 µl forward primer (SEQ ID No. 98)
1 µl reverse primer (SEQ ID No. 99)
1 µl gDNA
Made up to 25 µl with n.H_2O

PCR Cycle: (1) 94° C, 5'; (2) 94° C, 1'; (3) 50° C, 1'; (4) 68° C 1'30s; (5) 68° C, 10'; (6) 8° C, Pause; Cycles 2 to 4 were repeated 40 times

The finished amplicon (~1260 bp) was run out on a 1% agarose gel, the appropriate band was cut out and purified using the Qiagen gel extraction kit and eluted off the column in 30 µl H_2O. The amplicon was ligated into pGEM Teasy using the following reaction mixture:

5 µl 2x ligation buffer
1 µl pGEM Teasy vector
either 1, 2 or 3 µl of insert
1 µl T4 DNA ligase
Reaction made up to 10 µl with n.H_2O

The ligation reaction was incubated overnight in the fridge

2 µl of each ligation reaction was transformed by heatshock at 42°C into promega 96 select cells. After transformation, cells were incubated in SOC for 1 h at 37° C, 220 rpm. 50 and 150 µl aliquots were then spread over LB-Amp (100 µg/ml), IPTG-Xgal plates and left at 37° C overnight. Positive clones were identified by blue/white screening and were isolated and screened by PCR for correct insertion of

the 2031 OR insert using the above primers. Positive clones were sent away to MWG for sequence analysis.

11.2 Cloning of 2031 OR into the CbhB-Zeo vector

Plasmid DNA for 2031 OR in pGem Teasy (as described in 11.1) was digested overnight at 37° C with NheI. The 2031 OR insert fragment was then gel purified using the Qiagen gel extraction kit and ligated into CbhB-Zeo vector. This vector was constructed from pUC19 with the *A. fumigatus* CbhB promoter and terminator and the zeocin resistance gene.

Ligation:
- 1 µl of T4 DNA ligase
- 1 µl of 10x ligase buffer
- 1 µl of CbhB vector (linearised and alkaline phoshatase treated)
- 1 µl of insert
- 6 µl n.H_2O

Ligation reaction was left in the fridge overnight.

2 µls of each ligation reaction was transformed by electroporation at 2.5 Kvolts, 200 Ω, 25µF into Genehog cells. After transformation, cells were incubated in SOC for 1 h at 37° C, 220 rpm. 50 and 150 µl aliquots were then spread over LB-Amp (100 µg/ml) plates and left at 37° C overnight. Positive clones were isolated and screened by PCR for the correct insertion of the insert by PCR as above. Positives were sent to MWG for sequence analysis.

11.3 Transformation into Mycobank mutant 2031

The CbhB-Zeo-2031 plasmid was digested with ScaI overnight at 37° C. Linearised plasmid was then run out on a 1% agarose gel and purified using the Qiagen gel extraction kit. Plasmid DNA was eluted in 30 µls of nH_2O.

Mycobank mutant 2031 AF293 spores were swollen for 6 h at 37° C, 300 rpm, centrifuged 3500 rpm, 5' and resuspended in ice-cold nH_2O. Spores were spun

again, 3500 rpm, 5' then resuspended in 12.5 ml of YED medium and incubated for 1h at 30° C, 100 rpm. Spores were then counted and resuspend in EB buffer to a final concentration of $5x10^7$ spores per ml. 50 µl of swollen spores were then transformed with 1-10 µl of linearised CbhB-Zeo-2031 plasmid DNA at 1 Kvolt, 400 Ω, 25 µF. Spores were transferred in to YED buffer and left for 90' at 37° C, 100 rpm. 100 and 200 µl aliquots were then spread out on to CM-Zeocin (200 µg/ml) plates and incubated at 37° C for 2-3 days.

Positive transformants on the CM-Zeo plates were picked into 5 ml of SAB broth and incubated overnight at 37° C, 220 rpm. Biomass was then filtered and collected on to Whatman paper. DNA was extracted using the Fast prep kit and cleaned up over a Qiagen miniprep DNA column. DNA was eluted off column in 30 µl of nH_2O.

PCR Screening was performed using the following primer sets:

Set A: Ox7race_for (SEQ ID No. 51) + CbhBtR (SEQ ID No. 100)

Set B: Ox6race_rev (SEQ ID No. 50) + CbhBpF (SEQ ID No. 101)

PCR Reaction: 12.5 µl 2x Reddy mix
1 µl each primer, from set A or B
1 µl plasmid DNA
Made up to 25 uL with water

PCR Cycle: (1) 94° C, 5'; (2) 94° C, 1'; (3) 56° C, 1'; (4) 72° C 1'30s; (5) 72° C, 10'; (6) 8° C, Pause; Cycles (2) to (4) were repeated 40 times

Positive transformants which were demonstrated to have CbhB-Zeo-2031 in Mycobank mutant 2031 were put through the rehaploidation process to test their ability to grow on hygromycin compared with the untransformed mycobank mutant 2031. We found that the lethal 2031 phenotype was rescued by the insertion of the CbhB-Zeo-2031 plasmid, confirming the essentially of 2031 OR.

The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application

and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.

All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.

Each feature disclosed in this specification (including any accompanying claims, abstract and drawings), may be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features.

The invention is not restricted to the details of the foregoing embodiment(s). The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.

Sequence Listing

SEQ ID No 1

GTTCGACGTCATTGCCACGTTTCGACCCAAGGGCAGACGCCATGTCGCCGAGCGATCGCCGCGATATGCCTCGAATT
TGCGCCATTCGGCATCCAGTTTCCAGTGCCCTTCCCCGAATGACTGTCTCCACTATTCGGCAAGATTGTAAATCAAG
CCTGAAGAAGCGGAGCAATTCTTGGAAGTCGTATGTTCTACTGATTTCTGTGCCTGGCGCAGACGGGTATATAAATA
AAGATCACCGCACCGAGGAGTTTCTTACCAACCCATCAATAACCATCCACAATCTCCTACAACAAAAATGACTGTCG
CCGATATCGACGTTCCTCCTGCCGAGGGCATCCCCTACTTCACTCCGGCCCAGAACCCTCCTGCCGGTACGGCAGCT
AACCCCCAGACCAATGGCCAGAAGATCCCCAAGCTCTTCACGCCCTTGACCATCCGTGGCGTCACCTTCCAGAACCG
CCTTGGTGTAAGTCCGTTTGCCCTTGCTCATATCGACGAAAGCTAATCCCCCGTCAGCTCGCGCCCCTCTGCCAATA
CTCCGCCCAGGACGGCCACATGACCGACTACCACATCGCCCATCTGGGTGGGATCGCCCAACGCGGACCCGGCCTGA
TGCTGATTGAGGCGACCGCCGTCCAGCCCGAAGGCCGCATCACCCCTCAGGATGTCGGTCTGTGGAAGGACTCCCAG
ATCGCCCCGATGCGCCGGGTCATCGACTTCGTGCACAGCCAGGGCCAGAAGATCGGCGTGCAGCTTGCCCATGCCGG
CCGGAAAGCCACCACCGTTGCGCCCTGGATCTCATTCTCGGCCATCGCGACGGAGAAGGTCGGCGGATGGCCGGACC
GCGTCAAAGGGCCCGGCGATATCCCCTTTGCGGAGCCCTTCGCCAAGCCCAAGGCCATGACGCTGGATGAGATCGAG
CAGTTCAAGAAGGACTGGGTGGCGGCCACGAAGCGCGCCATCGCCGCCGGTGCGGACTTTGTCGAGATTCACAATGC
GCATGGATACCTGCTGTCGTCATTCCTCTCGCCGGCCGCCAACAACCGCACGGACCAGTACGGCGGGTCGTTCGAGA
ACCGCATCCGGCTGTCTCTCGAGATTGCGCAGTTGACTCGGGACGCCGTCGGCCCTCATGTGCCCGTTTTCCTGCGC
ATTTCGGCCTCGGACTGGTGCGAGGAGACCCTGCCGGAGCAGAGCTGGAAGTCGGAGGATACCGTGCGGTTCGCGCA
GGAGCTGGTCAAGCAGGGCGCCGTTGATCTGATCGATATCAGCAGCGGTGGTGTTCTCGCGCAGCAGAAGATCAAGT
CCGGCCCTGCCTTCCAGGTGCCTTTTGCCGTGGCCGTGAAGAAGGCCGTCGGCGACAAGCTGCTGGTTGCCGCCGTG
GGTGCCATCACCAACGGCAAGCAGGCGAATCAGATTCTAGAGGAGCAGGATATCGACGTTGCGCTGGTTGGCCGTGG
GTTCCAGAAGGATCCCGGTCTGGCCTGGACGTTTGCTCAGCACCTCGGCGTCGAAATCTCCATGGCCAACCAGATCC
GCTGGGGCTTCACCCGGCGTGGAGGCACCCCGTACATTGATCCTTCGGTGTACAAGCAGTCTATTTTCGATGTATAG
AGTATAGATAGAGTTGAAGATGATACCTCATAGACGATCAATGGACCCTTGCATATTATTTCTCGTCTCCTGCGTAT
GTTCAAGGTATTCACAGTAGCTGCGTCCTCTTAAGTTTCTCCGTCATTCGTTCTATTCTACTCCAATCGCAACGCAT
GGCGACCACGGATCGAGTCGAATTTCTCCGTCGTTCGTATCTGATCAATATAAAAAGCGGGGAATGGCTTGACCCCG
CGCAGAATGTCGATCTCTTCGCAAACTCTCGGTGTATAGGACGCTCAGCAACGATCAAGG

SEQ ID No 2

GTATGTTCTACTGATTTCTGTGCCTGGCGCAGACGGGTATATAAATAAAGATCACCGCACCGAGGAGTTTCTTACCA
ACCCATCAATAACCATCCACAATCTCCTACAACAAAAATGACTGTCGCCGATATCGACGTTCCTCCTGCCGAGGGCA
TCCCCTACTTCACTCCGGCCCAGAACCCTCCTGCCGGTACGGCAGCTAACCCCCAGACCAATGGCCAGAAGATCCCC
AAGCTCTTCACGCCCTTGACCATCCGTGGCGTCACCTTCCAGAACCGCCTTGGTCTCGCGCCCCTCTGCCAATACTC
CGCCCAGGACGGCCACATGACCGACTACCACATCGCCCATCTGGGTGGGATCGCCCAACGCGGACCCGGCCTGATGC
TGATTGAGGCGACCGCCGTCCAGCCCGAAGGCCGCATCACCCCTCAGGATGTCGGTCTGTGGAAGGACTCCCAGATC
GCCCCGATGCGCCGGGTCATCGACTTCGTGCACAGCCAGGGCCAGAAGATCGGCGTGCAGCTTGCCCATGCCGGCCG
GAAAGCCACCACCGTTGCGCCCTGGATCTCATTCTCGGCCATCGCGACGGAGAAGGTCGGCGGATGGCCGGACCCGC
GTCAAAGGGCCCGGCGATATCCCCTTTGCGGAGCCCTTCGCCAAGCCCAAGGCCATGACGCTGGATGAGATCGAGCA
GTTCAAGAAGGACTGGGTGGCGGCCACGAAGCGCGCCATCGCCGCCGGTGCGGACTTTGTCGAGATTCACAATGCGC
ATGGATACCTGCTGTCGTCATTCCTCTCGCCGGCCGCCAACAACCGCACGGACCAGTACGGCGGGTCGTTCGAGAAC
CGCATCCGGCTGTCTCTCGAGATTGCGCAGTTGACTCGGGACGCCGTCGGCCCTCATGTGCCCGTTTTCCTGCGCAT
TTCGGCCTCGGACTGGTGCGAGGAGACCCTGCCGGAGCAGAGCTGGAAGTCGGAGGATACCGTGCGGTTCGCGCAGG
AGCTGGTCAAGCAGGGCGCCGTTGATCTGATCGATATCAGCAGCGGTGGTGTTCTCGCGCAGCAGAAGATCAAGTCC
GGCCCTGCCTTCCAGGTGCCTTTTGCCGTGGCCGTGAAGAAGGCCGTCGGCGACAAGCTGCTGGTTGCCGCCGTGGG
TGCCATCACCAACGGCAAGCAGGCGAATCAGATTCTAGAGGAGCAGGATATCGACGTTGCGCTGGTTGGCCGTGGGT
TCCAGAAGGATCCCGGTCTGGCCTGGACGTTTGCTCAGCACCTCGGCGTCGAAATCTCCATGGCCAACCAGATCCGC
TGGGGCTTCACCCGGCGTGGAGGCACCCCGTACATTGATCCTTCGGTGTACAAGCAGTCTATTTTCGATGTATAGAG
TATAGATAGAGTTGAAGATGATACCTCATAGACGATCAATGGACCCTTGCATATTATTT

SEQ ID No 3

MTVADIDVPPAEGIPYFTPAQNPPAGTAANPQTNGQKIPKLFTPLTIRGVTFQNRLGLAPLCQYSAQDGHMTDYHIA
HLGGIAQRGPGLMLIEATAVQPEGRITPQDVGLWKDSQIAPMRRVIDFVHSQGQKIGVQLAHAGRKATTVAPWISFS
AIATEKVGGWPDRVKGPGDIPFAEPFAKPKAMTLDEIEQFKKDWVAATKRAIAAGADFVEIHNAHGYLLSSFLSPAA
NNRTDQYGGSFENRIRLSLEIAQLTRDAVGPHVPVFLRISASDWCEETLPEQSWKSEDTVRFAQELVKQGAVDLIDI
SSGGVLAQQKIKSGPAFQVPFAVAVKKAVGDKLLVAAVGAITNGKQANQILEEQDIDVALVGRGFQKDPGLAWTFAQ
HLGVEISMANQIRWGFTRRGGTPYIDPSVYKQSIFDV

SEQ ID No 4

atgtcgcaacctgttgtgcctgacatcgagaacaaacccgcgccgggtatctcgtactttactccggcgcaagagcc
gcctgctggcaccgctgctaatcctcagtctgatggatcggcacctcccaagctcttccggccgctttcggtgcggg

gtctgacctttcacaatcgcattggcgtgagtgcagtccaggcaattatgctatccatcctatgcgagcccttgcat
tggaacagccgcttacagggaatgataatgagtagctatcgccactctgccaatactcagccgacgatggacacatg
actccctggcatatggcacatcttggagggattgcccagcgagggccaggattcttgatggtcgaggcaacagcagt
cgaaccggaaggcaggatcaccccgcaggacctgggactatggaaagactcgcagattgagccattgagccgcgtga
tcgagtttgtccacagtcagaaccagcttatcggcgtgcagatcgcacacgcaggtcgcaaggccagcaccgtcgcg
ccatggctctcggccaacgataccgcctccgagaagatgggcggctggccaggccgcgtcaaaggcccgacaaatgt
gcccttcaccgttaagaaccctgtgccgaaggagatgaccaagcaggatatcgaggatctgaagaccgcctgggtgg
ccgctgtcaaacgggctgttaaggccggagccgactttatcgagatccacaatgcgcatggctatcttctgatgtcg
ttcctctcccctgcggtcaacacgagaacagacgagtacggaggcagttttgagaatcgcatccggctcagtctgga
gatcgccaagctcacccgcgaaaatgtgcccaaggatatgcctgtcttcctgcgggtctccgccaccgattggctgg
aggaggtgcagccgaacaagcccagctggcgaggcgtggacactgtccgatttgcgaagatcctggcagaaacgggt
tacgttgacgtgcttgacgtgagcagtggcggcactcattcggagcagcatatccacgcgaagccaggcttccaggc
acccttgctattgccgtcaagaacgccgtcggggacaaactcgcagtggcatcagtgggtatgattgccagcgcgc
atttggccaattccttgttggagaaggacggactggaccttgtgctggttggacgtggcttccagaagaacccgggg
ctggtgtgggcgtgggccgacgagctgaatgtagagatctccatggctaatcagatccgatggggtttctcgcggcg
cggtgctggtccttacctcaggaagaaactcgagaagatataa

SEQ ID No 5
ATGTCGCAACCTGTTGTGCCTGACATCGAGAACAAACCCGCGCCGGGTATCTCGTACTTTACTCCGGCGCAAGAGCC
GCCTGCTGGCACCGCTGCTAATCCTCAGTCTGATGGATCGGCACCTCCCAAGCTCTTCCGGCCGCTTTCGGTGCGGG
GTCTGACCTTTCACAATCGCATTGGCCTATCGCCACTCTGCCAATACTCAGCCGACGATGGACACATGACTCCCTGG
CATATGGCACATCTTGGAGGGATTGCCCAGCGAGGGCCAGGATTCTTGATGGTCGAGGCAACAGCAGTCGAACCGGA
AGGCAGGATCACCCCGCAGGACCTGGGACTATGGAAAGACTCGCAGATTGAGCCATTGAGCCGCGTGATCGAGTTTG
TCCACAGTCAGAACCAGCTTATCGGCGTGCAGATCGCACACGCAGGTCGCAAGGCCAGCACCGTCGCGCCATGGCTC
TCGGCCAACGATACCGCCTCCGAGAAGATGGGCGGCTGGCCAGGCCGCGTCAAAGGCCCGACAAATGTGCCCTTCAC
CGTTAAGAACCCTGTGCCGAAGGAGATGACCAAGCAGGATATCGAGGATCTGAAGACCGCCTGGGTGGCCGCTGTCA
AACGGGCTGTTAAGGCCGGAGCCGACTTTATCGAGATCCACAATGCGCATGGCTATCTTCTGATGTCGTTCCTCTCC
CCTGCGGTCAACACGAGAACAGACGAGTACGGAGGCAGTTTTGAGAATCGCATCCGGCTCAGTCTGGAGATCGCCAA
GCTCACCCGCGAAAATGTGCCCAAGGATATGCCTGTCTTCCTGCGGGTCTCCGCCACCGATTGGCTGGAGGAGGTGC
AGCCGAACAAGCCCAGCTGGCGAGGCGTGGACACTGTCCGATTTGCGAAGATCCTGGCAGAAACGGGTTACGTTGAC
GTGCTTGACGTGAGCAGTGGCGGCACTCATTCGGAGCAGCATATCCACGCGAAGCCAGGCTTCCAGGCACCCTTTGC
TATTGCCGTCAAGAACGCCGTCGGGGACAAACTCGCAGTGGCATCAGTGGGTATGATTGCCAGCGCGCATTTGGCCA
ATTCCTTGTTGGAGAAGGACGGACTGGACCTTGTGCTGGTTGGACGTGGCTTCCAGAAGAACCCGGGGCTGGTGTGG
GCGTGGGCCGACGAGCTGAATGTAGAGATCTCCATGGCTAATCAGATCCGATGGGGTTTCTCGCGGCGCGGTGCTGG
TCCTTACCTCAGGAAGAAACTCGAGAAGATATAA

SEQ ID No 6
MSQPVVPDIENKPAPGISYFTPAQEPPAGTAANPQSDGSAPPKLFRPLSVRGLTFHNRIGLSPLCQYSADDGHMTPW
HMAHLGGIAQRGPGFLMVEATAVEPEGRITPQDLGLWKDSQIEPLSRVIEFVHSQNQLIGVQIAHAGRKASTVAPWL
SANDTASEKMGGWPGRVKGPTNVPFTVKNPVPKEMTKQDIEDLKTAWVAAVKRAVKAGADFIEIHNAHGYLLMSFLS
PAVNTRTDEYGGSFENRIRLSLEIAKLTRENVPKDMPVFLRVSATDWLEEVQPNKPSWRGVDTVRFAKILAETGYVD
VLDVSSGGTHSEQHIHAKPGFQAPFAIAVKNAVGDKLAVASVGMIASAHLANSLLEKDGLDLVLVGRGFQKNPGLVW
AWADELNVEISMANQIRWGFSRRGAGPYLRKKLEKI

SEQ ID No 7
ATGGGTTCCAACGCCTTCCGGTCCCCCGCCGTCACCAAGTCCTCCTCCACCCCCTACTACACTCCCGCCAACAATGG
AGGCGCCGCCCTGCACCCCGACGACCCCACGACCCCTACGCTCTTCCGGCCCTTACAAATCCGCAATGTGACGCTCA
AGAACCGCATCATGGTGTCGCCCATGTGCATGTACTCCTGCGAGTCGGACCCGTCGTCTCCCCACGTCGGCGCCCTA
ACAAACTACCACCTGGCGCATCTGGGCCACCTCGCCCTCAAAGGCGCAGGCCTCGTCTTCATCGAAGCCACCGCCGT
GCAGCCCAACGGGCGCATCTCCCCCAACGACTCGGGCCTCTGGCAGGACGGCACCACCTCGGAACAATTCCTGGGGC
TGAAGCGGGTCGTCGAGTTCATGCACGCACAGGGCGCCAAGGTCGGGATCCAGCTTGCGCATGCGGGCCGGAAAGCG
AGTGCCGTTGCGCCGTGGCTGGCGGCGCAGGCGGGCAAGTCGAGTCTGAAGGCGGATGAGAGCGTTGGCGGGTGGCC
CGCGGATGTGGTGGGTCCGTCGGGCGGGGAGGAGCATATCTTTAGTCCCGAGGAGGATGCGTATTGGGTGCCGCGGG
CGCTGAGCACGGCCGAGGTCCGTCAGGTGGTGGCGGCGTTTGCGAAGAGCGCGCGGCTAGCGGTGCAGGCTGGGGTG
GATGTTATCGAGATCCATGGGGCGCATGGCTATCTCATCAACGAGTTCCTGAGCCCGGTCACGAATAAGCGGACGGA
TGCGTACGGCGGGAGCTTTGAGAACCGGACCCGGATCGTGCGCGAGGTTGCGGCGGCTATTCGTGCGGTGATTCCCG
AGGGGATGCCCCTGTTTCTGCGTATCAGCGCCACGGAGTGGTTGGAGGGTCAGCCGGTGGCCGCGGAGTCGGGCAGC
TGGGATATGCAGAGCTCGCTGGAGCTGGTCAAGAAGCTGCCCGAATGGGGCATTGACCTGGTGGATGTCAGCTCCGC
CGCGAACCACAAGGACCAGAAGATCAACCTGCACACGGCCTACCAGACGGACCTGGCCGGGCAGATTCGCCAGGCCA
TCCGAGCGGCTGGCGCGTCGACTCTTGTGGGTGCTGTAGGTCTGATCACCGATTCGGAACAGGCGAGGGGACTAGTT
CAGGGAGCGGACGAGGCGACTGCAGCCGAGGCAATGCTGTCGGGACCTGAACCCAAGGCGGATGCCATTCTGATAGC
CCGTCAGTTCCTGCGCGAGCCAGAATGGGTGTTTTCCACGGCGAGAAAGTTGGGCGTGCCGGTGACTGTCCCGGTGC
AGTTTGGCAGGGCCATTTAG

SEQ ID No 8

MGSNAFRSPAVTKSSSTPYYTPANNGGAALHPDDPTTPTLFRPLQIRNVTLKNRIMVSPMCMYSCESDPSSPHVGAL
TNYHLAHLGHLALKGAGLVFIEATAVQPNGRISPNDSGLWQDGTTSEQFLGLKRVVEFMHAQGAKVGIQLAHAGRKA
SAVAPWLAAQAGKSSLKADESVGGWPADVVGPSGGEEHIFSPEEDAYWVPRALSTAEVRQVVAAFAKSARLAVQAGV
DVIEIHGAHGYLINEFLSPVTNKRTDAYGGSFENRTRIVREVAAAIRAVIPEGMPLFLRISATEWLEGQPVAAESGS
WDMQSSLELVKKLPEWGIDLVDVSSAANHKDQKINLHTAYQTDLAGQIRQAIRAAGASTLVGAVGLITDSEQARGLV
QGADEATAAEAMLSGPEPKADAILIARQFLREPEWVFSTARKLGVPVTVPVQFGRAI

SEQ ID No 9

ATGGCTCTCCCTGACGTCGAAAACACCCCCGCCGCCGGCATCCCCTACTTTACACCAGCACAGAACCCTCCTGCTGG
AACAGCTGCCAACCCGCAAACCAGCGGCAATGCCGTCCCCAAGCTGTACACACCTCTGACGGTGCGTGGGGTGACCT
TCCACAACAGACTTGGCCTCGCGCCGCTCTGCCAGTACTCCGCAGAAGACGGCCACATGACAGACTACCACATCGCG
CACTTGGGAGGTATTGCCCAGCGCGGCCCCGGTCTCATGATGATCGAGGCAACCTCCGTCTCACCTGAAGGCAGAAT
CACGCCGCAGGACGTCGGTTTATGGAAGGACTCGCAGATTGCGCCCATGAAGCGCGTCATCGACTTCGTGCACTCGC
AGTCCCAGAAGATTGGCGTGCAGATTGCCCACGCCGGCCGCAAGGCTTCGAACATCGCCCCCTGGCTCATGAACAAG
GGCATCGTCGCGACGGAGAAGGTCGGTGGCTGGCCGGATCGTGTGATCGGCCCGTCCACCGTGCCCTTCCACGAGAC
TTTCCCCACCCCCAAGGCCATGACCAAGGACGACATCGAGCAGTTCAAGCGCGACTGGTTTGATGCGTGCAAGCGGG
CCATTGCCGCTGGCGCGGACTTCATCGAGATCCACAATGCCCACGGGTATCTTCTCTCGTCTTTCCTATCACCGTCT
TCCAACACGCGCACCGACGAGTACGGCGGCTCCTTTGAGAACCGCATCCGGCTCTCTCTCGAAATCGCCCAGGTCAC
CCGTGACGCCGTCGGCCCCAACGTTCCTGTTTTTCTCCGTGTCTCCGCGACGGACTGGATCGAGGAGACCCTCCCCG
AGGAATCGTGGAAGCTCTCTGACTCCGTCCGCTTCGCCGAAGCCCTCGCTGCCCAGGGCGCTATTGACCTGATCGAC
GTCTCTTCCGGCGGTGTCCACGCCGCGCAGAAGATCAAGTCCGGGCCGGCTTTCCAGGCTCCCTTCGCTGTGGCTAT
CAAGAAGGCCGTTGGCGATAAGCTCCTTGTTGCGACGGTGGGCACGATCACGAACGGTAAGCAGGCGAACAAGCTGC
TTGAGGAGGAGGGATTGGATGTTGCGCTTGTGGGACGTGGTTTCCAGAAGGATCCCGGTCTGGCGTGGACTTTCGCG
CAGCATCTTGATGTTGAGATTGCGATGGCGAGTCAGATTCGGTGGGGATTCACAAGGCGCGGGGGCACGCCTTATAT
CGACCCCAAAGCTTATAAGGAGAGCATCTTTGAGTAA

SEQ ID No 10

MALPDVENTPAAGIPYFTPAQNPPAGTAANPQTSGNAVPKLYTPLTVRGVTFHNRLGLAPLCQYSAEDGHMTDYHIA
HLGGIAQRGPGLMMIEATSVSPEGRITPQDVGLWKDSQIAPMKRVIDFVHSQSQKIGVQIAHAGRKASNIAPWLMNK
GIVATEKVGGWPDRVIGPSTVPFHETFPTPKAMTKDDIEQFKRDWFDACKRAIAAGADFIEIHNAHGYLLSSFLSPS
SNTRTDEYGGSFENRIRLSLEIAQVTRDAVGPNVPVFLRVSATDWIEETLPEESWKLSDSVRFAEALAAQGAIDLID
VSSGGVHAAQKIKSGPAFQAPFAVAIKKAVGDKLLVATVGTITNGKQANKLLEEEGLDVALVGRGFQKDPGLAWTFA
QHLDVEIAMASQIRWGFTRRGGTPYIDPKAYKESIFE

SEQ ID No 11

ATGACAGTTCCATACCAAGTAAAACCATCAGATGAAATCAAAGGTGCTCCTGAGGTTTCCTATTACACTCCAGAACA
GCCTGTTCCGGCTGGTACTTTTTATCCCCAATCGTCAGATGAAGTTGCTCCCAAAATTTTTCAACCTTTAAAGATTG
GTAAGCTTGCTTTGCCAAACAGAATTGGGGTATCTCCAATGTGTCAATATTCTGCTGATTATAATTTTGAAGCAACT
CCATACCATTTAATCCATTATGGTTCATTAGTGAATCGTGGGCCAGGTATCACCATTGTTGAAAGCACGGCTGTTTC
TCCTGAGGGTGGATTATCACCTCATGATTTAGGAATCTGGAAGGATGAACAAGCAGAGAAATTGAAACCAATTGTCG
ATTACGCTCATTCTCAAAAGCAATTAATTGCCATCCAATTGGGCCATGGTGGTAGAAAAGCTTCTGGTCAGCCCTTA
TTTTTGCACTTGGAACAAGTTGCAGATAAATCTGTCAATGGGTTTGCCGACAAAGCAGTTGCTCCTTCTGCATTGGC
ATTCAGACCAAATGGTAATTTACGTGTTCCTAATGAGTTGACCAAAGATGAAATCAAACGTGTTGTTAAGGATTTTG
GTGCTGCTGCTAGAAGAGCTGTTGAAATCAGTGGCTTTGATGCAGTTGAGATTCATGGTGCTCATGGTTATTTGATT
AATGAGTTCTATAGTCCTATTTCAAACAAGAGAACAGATGAATACGGTGGCAGTTTTGAAAATAGAACCAGATTTTT
AAAGGAAGTTATCGATAGTGTTAAATCAAGTATTCCAAACGATGTTCCAGTGTTTTTGAGAATCTCTGCTGCTGAAA
ATAGTCCTGATCCAGAAGCTTGGACTATTGAAGATTCCAAAAAATTAGCTGACATTTTAGTAGAAAAGGGTATTGCT
TTGGTTGATGTTTCATCTGGTGGTAACGATTATAGACAACCACCAAGATCTGGGATCAGTAAAGAGTTGAGAGAGCC
AATCCATGTTCCGTTGTCTCGTGCAATTAAACAACATGTTGGTGACAAGTTATTGGTCAGTTGCGTTGGTGGGCTTG
AAAAAGATCCTGAATTGCTCAACAAATATTTAGAAGAAGGAACATTTGATCTTGCTTTGATCGGTAGAGGATTTTTA
AGAAATCCAGGTTTGGTATGGGAGTTTGCCGATAAACTTGGTGTTAGACTCCACCAGGCCTTGCAGTTAGGTTGGGG
TTTCTGGCCCAACAAACAACAAATTGTTGATTTGATTGAAAGAACATCTAAATTAGAAGTAAATTAG

SEQ ID No 12

MTVPYQVKPSDEIKGAPEVSYYTPEQPVPAGTFYPQSSDEVAPKIFQPLKIGKLALPNRIGVSPMCQYSADYNFEAT
PYHLIHYGSLVNRGPGITIVESTAVSPEGGLSPHDLGIWKDEQAEKLKPIVDYAHSQKQLIAIQLGHGGRKASGQPL
FLHLEQVADKSVNGFADKAVAPSALAFRPNGNLPVPNELTKDEIKRVVKDFGAAARRAVEISGFDAVEIHGAHGYLI
NEFYSPISNKRTDEYGGSFENRTRFLKEVIDSVKSSIPNDVPVFLRISAAENSPDPEAWTIEDSKKLADILVEKGIA
LVDVSSGGNDYRQPPRSGISKELREPIHVPLSRAIKQHVGDKLLVSCVGGLEKDPELLNKYLEEGTFDLALIGRGFL
RNPGLVWEFADKLGVRLHQALQLGWGFWPNKQQIVDLIERTSKLEVN

SEQ ID No 13

ATGGAAAACAACAATACTATACCGGCATTATTTCAACCCATAAAGATCAGTGACTCGATCACATTACCTAATAGAAT
TGGTGTTTCACCAATGTGCATGTATTCATCGTCACCAACTGACAATCAAGCCACTCTGTTTCATTTTGTTCATTATG
GATCATTTGCTGTACGTGGACCAGCATTAATCATTTTAGAGAGTATCTTTGTGTCCGAAAATTCCGGATTATCCATT
CATGATTTAGGTCTTTGGAATGATGATCAAGCTCACAGTTTACGGAAAATTGTTGATTTTATTCATGATCAAGACGG
AATTTGCTGTATACAATTGAATCACGCTGGGCGAAAGATTGTTGAAGGGGTACCATTCCAACAAATACAACATGGTT
GGCAAGAACATTGTGTGGGGCCATCTACTGAGCCATTTAGTGATTCACACAATACACCACGAGAATTGACTGTTAAT
GAAATAAATTCAATTGTGGAAGACTTTGCCAATGCAGCTTGGCGGGCTGTGGAAATCTCAAAATTCGATGCCATTGA
AATACATTGTGCTAATGGATGTTTAATACACCAATTTTTAAGTAAATTGACAAACAAGAGAGCTGACCAATACGGGG
GCTCATTTGAAAACAGAGTTAGATTTCTTTTACAAATAATTGAGAATATAAAACGAAAGATAGAAACACCGATTTTC
TTAAAGTTTCCAATGTCAGATAATTGTAGTGATCCGGAAGCGTGGTCTACGGAAGATGCATTGAAGTTGGCCGATCT
TGTTATTGATTTAGGAGTAAAGGTGATCGACGTTACATCAGGTGGAAATGTTGCGCATTGCAAATCTAGATATCTAT
TAAATGACGACAAACAACTACCTTCTCAAGTGCCCTTGGCTCGTAAATTGAAAAGCCACATTAGAAACCGATGTTTG
ATCGCATGCAGTGGAGGATTAGATCGAGACATATTTAAACTCGATGAGTTTATTGCTAATGGTGACTTTGATATAGC
ATTGATAGGTAAAGGATTTCTCAAAAACACTGGATTGATCAGCCGTATTGCTGACCAATTGCAAGCACAATTCAGAA
CAGCACCTCAATATAAGTTGGCCTTATCATAA

SEQ ID No 14

MENNNTIPALFQPIKISDSITLPNRIGVSPMCMYSSSPTDNQATLFHFVHYGSFAVRGPALIILESIFVSENSGLSI
HDLGLWNDDQAHSLRKIVDFIHDQDGICCIQLNHAGRKIVEGVPFQQIQHGWQEHCVGPSTEPFSDSHNTPRELTVN
EINSIVEDFANAAWRAVEISKFDAIEIHCANGCLIHQFLSKLTNKRADQYGGSFENRVRFLLQIIENIKRKIETPIF
LKFPMSDNCSDPEAWSTEDALKLADLVIDLGVKVIDVTSGGNVAHCKSRYLLNDDKQLPSQVPLARKLKSHIRNRCL
IACSGGLDRDIFKLDEFIANGDFDIALIGKGFLKNTGLISRIADQLQAQFRTAPQYKLALS

SEQ ID No 15

ATGGCCGACTTCACCCAGAAGAAGACCTCCTCCCCCGCGGCCCCGGGTGTTCCCTTCTACACCCCGGCCCAGGTCCC
CGCCGCCGGCACTCCCCTCCCCTCCACCCCCGGCGATGTCCCTACTCTCTTCACCCCTCTCAAGATCCGTGGTGTTG
AGCTCCAGAACCGCTTCGCCGTTGCGCCCATGTGCACCTACTCTGCCGACGATGGCCACATGACCGACTGGCACCTT
GTCCACCTGGGCTCCTTCGCCCTCCGCGGTGTCCCCCTCACCATCTTCGAGGCCACCGGCGTCCTCCCCAACGGCCG
CATCACCCCCGAGTGCTCTGGTCTCTGGCAGGACTCCCAGATTGCGCCCCTCAAGCGCATCGTCGACTACATCCACT
CCCAGGGCCAGAAGGCCGGTATCCAGCTTGCCCACGCCGGCCGCAAGGCCTCCACCAAGGCCCCCTGGCACTACCAG
CGCGGCAAGAGCGAGCTTGCCGGCCCCGAGCAGGGTGGCTGGCCCGAGAACGTCTGGGCCCCCAGCGCCATCAGCTA
CAACGAGGAGACCTTCCCCTTCCCCAAGGAGATGACCGTCGAGCAGATCCACGAGCTCGTCGAGGCCTGGAAGGCGT
CTGCCCAGCGTGCCCTCAAGGCCGGCTTCGACCTCATTGAGATCCACGCCGCCCACGGCTACCTCATTTCCGAGTTC
TTGAGCCCCATCTCCAACCAGCGTACCGACCAGTACGGTGGCTCCTTCGAGAACCGCACCCGCGTTCTCCGCGAGAT
CATCTCGGCCGTCCGCTCCGTCATCCCCGAGGACATGCCCCTCTTCGTCCGTGTCTCCGCCACCGAGTGGATGGAGT
ACACCGGCCAGCCCTCGTGGGACCTCCAGCAGACCATTGAGCTCGCCAAGATCCTCCCCGACCTCGGCGTCGACCTC
CTCGACGTCTCTTCCGGCGGCAACAACAAGGACCAGAAGATCAACGTCCACACCTACTACCAGATCGACATGGCCGA
GCAGATCCGCGCGGCCGTGCACGAGGCCGGCAAGCAGCTCCTCGTCGGTGCCGTCGGCTTGGTCACCTCGGCTGAGA
TCGCCAAGGAGACCGTCCAGGAGAAGGAGGATGGCAGAGTCACCATCCAGCGCGAGAACGGCGCCAAGACTCGTGCC
GATATGGTCCTTGTTGCCAGGCAGTTCTTGAAGGAGCCCGAGTTCGTCCTCACTGTCGCCGACGAGTTGGGTGTTGA
TGTCAAGGCCCCTGTTCAGTACCTCCGTGGTCCTCTTAGCAGCAGGCCCAAGAAGTTGACCACTGTTCCTTAA

SEQ ID No 16

MADFTQKKTSSPAAPGVPFYTPAQVPAAGTPLPSTPGDVPTLFTPLKIRGVELQNRFAVAPMCTYSADDGHMTDWHL
VHLGSFALRGVPLTIFEATGVLPNGRITPECSGLWQDSQIAPLKRIVDYIHSQGQKAGIQLAHAGRKASTKAPWHYQ
RGKSELAGPEQGGWPENVWAPSAISYNEETFPFPKEMTVEQIHELVEAWKASAQRALKAGFDLIEIHAAHGYLISEF
LSPISNQRTDQYGGSFENRTRVLREIISAVRSVIPEDMPLFVRVSATEWMEYTGQPSWDLQQTIELAKILPDLGVDL
LDVSSGGNNKDQKINVHTYYQIDMAEQIRAAVHEAGKQLLVGAVGLVTSAEIAKETVQEKEDGRVTIQRENGAKTRA
DMVLVARQFLKEPEFVLTVADELGVDVKAPVQYLRGPLSSRPKKLTTVP

SEQ ID No 17

atggctacttccactacctccgacctcaaactctcccaacccctcaccctccccaatggccttaccctccccaaccg
cctcgtcaaagccgccatggccgaacaaatgggcttcggcaaccacctgcccaaccccgaactcgccgccgtctacg
ccacctgggcccgcggcgactggggcctgattctcaccggcaacgtccaagtcgaccacgcgcacaagggcgacgcc
cacgacatcagccccaaccaccccggcaccacgcccgagcagaccgtcacggccttcaaggcctgggcggacgccgc
gcgcctgaatggccagtccaaaacgcctgtggtcgtgcagatcaaccaccctggtcgccagagtccgatgggcgcgg
gcacgcggggactgtgggagaaggcggtggcgccctcgccggtgccgttggtgttgggagaggcgtttgtgcctcgc
ttgttgtcgaaagtgcttttcggcacgccgcgggagctgacggttgcggagatcaaggatatcgtgcaaaagtttgc
ggtgacggcgaggatcacggccgaggccgggttcaatggcgtggagatccatgcggcgcatggatacctgttggcgc

agttcttgagcaagaagacaaacaggcgcggggatgagtatggcgggtcggctgagaacagggcgaggattgttggg
gagattattaaggagtgcaggaggcaggtgactgaggcggtgggtgaagaggaggcgaagaagtttgtggtgggaat
caagctgaacagtgcggattggcaggcgggacgcgatggaaaggaggaggaggagacggatacggcggaggaggtgt
tgaagcagattgagctttttgagcagtgggggatcgactttgtcgaggttagcggtggcagttatgaggatcctcag
gtaagttttggtgttgtttgagggatggggcaaggggttgtctgtcgtgaacaacaaaaggggcacggaacaaatgc
taacgccatacagatggccaacggtcccaagcccgaaaagtccgaacgcaccatggcccgcgaggccttcttcctcg
agttcgccaagatcatccgcaccaagttccccaagcttcctctcatggtcaccggcggcttccgcactcgtcagggc
atggaggccgctttggaatccgatgattgcgacatgatcggtatcggacgcccggccatcatcaacccttcgcttcc
cgccaacttgatcctcaacccggaggtgccggatgcggatgcccgcttgttcgacaagaagagggctgagccgcact
ggatcgttgagaagttgggcatgaagtccattgttggtgctggtgttgaggtggtacgtcacgttccaaccccattt
gcttcattgtgtttccgagtatgtcatgctgacttggttcttttctagacgtggtatgtgagcgagctcaagaagct
ggccaagttttag

SEQ ID No 18

ATGGCTACTTCCACTACCTCCGACCTCAAACTCTCCCAACCCCTCACCCTCCCCAATGGCCTTACCCTCCCCAACCG
CCTCGTCAAAGCCGCCATGGCCGAACAAATGGGCTTCGGCAACCACCTGCCCAACCCCGAACTCGCCGCCGTCTACG
CCACCTGGGCCCGCGGCGACTGGGGCCTGATTCTCACCGGCAACGTCCAAGTCGACCACGCGCACAAGGGCGACGCC
CACGACATCAGCCCCAACCACCCCGGCACCACGCCCGAGCAGACCGTCACGGCCTTCAAGGCCTGGGCGGACGCCGC
GCGCCTGAATGGCCAGTCCAAAACGCCTGTGGTCGTGCAGATCAACCACCCTGGTCGCCAGAGTCCGATGGGCGCGG
GCACGCGGGGACTGTGGGAGAAGGCGGTGGCGCCCTCGCCGGTGCCGTTGGTGTTGGGAGAGGCGTTTGTGCCTCGC
TTGTTGTCGAAAGTGCTTTTCGGCACGCCGCGGGAGCTGACGGTTGCGGAGATCAAGGATATCGTGCAAAAGTTTGC
GGTGACGGCGAGGATCACGGCCGAGGCCGGGTTCAATGGCGTGGAGATCCATGCGGCGCATGGATACCTGTTGGCGC
AGTTCTTGAGCAAGAAGACAAACAGGCGCGGGGATGAGTATGGCGGGTCGGCTGAGAACAGGGCGAGGATTGTTGGG
GAGATTATTAAGGAGTGCAGGAGGCAGGTGACTGAGGCGGTGGGTGAAGAGGAGGCGAAGAAGTTTGTGGTGGGAAT
CAAGCTGAACAGTGCGGATTGGCAGGCGGGACGCGATGGAAAGGAGGAGGAGGAGACGGATACGGCGGAGGAGGTGT
TGAAGCAGATTGAGCTTTTTGAGCAGTGGGGGATCGACTTTGTCGAGGTTAGCGGTGGCAGTTATGAGGATCCTCAG
ATGGCCAACGGTCCCAAGCCCGAAAAGTCCGAACGCACCATGGCCCGCGAGGCCTTCTTCCTCGAGTTCGCCAAGAT
CATCCGCACCAAGTTCCCCAAGCTTCCTCTCATGGTCACCGGCGGCTTCCGCACTCGTCAGGGCATGGAGGCCGCTT
TGGAATCCGATGATTGCGACATGATCGGTATCGGACGCCCGGCCATCATCAACCCTTCGCTTCCCGCCAACTTGATC
CTCAACCCGGAGGTGCCGGATGCGGATGCCCGCTTGTTCGACAAGAAGAGGGCTGAGCCGCACTGGATCGTTGAGAA
GTTGGGCATGAAGTCCATTGTTGGTGCTGGTGTTGAGGTGACGTGGTATGTGAGCGAGCTCAAGAAGCTGGCCAAGT
TTTAG

SEQ ID No 19

MATSTTSDLKLSQPLTLPNGLTLPNRLVKAAMAEQMGFGNHLPNPELAAVYATWARGDWGLILTGNVQVDHAHKGDA
HDISPNHPGTTPEQTVTAFKAWADAARLNGQSKTPVVVQINHPGRQSPMGAGTRGLWEKAVAPSPVPLVLGEAFVPR
LLSKVLFGTPRELTVAEIKDIVQKFAVTARITAEAGFNGVEIHAAHGYLLAQFLSKKTNRRGDEYGGSAENRARIVG
EIIKECRRQVTEAVGEEEAKKFVVGIKLNSADWQAGRDGKEEEETDTAEEVLKQIELFEQWGIDFVEVSGGSYEDPQ
MANGPKPEKSERTMAREAFFLEFAKIIRTKFPKLPLMVTGGFRTRQGMEAALESDDCDMIGIGRPAIINPSLPANLI
LNPEVPDADARLFDKKRAEPHWIVEKLGMKSIVGAGVEVTWYVSELKKLAKF

SEQ ID No 20

atgtcggcagaaaagaagactttgagcaaaccggccgccggggtgccttactacaccccagcccaggagccgccggc
agggacccctttgcagcagcaggacgccatcccaacgctgttcaagcctctgaagatccgtggcgtcgagctctcca
accgctttggcgtctcgcccatgtgcacctactcagccgacgatggccacctgaccgacttccacttggtgcacctg
ggccagttcgccctgcacggcacggccctgaccattgtcgaggccacatccgtcacgcccaacggacgcatctcgcc
cgaggacagcggcctgtggcaagacagccagatcgctcctctgcgccgcatcgtcgactacgtgcacagccagggcc
aaaagatcgccatccaactggctcatgccggccgcaaggccagcacaaaggccccctggcacgactccttcaccccc
agcggcgagtataagccgagagagggcttacaggtcgtcggacccgagtatggcggctggcctgatgacgtctgggc
cccgagcgccatcccgttctcggaggactttccgaacccaaggagatgaccgttgaggagattgagggactcgtca
ccagctttgtggacgctgccaagcgtgccatcgaggccggcgtcgacattattgagattcacggcgctcacggttac
ctgatcaccgagttcctttcgccgctatcaaacgtaagtggagatactttgtgtggggctgtgcgcatactccctcg
ggtgtgacttctattaacattttatttcctggcacgcagaaacggacagacaagtacggcggcagctttgagaaccg
cacccgggtcctgatcgatattatcaaggccgtccgggcagtgattcccgaggagatgccactcttcgtccgaatct
ccgcgaccgaatggatggagtacgccggcgagcctagctgggacctcgagcagagcacacagcttgccaagctcctc
ccggacctgggtgtcgacctgctcgacgtcagctcgggcggaaactcggtggcccaaaagatcgagctcacgccgta
ctaccagatcgacctggcagccaagatccgcgaggccgtcggcgataggttgctcataggcgcggtcggcaacatca
acacggctgacattgcgcgcgatgtcgtggatgagcagggcgccgagaaggtggccgaggccaagcagacgcatgac

accatcgaggtcgtgagcgaatcacatggcggcaagaccaaggcggatctggtcctcattgctcgccagttcctgcg
cgagcctgagtttgtgctgaggacggcgcataaccttggggtcaatgtgcagtggcctcaccaataccacagagcag
tgtggcgcaagggtgcaaggatttga

SEQ ID No 21

ATGTCGGCAGAAAAGAAGACTTTGAGCAAACCGGCCGCCGGGGTGCCTTACTACACCCCAGCCCAGGAGCCGCCGGC
AGGGACCCCTTTGCAGCAGCAGGACGCCATCCCAACGCTGTTCAAGCCTCTGAAGATCCGTGGCGTCGAGCTCTCCA
ACCGCTTTGGCGTCTCGCCCATGTGCACCTACTCAGCCGACGATGGCCACCTGACCGACTTCCACTTGGTGCACCTG
GGCCAGTTCGCCCTGCACGGCACGGCCCTGACCATTGTCGAGGCCACATCCGTCACGCCCAACGGACGCATCTCGCC
CGAGGACAGCGGCCTGTGGCAAGACAGCCAGATCGCTCCTCTGCGCCGCATCGTCGACTACGTGCACAGCCAGGGCC
AAAAGATCGCCATCCAACTGGCTCATGCCGGCCGCAAGGCCAGCACAAAGGCCCCCTGGCACGACTCCTTCACCCCC
AGCGGCGAGTATAAGCCGAGAGAGGGCTTACAGGTCGTCGGACCCGAGTATGGCGGCTGGCCTGATGACGTCTGGGC
CCCGAGCGCCATCCCGTTCTCGGAGGACTTTCCGAACCCCAAGGAGATGACCGTTGAGGAGATTGAGGGACTCGTCA
CCAGCTTTGTGGACGCTGCCAAGCGTGCCATCGAGGCCGGCGTCGACATTATTGAGATTCACGGCGCTCACGGTTAC
CTGATCACCGAGTTCCTTTCGCCGCTATCAAACAAACGGACAGACAAGTACGGCGGCAGCTTTGAGAACCGCACCCG
GGTCCTGATCGATATTATCAAGGCCGTCCGGGCAGTGATTCCCGAGGAGATGCCACTCTTCGTCCGAATCTCCGCGA
CCGAATGGATGGAGTACGCCGGCGAGCCTAGCTGGGACCTCGAGCAGAGCACACAGCTTGCCAAGCTCCTCCCGGAC
CTGGGTGTCGACCTGCTCGACGTCAGCTCGGGCGGAAACTCGGTGGCCCAAAAGATCGAGCTCACGCCGTACTACCA
GATCGACCTGGCAGCCAAGATCCGCGAGGCCGTCGGCGATAGGTTGCTCATAGGCGCGGTCGGCAACATCAACACGG
CTGACATTGCGCGCGATGTCGTGGATGAGCAGGGCGCCGAGAAGGTGGCCGAGGCCAAGCAGACGCATGACACCATC
GAGGTCGTGAGCGAATCACATGGCGGCAAGACCAAGGCGGATCTGGTCCTCATTGCTCGCCAGTTCCTGCGCGAGCC
TGAGTTTGTGCTGAGGACGGCGCATAACCTTGGGGTCAATGTGCAGTGGCCTCACCAATACCACAGAGCAGTGTGGC
GCAAGGGTGCAAGGATTTGA

SEQ ID No 22

MSAEKKTLSKPAAGVPYYTPAQEPPAGTPLQQQDAIPTLFKPLKIRGVELSNRFGVSPMCTYSADDGHLTDFHLVHL
GQFALHGTALTIVEATSVTPNGRISPEDSGLWQDSQIAPLRRIVDYVHSQGQKIAIQLAHAGRKASTKAPWHDSFTP
SGEYKPREGLQVVGPEYGGWPDDVWAPSAIPFSEDFPNPKEMTVEEIEGLVTSFVDAAKRAIEAGVDIIEIHGAHGY
LITEFLSPLSNKRTDKYGGSFENRTRVLIDIIKAVRAVIPEEMPLFVRISATEWMEYAGEPSWDLEQSTQLAKLLPD
LGVDLLDVSSGGNSVAQKIELTPYYQIDLAAKIREAVGDRLLIGAVGNINTADIARDVVDEQGAEKVAEAKQTHDTI
EVVSESHGGKTKADLVLIARQFLREPEFVLRTAHNLGVNVQWPHQYHRAVWRKGARI

SEQ ID No 23

ATGACTATTGTTAATGAAGGAGCCGAAAATGTTGGTTATTTTACACCTGCGCAAAAAATACCAGCTGGAGCGGCGAT
AGGTGTACCGCAAACAAAATTATTTACTCCTCTTAAAATTAGAGGAGTGGAGTTCCATAACAGAATGTTTGTTTCGC
CGATGTGCACTTATTCCGCTGACCAAGAAGGGCATTTGACAGATTTTCACCTAGTACATCTTGGAGCGATGGGAATG
CGTGGGCCTGGCCTTGTAATGGTAGAAGCGACAGCGGTTTCCCCAGAGGGACGAATTTCACCTAATGATTCAGGATT
ATGGATGGAGTCGCAAATGAAGCCGTTACGAAGAATTGTTGAATTTGCTCATTCGCAAAATCAAAAAATTGGGATTC
AATTGGCGCATGCTGGTAGAAAGGCTAGCACCACTGCTCCTTATCGAGGATACACAGTTGCGACTGAAGCTCAAGGT
GGGTGGGAGAATGATGTTTATGGACCAAATGAAGACAGGTGGGACGAAAACCACGCTCAACCTCATAAGTTAACTGA
AAAGCAATATGATGAATTAGTGGATAAGTTTGTTGTTGCTGCGAAGCGTGCAGTTGAAATAGGTTTTGATGTAATTG
AAATTCATGGCGCTCATGGTTATCTTATATCGTCAACAGTTAGTCCTGCCACTAATGACCGCAATGACAAGTATGGT
GGGACATTTGAGAAACGTATTTTGTTTCCTATGGAAGTTGTCCATTCTGTTCGTAAAGCAATTCCAGATAGTATGCC
CTTGTTTTATAGAGTAACGGCTACAGATTGGTTGCCCAAAGGACAAGGATGGGAGATAGAAGATACAGTTGCATTAG
CAGCGAGGCTTCGCGATGGTGGTGTTGACTTGATAGATGTTAGCTCTGGTGGTAATCACAAGGATCAAAGAATTGAG
GTGAAGGATTGCTATCAAGTTCCTTTTGCGGAAAAGATTAAGGATCAAGTGAATGGAATACTACTTGGCGCTGTCGG
AATGATCAGGGATGGTCTTACGGCGAATGAAATCCTAGAAAGTGGAAAAGCTGATGTTACTTTTGTCGCAAGGGAGT
TCTTAAGGAACCCGTCGTTGGTGCTAGACAGCGCGAACCAGTTGGGTGAAAATGTTGCATGGCCAGTTCAGTATGAC
TATGCAGTTAAGGGACACAGAAAGTTACGTTGA

SEQ ID No 24

MTIVNEGAENVGYFTPAQKIPAGAAIGVPQTKLFTPLKIRGVEFHFTNRMFVSPMCTYSADQEGHLTDFHLVHLGAM
GMRGPGLVMVEATAVSPEGRISPNDSGLWFTMESQMKPLRRIVEFAHSQNQKIGIQLAHAGRKASTTAPYRGYTVAT
EAQGGWENDVYGPFTNEDRWDENHAQPHKLTEKQYDELVDKFVVAAKRAVEIGFDVIEIHGAHGYLISSTVSPAFTT
NDRNDKYGGTFEKRILFPMEVVHSVRKAIPDSMPLFYRVTATDWLPKGQGWEIEDTVAFTLAARLRDGGVDLIDVSS
GGNHKDQRIEVKDCYQVPFAEKIKDQVNGILLGAVGMIRDGLFTTANEILESGKADVTFVAREFLRNPSLVLDSANQ
LGENVAWPVQYDYAVKGHRKLR

SEQ ID No 25

CGAAACCTGGACCCAAACAAACAGCTGACCCTCTCCTTGACAACAAAGCCGGCCATCCTCGCCGACGATTGCCTCTA
CCCCCGCATAGTCACACTCGCACGTCCGTTCTGCCACCGTCAAACAGACAGCATGACGGGCACCGCGAACAAGGCCG
CCCCCGGTGTGCCGTTTTACACCCCGGCCCAGGAGCCTCCCGCGGGAACGCCAGTCGACGCCAGCACGGCTCCGACG
CTCTTCAAGCCCCTCCGCATCCGCGACCTCACCATCAACAACCGCATCTGGGTCAGCCCCATGTGCCAGTACTCCGC
CGACAATGGCCACGCGACCGACTACCACCTCGTCCACCTGGGCCAGTTCGCCCTGCACGGCGCCGCCCTGTCCATGG
TCGAGGCCACCGCCGTCGAGGCTCGTGGCCGCATCTCCCCCGAGGATGTCGGTTTGTGGCAGGACTCGCAGATTGCG
CCGCTGAAGCGCATCGTCGACTTTATCCACTCGCAGAACCAGGTCGCGGCCATCCAGCTCGCCCACGCCGGTCGCAA
GGCTAGCACCCTGGCACCGTGGATCACCGAGGCTCGCGGCAAGGCGCTGGCTCAGGAGAGCGAGAACGGCTGGCCCG
ACGACGTTGTGGCTCCCAGCGCGATTCCTTACACCAAGGACTGGGCCACACCGCGTGAGTTGACTACCGAGGRRGTC
GAGGGTCTGGGTGAAGAAGTTCGCCGAGTCGGCCAAGAGGTCAAATCGAGCTGGTTTTGACGTCATTGAGATCCACG
CCGCTCA

SEQ ID No 26

ATGACGGGCACCGCGAACAAGGCCGCCCCCGGTGTGCCGTTTTACACCCCGGCCCAGGAGCCTCCCGCGGGAACGCC
AGTCGACGCCAGCACGGCTCCGACGCTCTTCAAGCCCCTCCGCATCCGCGACCTCACCATCAACAACCGCATCTGGG
TCAGCCCCATGTGCCAGTACTCCGCCGACAATGGCCACGCGACCGACTACCACCTCGTCCACCTGGGCCAGTTCGCC
CTGCACGGCGCCGCCCTGTCCATGGTCGAGGCCACCGCCGTCGAGGCTCGTGGCCGCATCTCCCCCGAGGATGTCGG
TTTGTGGCAGGACTCGCAGATTGCGCCGCTGAAGCGCATCGTCGACTTTATCCACTCGCAGAACCAGGTCGCGGCCA
TCCAGCTCGCCCACGCCGGTCGCAAGGCTAGCACCCTGGCACCGTGGATCACCGAGGCTCGCGGCAAGGCGCTGGCT
CAGGAGAGCGAGAACGGCTGGCCCGACGACGTTGTGGCTCCCAGCGCGATTCCTTACACCAAGGACTGGGCCACACC
GCGTGAGTTGACTACCGAGGRGTCGAGGGTCTGGGTGAAGAAGTTCGCCGAGTCGGCCAAGAGGTCAAATCGAGCTG
GTTTTGACGTCATTGAGATCCACGCCGCT

SEQ ID No 27

MTGTANKAAPGVPFYTPAQEPPAGTPVDASTAPTLFKPLRIRDLTINNRIWVSPMCQYSADNGHATDYHLVHLGQFA
LHGAALSMVEATAVEARGRISPEDVGLWQDSQIAPLKRIVDFIHSQNQVAAIQLAHAGRKASTLAPWITEARGKALA
QESENGWPDDVVAPSAIPYTKDWATPRELTTEXSRVWVKKFAESAKRSNRAGFDVIEIHAA

SEQ ID No 28

GAACTGCTGTAGATGTGGTTGAATTGGTATATTAGACCGGAGTACTCTATATGCGAGAGACTATACATTGAAGTTGC
CAACGTTCTTCCAGATTGATTAATCATGGCTTACGAGATAATCGACAACGTTGCGGCTGAAGGGGTTCCATATTACA
CACCGGCTCAAGACCCGCCAGCTGGTACGCAGACAAGCGGCTCAACGAAGCTATTCACACCCATCACCATCCGCGGC
GTCACATTCCCAAACCGCCTCTTCCTTGCCCCTCTCTGCCAATACTCCGCCAAAGATGGTTATGCCACTGATTGGCA
CTTGACTCACCTCGGGGGAATAATCCAAAGAGGCCCCGGATTGTCCATGGTGGAGGCTACCGCTGTACAAAACCACG
GTCGCATCACACCTCAGGATGTTGGTCTGTGGGAAGACGGCCAGATCGAGCCTCTGAAGCGCATCACCACTTTCGCG
CACAGTCAGAGCCAGAAAATTGGTATCCAGCTGTCGCATGCGGGTCGCAAGGCCAGTTGCGTATCTCCCTGGCTAAG
CGTAAATGCTGTCGCGGCGGAAGAAGTGGGTGGCTGGCCAGACAATATCGTTGCTCCCTCGGCCATCGCACAAGAAA
ATGGTGTGAACCCAGTTCCCAAGGCTTTCACGAAGGAGGATATAGAGCAACTCAAGAGCGACTACGTGGAAGCGGCA
AAACGAGCCATCCATGCTGGTTTCGATGTTATCGAAATTCATGCAGCTCATGGATATCTACTGCATCAATTCTTGAG
TCCGGTAAGCAATCAAAGAACCGACGAGTATGG

SEQ ID No 29

ATGGCTTACGAGATAATCGACAACGTTGCGGCTGAAGGGGTTCCATATTACACACCGGCTCAAGACCCGCCAGCTGG
TACGCAGACAAGCGGCTCAACGAAGCTATTCACACCCATCACCATCCGCGGCGTCACATTCCCAAACCGCCTCTTCC
TTGCCCCTCTCTGCCAATACTCCGCCAAAGATGGTTATGCCACTGATTGGCACTTGACTCACCTCGGGGGAATAATC
CAAAGAGGCCCCGGATTGTCCATGGTGGAGGCTACCGCTGTACAAAACCACGGTCGCATCACACCTCAGGATGTTGG
TCTGTGGGAAGACGGCCAGATCGAGCCTCTGAAGCGCATCACCACTTTCGCGCACAGTCAGAGCCAGAAAATTGGTA
TCCAGCTGTCGCATGCGGGTCGCAAGGCCAGTTGCGTATCTCCCTGGCTAAGCGTAAATGCTGTCGCGGCGGAAGAA
GTGGGTGGCTGGCCAGACAATATCGTTGCTCCCTCGGCCATCGCACAAGAAAATGGTGTGAACCCAGTTCCCAAGGC
TTTCACGAAGGAGGATATAGAGCAACTCAAGAGCGACTACGTGGAAGCGGCAAAACGAGCCATCCATGCTGGTTTCG
ATGTTATCGAAATTCATGCAGCTCATGGATATCTACTGCATCAATTCTTGAGTCCGGTAAGCAATCAAAGAACCGAC
GAGTATGG

SEQ ID No 30

MAYEIIDNVAAEGVPYYTPAQDPPAGTQTSGSTKLFTPITIRGVTFPNRLFLAPLCQYSAKDGYATDWHLTHLGGII
QRGPGLSMVEATAVQNHGRITPQDVGLWEDGQIEPLKRITTFAHSQSQKIGIQLSHAGRKASCVSPWLSVNAVAAEE
VGGWPDNIVAPSAIAQENGVNPVPKAFTKEDIEQLKSDYVEAAKRAIHAGFDVIEIHAAHGYLLHQFLSPVSNQRTD
EY

SEQ ID No 31

TTTGGATGGTATAATAATAATTCTATTTGTGAAACATACGGGGCTGGTCTTGATCAAGAACGGTCCATCTATGGTCT
ATAAAGAACTCTTGTTCACTTTCTTTCCACGTCCCTTGAAGCTCCAATCAATCTGGTTCGCCATCTTGACCTCCACG
CCAAGCTCGTTAGCAAAAGCTCGAACCAGACCAGGATTCTGTTGGAACCAACGTCCAGCCCTCACAATGTCGATACC
AGATTGCAAAACCTCTTCAGCAAGATGTCCAGTCTTGATTCCACCTACTGCTGAAACAAGTACACTATCGCCAACAG
CCTTCTTTACCTGTTTGGCGAGGTCTACCTGGTAAGCAGGACCGGACTTGATGGCGATGGCGGACTTAGGATGGATA
CCGCCTGAGCTGACGTCCACCAAGTCTACTCCATGCTTGGGCAAGATACGCGCGAGTTGACAAGTCTGCTCGACTGT
CCAGCTTTCAGGAAACTCGTCTTTGAATTGAGAGTCAAACTCGAACCAATCAGTTGCACTGACACGAACGAGGACAG
GTGTAGTTTCGGGGATGGCAGCGCGGATGAGGTCAAGGATTTCCAAGACAACTCTGATACGGTTCTCGAAACTGCCA
CCATACTCGTCGGTT

SEQ ID No 32

AACCGACGAGTATGGTGGCAGTTTCGAGAACCGTATCAGAGTTGTCTTGGAAATCCTTGACCTCATCCGCGCTGCCA
TCCCCGAAACTACACCTGTCCTCGTTCGTGTCAGTGCAACTGATTGGTTCGAGTTTGACTCTCAATTCAAAGACGAG
TTTCCTGAAAGCTGGACAGTCGAGCAGACTTGTCAACTCGCGCGTATCTTGCCCAAGCATGGAGTAGACTTGGTGGA
CGTCAGCTCAGGCGGTATCCATCCTAAGTCCGCCATCGCCATCAAGTCCGGTCCTGCTTACCAGGTAGACCTCGCCA
AACAGGTAAAGAAGGCTGTTGGCGATAGTGTACTTGTTTCAGCAGTAGGTGGAATCAAGACTGGACATCTTGCTGAA
GAGGTTTTGCAATCTGGTATCGACATTGTGAGGGCTGGACGTTGGTTCCAACAGAATCCTGGTCTGGTTCGAGCTTT
TGCTAACGAGCTTGGCGTGGAGGTCAAGATGGCGAACCAGATTGATTGGAGCTTCAAGGGACGTGGAAAGAAAGTGA
ACAAGAGTTCTTTATAG

SEQ ID No 33

TDEYGGSFENRIRVVLEILDLIRAAIPETTPVLVRVSATDWFEFDSQFKDEFPESWTVEQTCQLARILPKHGVDLVD
VSSGGIHPKSAIAIKSGPAYQVDLAKQVKKAVGDSVLVSAVGGIKTGHLAEEVLQSGIDIVRAGRWFQQNPGLVRAF
ANELGVEVKMANQIDWSFKGRGKKVNKSSL

SEQ ID No 34
AGGAAGTTGCATGTCACTTGTAGTGACAGGGCGTCGTGTAAATTTTATAAATACCTATACTTGTTTGTTCACTTCTA
TGCTACTCATATCAATCCGAGAAGATCAAACAGTCCCCTATACACACTTGTCAAGACCTATCTATTATTTCAAAAAT
CAGCAATATGGCTGAGACAATGCCTAAGTGTGAGGCAAATGGCCATCACAAAATCATCATCAATAAGGAAGCTCCGA
ATGTTCCTTTCTATACTCCAGTGCAAGATCCACCAGCAGGAACGTCTTACGATGTTCAGCCTGAAGGAAGCCTATTC
TCTCTTATTAAAATAAGAAACCTGACTCTTCAAAACCGGATTTTTGTCTCCCCAATGTGTCAATATTCAGCAAAGGA
TGGTGTCATGACCCCCTGGCACAAACAACACCTGGGCAGCTTCGCAGCACGAGGTCCGGGTCTCATTGTCACAGAAG
TCAACGCAGTTTCACCAGAGGGACGAATCAGTCCTGAGGATGCAGGCATCTACGATGATGGGCAGCTTGGACCTCTC
CGGGATATTGTGGACTTTGTACACAGCCAGGGCGCCAAGATTGCTATTCAGATAGGTCATGCTGGGAGAAAAGCGAG
CACAGTCGTACCGTGGCTGGACCGCAAGAACACTGCTTTTA

SEQ ID No 35

MPKCEANGHHKIIINKEAPNVPFYTPVQDPPAGTSYDVQPEGSLFSLIKIRNLTLQNRIFVSPMCQYSAKDGVMTPW
HKQHLGSFAARGPGLIVTEVNAVSPEGRISPEDAGIYDDGQLGPLRDIVDFVHSQGAKIAIQIGHAGRKASTVVPWL
DRKNTAF

SEQ ID No 36

GCACGAGGGATTATTGACAACATCGCGGCTGAAGGGGCTCCCTACTACACGCCTGCTCAAGACYCTCCAGCAGGCAC
ACAGACCAGCGGCTCAACCAAGGTTTTCACACBCATCACCATCCGAGGCGTCACATTCCCAAACCGTCTCTTTCTTG
CCCCTCTCTGTCAATACTCCGCCAAAGATGGATATGCTACTGATTGGCACTTGACTCATCTCGGAGGCATTATCCAA
CGAGGCCCGGGACTGTCCATGGTAGAGGCCACCGCTGTTCAAAACCACGGTCGCATCACGCCTCAGGACGTTGGTCT
CTGGGAAGATGGACAAATCGAGCCCTTTGAAGCGCATCACTACTTTTGCCCACAGCCAAAGCWCAGAAGATTGGTAT
TCAGCTCTCGCACGCTGGTCGTAAGGCTAGTTGTGTATCTCCGTGGTTGAGCATCAACGCTGTTGCCGCTAAGGAAG
TCGGTGGCTGGCCAGACAACATTGTTGCTCCTTCTGCCATCGCACAAGAAGCTGGCGTGAACCCTGTTCCCAAGGCC
TTCACCAAGGAGGATATCGAGGAACTCAAGAATGACTTTCTGGCTGCAGCMAAACGAGCCAWCCGCGCTGGTTTTGA
TGTCATCGAGATCCATGCAGCTCATGGATACKTGCTTCACCAGTTCTTGAGTCCAGTCAGTAACCAAAGAACCGATG
AGTATGGTGGCAGCTTCGAGAACCGTATCAGAGTCGTCTTGGAGATCATTG

SEQ ID No 37
GCACGAGGGATTATTGACAACATCGCGGCTGAAGGGGCTCCCTACTACACGCCTGCTCAAGACYCTCCAGCAGGCAC
ACAGACCAGCGGCTCAACCAAGGTTTTCACACBCATCACCATCCGAGGCGTCACATTCCCAAACCGTCTCTTTCTTG
CCCCTCTCTGTCAATACTCCGCCAAAGATGGATATGCTACTGATTGGCACTTGACTCATCTCGGAGGCATTATCCAA

CGAGGCCCGGGACTGTCCATGGTAGAGGCCACCGCTGTTCAAAACCACGGTCGCATCACGCCTCAGGACGTTGGTCT
CTGGGAAGATGGACAAATCGAGCCCTTGAAGCGCATCACTACTTTTGCCCACAGCCAAAGCCAGAAGATTGGTATTC
AGCTCTCGCACGCTGGTCGTAAGGCTAGTTGTGTATCTCCGTGGTTGAGCATCAACGCTGTTGCCGCTAAGGAAGTC
GGTGGCTGGCCAGACAACATTGTTGCTCCTTCTGCCATCGCACAAGAAGCTGGCGTGAACCCTGTTCCCAAGGCCTT
CACCAAGGAGGATATCGAGGAACTCAAGAATGACTTTCTGGCTGCAGCMAAACGAGCCAWCCGCGCTGGTTTTGATG
TCATCGAGATCCATGCAGCTCATGGATACKTGCTTCACCAGTTCTTGAGTCCAGTCAGTAACCAAAGAACCGATGAG
TATGGTGGCAGCTTCGAGAACCGTATCAGAGTCGTCTTGGAGATCATTG

SEQ ID No 38

ARGIIDNIAAEGAPYYTPAQDXPAGTQTSGSTKVFTXITIRGVTFPNRLFLAPLCQYSAKDGYATDWHLTHLGGIIQ
RGPGLSMVEATAVQNHGRITPQDVGLWEDGQIEPLKRITTFAHSQSQKIGIQLSHAGRKASCVSPWLSINAVAAKEV
GGWPDNIVAPSAIAQEAGVNPVPKAFTKEDIEELKNDFLAAXKRAXRAGFDVIEIHAAHGYXLHQFLSPVSNQRTDE
YGGSFENRIRVVLEII

SEQ ID No 39

CCTCAAGATCCGAGGTCTTACCCTCCAGAACCGTATTATGTTGAGGGGGCTCTGCCAGTACTCTGCTCCCGACGGAC
ACTACACAATGTGGCATCACACCCACATGGGCGGCATCATCCAACGCGGTCCCGGACTCACCTGCGTTGAAGCCACA
GCCGTGACTCCTCAAGGTCGCATCACGCCTGAAGACGTCGGTATCTGGCAAGATTCTCAGATCGAGCCTCTTGCCAA
GGTCGTCGAGTTTGCCCACTCCCAGAACCAGAAGATCATGATTCAGTTGGCGCATGCGGGCCGCAAAGCGAGCACTG
TGGCACCATGGTTAAGCGGCGGCGATGTTGCTGGTGAGGACGTCAACGGATGGCCACAGGATGTCTGGGCGCCCAGT
GCGATTCCATGGAACGAGAAGCACGCTGTCCCAAAGGAGATGTCGTTGGATGATATCGAGGCTTTCAAGAAGGCGTT
TGGAGAGGCGGTCAAGCGGGCATTGAAGGCTGGATTTGATGTTATTGAGATTCACAATGCTCACGGATACCTCCTCC
ACGAATTCATCTGCCTGAGAGCAACACCAGGACCGACAAGTACGGGCGGAAGCTGGGAAAACCGCACTCGTCTGACA
ATGGAAAGTCGTCGACCTTGTCCGCAGCATT

SEQ ID No

40LKIRGLTLQNRIMLRGLCQYSAPDGHYTMWHHTHMGGIIQRGPGLTCVEATAVTPQGRITPEDVGIWQDSQIEPL
AKVVEFAHSQNQKIMIQLAHAGRKASTVAPWLSGGDVAGEDVNGWPQDVWAPSAIPWNEKHAVPKEMSLDDIEAFKK
AFGEAVKRALKAGFDVIEIHNAHGYLLHEFICLRATPGPTSTGGSWENRTRLTMESRRPCPQH

SEQ ID No 41

GACTGCCGAGTAAACGCGCCGGCAAGGAGGCGGGAGGATGGCCGGAGGATGTTGTGGGTCCGTCGGGTGGGGAGGAC
TTTACGTGGGATGAGAGGTCCTCGAGCGACCCTAGTGGAGGCTACTATGCGCCGAGAGAGTTGTCGGTCAGAGAGAT
CAAGGAGATGGTCCAAGACTGGGCGACAGCAGCGAAAAGGGCGGTGAAAGCGGGCGTGGATGTAATCGAAATCCACG
GCGCGCATGGGTACCTCATCCACGAATTCCTCTCACCCATTACCAACCGCCGGACAGATTCTTACGGCGGTTCTTTC
GAAAACCGTACCCGTCTACTCATTGAAATCGTAACAGCCGTCCGAGCCGCGATGCCCTCCAGCATGCCTCTCTTCCT
CCGCCTCTCCTCTACAGAATGGATGGAAGATACCGACATCGGCAAGAAGTTCGGAAGCTGGGATGTCGAAAGCACGA
TCAAGATCTCCAAAATCCTGGCCGACTTGGGCGTTGATCTCCTCGACGTGTCTTCCGGTGGGAATCATCCTCAGCAG
AAAATCAACATGTTCAACACC

SEQ ID No 42

LPSKRAGKEAGGWPEDVVGPSGGEDFTWDERSSSDPSGGYYAPRELSVREIKEMVQDWATAAKRAVKAGVDVIEIHG
AHGYLIHEFLSPITNRRTDSYGGSFENRTRLLIEIVTAVRAAMPSSMPLFLRLSSTEWMEDTDIGKKFGSWDVESTI
KISKILADLGVDLLDVSSGGNHPQQKINMFNT

SEQ ID No.

ATGTCCCCACCACGCTTCGAAGCGGCCCCTGCCGACCCCTCACCGCTCGGCACGCCGCTCAAATACCCCGTCTCGGG
GCGGTCGGCGCCCAACCGGTTCCTCAACGCGGCCATGTCGGAGGGCCTGGCGACGTTTGACGAGGCGGACCCGTCCA
AGCGCGGCATCCCGACGGAGCAGCTGGTGCAGCTGTACCGGCGCTGGGGCCAGGGCGAGTGGGGCCAGATCCAGACG
GGCAACGTCATGATCGACCCGGAGCACCTCGAGGCCCCGGGCAACATGGTGGTGCCGCGCGACGCCGAGCCCTCGGG
CGAGCGCTTCGACATGTTTTCCAAGCTCGCCGCCGCCGCCAAGGAGCACGGCAGCCTCATCGTCGCGCAGGTCGGAC
ACCCCGGTCGCCAGGCCCGCGGCAGCGTCCAGCAGCACCCCATTAGCGCCAGCGACGTGCAGCTTAAGCAGGAGATG
TTTGGGTCAAAGTTTGGCGTGCCCAGGCCCGCTACCAAGGAGGATATTAAGGCGGTGATTGAGGGTTTTGCCCACAC
GGCCGAGTACCTTGAAAAGGCCGGTTTCGACGGTATCGAATTGCACGCCGCCCACGGTTACCTGCTGGCCCAATTCC
TGTCCGAAACAACCAACCAGCGCACCGACGAGTACGGCGGCAGCCTCGAAAACCGCATGCGGCTAATCCTCGAGGTC
ACGGCCGAGGTCCGCAGGCGGACGAGCAAGAATTTCATCCTCGGCATCAAAATTAACAGCGTCGAGTTCCAGGAGAA
GGGTTTCAAGCCAGAGGAGGCGGTGCAGTTGTGCGAGGCCCTCGAGGCCGCGGGCATGGATTTTGTCGAGACGAGCG
GCGGCACCTATGAGAGTTTTGGTTTTGCGCACCGCAAGGAGTCCAGCCGCAAGCGGGAGAACTATTTTATCGAGTTC
GCCGAGGTCATCCGCAAGGCCGTCAAGCACATGGTGGTCTACACCACCGGCGGCTTCAAGACGGTGGGCGCCATGGT
CGACGCGCTGCAGGGCGTCGATGGGATAGGCATCGGGCGCGCAGCCGGTTCGGAGCCGGACCTCGCCAAGGACATCA
TCGCGGGCAAGGTGTCCAGCATTATCAAATACGCCATGGGGGAGGACGAGTTTGTGCTGCAGTTGACTGCCTGCTCG

GCGCAAATAAGGCTGATGGCCAAGGGCGAGGAGCCGTTTGACATCTCAAACGCCGACGAGGTGGCGCGGGTGACGCA
GTTGATGGCGGAGGGCAAGGTG

SEQ ID No. 44
MSPPRFEAAPADPSPLGTPLKYPVSGRSAPNRFLNAAMSEGLATFDEADPSKRGIPTEQLVQLYRRWGQGEWGQIQT
GNVMIDPEHLEAPGNMVVPRDAEPSGERFDMFSKLAAAAKEHGSLIVAQVGHPGRQARGSVQQHPISASDVQLKQEM
FGSKFGVPRPATKEDIKAVIEGFAHTAEYLEKAGFDGIELHAAHGYLLAQFLSETTNQRTDEYGGSLENRMRLILEV
TAEVRRRTSKNFILGIKINSVEFQEKGFKPEEAVQLCEALEAAGMDFVETSGGTYESFGFAHRKESSRKRENYFIEF
AEVIRKAVKHMVVYTTGGFKTVGAMVDALQGVDGIGIGRAAGSEPDLAKDIIAGKVSSIIKYAMGEDEFVLQLTACS
AQIRLMAKGEEPFDISNADEVARVTQLMAEGKV

SEQ ID No. 45
AGCTTAGACCTACAGAGAGCATTGCTACTGTAAGTTGTATTTCGCCTTCTCGCATAGAACAAAATATAACTGATGGT
GTAGGTATAAAACTAGCATCCTCTTCCACCTTTCAGATCCCCCTGACAAGCACCTTATGGCTTTCGATGGAAACAGC
TATTCCTTCTACTGGTAAAAATAGGATACCAGAGGCTACAATCAATACACCCTCGATAGAGGCTGTCGAATGTGGCC
AACTGGCAACGCTGCGGTTAGTCATCGTCGGAGACTTTCTGGGATTCATTTTCTTCCGAGTCTCCGCCTGCTTATTA
AGGCATCAATCTGGATGCTCCACTGTGGTACATCCAATTTTCGATTTTTCTTCGGCAGAGGCAAGGATTCCACTGGT
TCAGTCTAGGCATTTAGAAGATCAAAGCTGTCCTGTACCTCCGTACCTGGGTGTTCGACGTCATTGCCACGTTTCGA
CCCAAGGGCAGACGCCATGTCGCCGAGCGATCGCCGCGATATGCCTCGAATTTGCGCCATTCGGCATCCAGTTTCCA
GTGCCCTTCCCCGAATGACTGTCTCCACTATTCGGCAAGATTGTAAATCAAGCCTGAAGAAGCGGAGCATTCTTGGA
AGTCGTATGTTCTACTGATTCTGTGCCTGGCGCAGACGGGTATATAATAAAGATCACGCACCGAGGAGTTCTTA

SEQ ID No. 46
GTTCGACGTCATTGCCACG

SEQ ID No. 47
CCTTGATCGTTGCTGAGCG

SEQ ID No. 48
ATGACTGTCGCCGATATCG

SEQ ID No. 49
CTATACATCGAAAATAGACTGC

SEQ ID No. 50
CCGTCCTGGGCGGAGTATTGGCAGAG

SEQ ID No. 51
GCGAATCAGATTCTAGAGGAGCAGGATATCG

SEQ ID No. 52
GCTCAGCACCTCGGCGTCGAAATCTCC

SEQ ID No. 53
TCTGCCAATACTCCGCC

SEQ ID No. 54
CTTTCCGGCCGGCATG

SEQ ID No. 55
GGTATTGAGGGTCGCATGACTGTCGCCGATATCGA

SEQ ID No. 56
AGAGGAGAGTTAGAGCCTACATCGAAAATAGACTGCTTGTACACC

SEQ ID No. 57
GGTATTGAGGGTCGCATGTCGCAACCTGTTGTG

SEQ ID No. 58
AGAGGAGAGTTAGAGCCTATATCTTCTCGAGTTTCTTCC

SEQ ID No. 59
GGTATTGAGGGTCGCATGGGTTCCAACGCCTTC

SEQ ID No. 60
AGAGGAGAGTTAGAGCCTAAATGGCCCTGCCAAACTG

SEQ ID No. 61
GGTATTGAGGGTCGCATGGCTCTCCCTGACGTCGAAA

SEQ ID No. 62
AGAGGAGAGTTAGAGCCTACTCAAAGATGCTCTCC

SEQ ID No. 63
GGTATTGAGGGTCGCATGACAGTTCCATACCAAG

SEQ ID No. 64
AGAGGAGAGTTAGAGCCTAATTTACTTCTAATTTAGATGTTC

SEQ ID No. 65
GGTATTGAGGGTCGCATGTCGGCAGAAAAGAAG

SEQ ID No. 66
AGAGGAGAGTTAGAGCCCAAATCCTTGCACCCTTGCGCC

SEQ ID No. 67
CAGACCAATGGCCAGAAGA

SEQ ID No. 68
AGATGGGCGATGTGGTAGTC

SEQ ID No. 69
gccgcttacagggaatgata

SEQ ID No. 70
atggctcaatctgcgagtct

SEQ ID No. 71
CGACTCTTGTGGGTGCTGTA

SEQ ID No. 72
GTGGAAAACACCCATTCTGG

SEQ ID No. 73
CCCCAATCGTCAGATGAAGT

SEQ ID No. 74
CTGGCCCACGATTCACTAAT

SEQ ID No. 75
caaaagatcgccatccaact

SEQ ID No. 76
Ctggtgacgagtccctcaat

SEQ ID No. 77
ccagcagatgttcgaccccaag

SEQ ID No. 78
cagtgaactccatctcgtccatac

SEQ ID No. 79
TCCGTGGCGTCACCTTCC

SEQ ID No. 80
CAGATGGGCGATGTGGTAGTC

SEQ ID No 81
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 60

```
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg  120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc  180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcaggcgcc  240
attcgccatt caggctgcgc aactgttggg aagggcgatc ggtgcgggcc tcttcgctat  300
tacgacagct gtctcttata cacatctcaa ccatcatcga tgaattttct cgggtgttct  360
cgcatattgg ctcgaattcg agctcggtac ccggggatcc tctagaagtc ctgaatagta  420
gtttgtggat taacattgtt ccgatgtagg aatcatgatc ccaaccagaa gagctggaca  480
gcccctcttc cagagcattt ttggtgggat gttttggctt agtgcgatgc aactggacaa  540
agtccttccg tttctactgc gtcttacatc atctggtatc tacgcaagcc gcccacttac  600
catatgaata agaggcactc aggttttccc tcacccccc gaagcgatgg taagcgggtg  660
ccaaatgcat cgggagtttc tctatcataa taacctaggt attccgtaat ctattaccag  720
tctttccgaa gagctggtag caactgcacg agatttgtag gagcgagtac ccggctggac  780
gagcacgcag cacggctatt ggtcagcatg gtagctaccg aggggaggca ggccgcccaa  840
atatcgtgag tctcctgctt tgcccggtgt atgaaaccgg aaaagctgct atagagcttc  900
tgggcggcgc atgtcgggaa accagcagca agctgaccca gaaagacccg tcctcaagcc  960
attaccgtac taatcaatta tttgtgtagc aacactggga agctgtagtg cataggctgg 1020
agcagctatt tggcctttag ccccgtctgt ccgcccggtg tgcggtttcg actggcgcgc 1080
aagctcaagg tgatcaggtc gttgcgtcag tcggagacaa caagccattg ccttttctac 1140
tgcccctccc ccgctggtgg ccttttctc tcatcttctc ctctcttccc atcatcagca 1200
tcattaatct actgtctctc tttctttcta tcattctata aagtaagaac atatccatct 1260
tccctcaatc ccgtctacaa tagtgtcctc ttcactactc tgtctctatc tctcaaagct 1320
tgactgacat ttaccccgct cagtaccaga cgaatctaca cagaattcga gctcactaaa 1380
ccatggccaa gttgaccagt gccgttccgg tgctcaccgc gcgcgacgtc gccggagcgg 1440
tcgagttctg gaccgaccgg ctcgggttct cccgggactt cgtggaggac gacttcgccg 1500
gtgtggtccg ggacgacgtg accctgttca tcagcgcggt ccaggaccag gtggtgccgg 1560
acaacaccct ggcctgggtg tgggtgcgcg gcctggacga gctgtacgcc gagtggtcgg 1620
aggtcgtgtc cacgaacttc cgggacgcct ccgggccggc catgaccgag atcggcgagc 1680
agccgtgggg gcgggagttc gccctgcgcg acccggccgg caactgcgtg cacttcgtgg 1740
ccgaggagca ggactgagaa ttccactagt gcagaaagct gttttccttg ctctgtggta 1800
taagtctagt gccactattc tatgatgagt tgatgactct ttcatgactg gaaggcttac 1860
attctccaag atcatgtctc actcaaaact tatctcgggt tcactttcgg gttccatata 1920
tctcatcatt tctgggttta gaaacatctc tctcgttttt gcagctcttc tacgtactcc 1980
tagcggtttc actgaaatga atacatttgg gtaacctaat tgccaattca tatcttcctg 2040
agggcagtaa cacatcacgt acattctatc agctgtgata gagttacaaa actagcaata 2100
cttttatgct tcctcctttc ttaccattta cacatccgct ttctctctgc tcttgatctt 2160
ggcccctgat tgtattgtca cctcaccaaa ttcaagtcat cacctcttct ctagagtcga 2220
cttttatgga cagcaagcga accggaattg ccagctgggg cgccctctgg taaggttggg 2280
aagccctgca aagtaaactg gatggctttc tcgccgccaa ggatctgatg gcgcagggga 2340
tcaagctctg atcaagagac aggatgagga tcgtttcgca tgattgaaca agatggattg 2400
cacgcaggtt ctccggccgc ttgggtggag aggctattcg gctatgactg ggcacaacag 2460
acaatcggct gctctgatgc cgccgtgttc cggctgtcag cgcaggggcg cccggttctt 2520
tttgtcaaga ccgacctgtc cggtgccctg aatgaactgc aagacgaggc agcgcggcta 2580
tcgtggctgg ccacgacggg cgttccttgc gcagctgtgc tcgacgttgt cactgaagcg 2640
ggaagggact ggctgctatt gggcgaagtg ccggggcagg atctcctgtc atctcacctt 2700
gctcctgccg agaaagtatc catcatggct gatgcaatgc ggcggctgca tacgcttgat 2760
ccggctacct gcccattcga ccaccaagcg aaacatcgca tcgagcgagc acgtactcgg 2820
atggaagccg gtcttgtcga tcaggatgat ctggacgaag agcatcaggg gctcgcgcca 2880
gccgaactgt tcgccaggct caaggcgagc atgcccgacg gcgaggatct cgtcgtgacc 2940
catggcgatg cctgcttgcc gaatatcatg gtggaaaatg gccgcttttc tggattcatc 3000
gactgtggcc ggctgggtgt ggcggaccgc tatcaggaca tagcgttggc tacccgtgat 3060
attgctgaag agcttggcgg cgaatgggct gaccgcttcc tcgtgcttta cggtatcgcc 3120
gctcccgatt cgcagcgcat cgccttctat cgccttcttg acgagttctt ctgaattatt 3180
aacgcttaca atttcctgat gcggtatttt ctcgcatgca tcactagtga attcgcggcc 3240
gcctgcaggt cgacctgcag gcatgcaagc ttgccaacga ctacgcacta gccaacaaga 3300
gcttcagggt tgagatgtgt ataagagaca gctgtcttaa tgaatcggcc aacgcgcggg 3360
gagaggcggt ttgcgtattg ggcgctcttc cgcttcctcg ctcactgact cgctgcgctc 3420
ggtcgttcgg ctgcggcgag cggtatcagc tcactcaaag gcggtaatac ggttatccac 3480
agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa 3540
ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc cgccccctg acgagcatca 3600
caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc 3660
gtttccccct ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata 3720
cctgtccgcc tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta 3780
tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac ccccgttca 3840
gcccgaccgc tgcgccttat ccggtaacta tcgtcttgag tccaacccgg taagacacga 3900
cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg 3960
```

tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagga cagtatttgg 4020
tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg 4080
caaacaaacc accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag 4140
aaaaaaagga tctcaagaag atcctttgat cttttctacg gggtctgacg ctcagtggaa 4200
cgaaaactca cgttaaggga ttttggtcat gagattatca aaaaggatct tcacctagat 4260
ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc 4320
tgacagttac caatgcttaa tcagtgaggc acctatctca gcgatctgtc tatttcgttc 4380
atccatagtt gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc 4440
tggccccagt gctgcaatga taccgcgaga cccacgctca ccggctccag atttatcagc 4500
aataaaccag ccagccggaa gggccgagcg cagaagtggt cctgcaactt tatccgcctc 4560
catccagtct attaattgtt gccgggaagc tagagtaagt agttcgccag ttaatagttt 4620
gcgcaacgtt gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc 4680
ttcattcagc tccggttccc aacgatcaag gcgagttaca tgatccccca tgttgtgcaa 4740
aaaagcggtt agctccttcg gtcctccgat cgttgtcaga agtaagttgg ccgcagtgtt 4800
atcactcatg gttatggcag cactgcataa ttctcttact gtcatgccat ccgtaagatg 4860
cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtgta tgcggcgacc 4920
gagttgctct tgcccggcgt caatacggga taataccgcg ccacatagca gaactttaaa 4980
agtgctcatc attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgctgtt 5040
gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt 5100
caccagcgtt tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa agggaataag 5160
ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta 5220
tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat 5280
aggggttccg cgcacatttc cccgaaaagt gccacctgac gtctaagaaa ccattattat 5340
catgacatta acctataaaa ataggcgtat cacgaggccc tttcgtc 5387

SEQ ID No. 82
ATGACAGTTCAATCACAGCAACAATCCCAGGCTATTCCCGTCCTTTCTTCCCAGAATGGCACTGAACCCCAAGACGC
AAACAAGGAGGTTGTTCAGAATGTCGCTGCCAAAGGAGTGCAATACTTCAACCCTGAGCAACTTCCTGCACCAGGTC
TCGGTATAAACGGTCCCAATAATACTCTACCAAAGGTCTTTACACCCATCAAGATTCGCGGCATGACCATGCCCAAC
CGTATCTGGGTCAGCCCCATGTGCCAATACAGTGCCCGTGACGGCTTTCAGCAGCCTTGGCACTTTGCCCACTACGG
CGGACTGGCCCAACGTGGCCCTGGCCTCATCATGCTAGAAGCTACCGCAGTTCAAGCACGTGGCCGTATCACACCTG
AAGATTCTGGCATCTGGCTAGACTCTCATGTTGAGGGACTGCGAAAGCACGTCGAGTTTGCCCATGCCAACAACTCT
CTTATCGGTATCCAGATTGGCCATGCTGGTCGCAAGGCCTCCTGCGTTGCTCCTTGGTTAGACGCCGGACTTGCCGC
TGAAAAGGCCGCTGGTGGATGGCCCGATGACGTTGTCGGACCTAGCAACGAGCCTTTTGCTCCTGGCTACCCTACCC
CCCGTGCTATTACTCTTGAAGAGATTGAACAGTTGAAGGAGGACTTTGTTTCCGGTGTTCGTCGAGCGGTTGAAGCA
GGATTTGACACTATCGACTTCCATTTCGCTCACGGTTATCTTGTTTCCAGCTTCCTGTCCCCTGCCACCAACAAGCG
TACCGACAAGTACGGAGGTAGCTTCGAGAACAGAGTGCGCCTTGCTCTCGAGATTGTCGAGGCTGCACGAGCTGTTA
TGCCTGAGGACATGCCCTTGTTCACTCGCATCAGTGGAACTGACTGGCTGGAGAACAACCCTGAGTACGAGGGAGAG
ACCTGGACTCTTGAGCAGAGCATCAAGCTTGCACACCAGTTAGCAGACCGTGGTGTCGATGTTTTGGATGTTTCCAG
TGGTGGCATCCACAAGATGCAAAAGGTCGCTGCTGGTCCCGGTTACCAGGCACCTCTTGCCAAGGCGATCAAGAAGT
CAGTTGGAGACAAGATGTTGATCAGCACTGTTGGTAGCATCAAGATAGGTACCCTTGCGGAGGAGATCATCGCTGGA
GGAGAGGACGATACCCCCTTGGATCTTGTGGCTTCAGGCCGTCTGTTCCAGAAGAACACTGGACTTGTTTGGTCATG
GGCTGACGATCTGAACACTTCTATCCAGATCGCTCATCAGATCGCATGGGGTTTCGGTGGCAGAGCTAAGAAGAACG
CTCCCAAGCTTGTCTTA

SEQ ID No. 83
FG00074.1 hypothetical protein 38131394594
MTVQSQQQSQAIPVLSSQNGTEPQDANKEVVQNVAAKGVQYFNPEQLPAPGLGINGPNNTLPKVFTPIKIRGMTMPN
RIWVSPMCQYSARDGFQQPWHFAHYGGLAQRGPGLIMLEATAVQARGRITPEDSGIWLDSHVEGLRKHVEFAHANNS
LIGIQIGHAGRKASCVAPWLDAGLAAEKAAGGWPDDVVGPSNEPFAPGYPTPRAITLEEIEQLKEDFVSGVRRAVEA
GFDTIDFHFAHGYLVSSFLSPATNKRTDKYGGSFENRVRLALEIVEAARAVMPEDMPLFTRISGTDWLENNPEYEGE
TWTLEQSIKLAHQLADRGVDVLDVSSGGIHKMQKVAAGPGYQAPLAKAIKKSVGDKMLISTVGSIKIGTLAEEIIAG
GEDDTPLDLVASGRLFQKNTGLVWSWADDLNTSIQIAHQIAWGFGGRAKKNAPKLVL

SEQ ID No. 84
ATGGACACGTCTCGATTCGTGTCTGGTCTCACACCGCCTCTCGTCGACTCGATCGATGCACTCAAGATCAGCAACTT
TGTCCCCACTCGAAGTGGCCACCCTCCTCCTGGCTCGGTCCCGGAATCCATCCTGCCAGAGGGTGTCAAAAAACCGG
CTTTGTTCCAAACGTTGACATTGCCCTTTGCTGCACCGGAACAGGCGGGTAAGATGACCTTCAAGAACCGCATCATT
GTCTCTCCCATGTGCCAGTACTCTGCGAACAATGGTCTTCCTACTCCGTACCACATTGCGCATTTGGGATCGTTTGC
CCTGCACGGTGTGGGAAACGTCATGGTCGAAGCATCTGGTGTTGAGCCAGAGGGGAGGATCACGCCTCAGGACCTGG
GTATTTGGTCGGAACAGCATCGGGATGCACACAAGGCGCTGGTGTCGGTGCTCAAGTCCTTCACGGATGGTCTGGGT
GTAGGGCTGCAACTGGCGCATGCGGGAAGGAAGGCCTCGGACTGGTCACCTTTCTACCGCGGAGAAAAGAAGCAAAA
GTTTGTGACGCAGGAGGAAGGTGGCTGGCCGGATCGTGTCGTCGCTCCTTCGGCCATCGCATATGCGCAAGGTCACG
TTACCCCTCGAGCTCTCACGACCGAGGACATCAACAAGTTGCAAGACAAATTCGTTCAGTCGGCACGATGGGCGTTT
GAAGCTGGGTATGACTACGTCGAACTTCACAGCGCTCACGGATACCTGATGCACTCGTTCCTCAGCCCGTTGACCAA

TCAGCGTACCGACGAGTACGGCGGTAGCCTGGAGAACCGCGCTCGATTTCTGCTCAACGTTGCCCGTCGAATCCGCC
AAGAATTCCCCAACAAGGGTCTCTGGGTGCGCGTCAGCTCCACCGACTGGGCCGACCAAGCGCACCAAGCCGACTCT
TGGACCGTTGACCAGACGGTTGAACTCGCCAAGATGCTCCAAGAGGCTCGAGTCGACCTGCTAGACGTCAGCTCCGG
CGGCCTGGTTCCATTCCAAAAAATCACCGTGGGAGCCGGATACCAGCTATTCGGAGCAAAAGCCGTTCGCGATGCTC
TGGCCAAAATCGAACCCGACGCGTCCAAACGCATGCTCGTCGGGGCCGTGGGAATGATGGAAGGTTCCTACGATTCG
CCCAACGGCCAAGACCGCAGCCAGATTGGCAAGTTGGCCGAGCAGTCGATTCAGAGCGGAGAGTGTGATGCGGTACT
GTTGGCACGTGGATTGATGTCCTACCCAAGCTGGACCGAGGATGCTAGTGTAGCGCTGATGGGTACCAGGGCAGCTG
GCAACCCGCAGTACCATCGCGTTCACGTGGCTAAGAAGTGA

SEQ ID No. 85
MDTSRFVSGLTPPLVDSIDALKISNFVPTRSGHPPPGSVPESILPEGVKKPALFQTLTLPFAAPEQAGKMTFKNRII
VSPMCQYSANNGLPTPYHIAHLGSFALHGVGNVMVEASGVEPEGRITPQDLGIWSEQHRDAHKALVSVLKSFTDGLG
VGLQLAHAGRKASDWSPFYRGEKKQKFVTQEEGGWPDRVVAPSAIAYAQGHVTPRALTTEDINKLQDKFVQSARWAF
EAGYDYVELHSAHGYLMHSFLSPLTNQRTDEYGGSLENRARFLLNVARRIRQEFPNKGLWVRVSSTDWADQAHQADS
WTVDQTVELAKMLQEARVDLLDVSSGGLVPFQKITVGAGYQLFGAKAVRDALAKIEPDASKRMLVGAVGMMEGSYDS
PNGQDRSQIGKLAEQSIQSGECDAVLLARGLMSYPSWTEDASVALMGTRAAGNPQYHRVHVAKK

SEQ ID No. 86
MSALFEPYTLKDVTLRNRIAIPPMCQYMAEDGLINDWHQVHYASMARGGAGLLVVEATAVAPEGRITPGCAGIWSDA
HAQAFVPVVQAIKAAGSVPGIQIAHAGRKASANRPWEGDDHIGADDARGWETIAPSAIAFGAHLPNVPRAMTLDDIA
RVKQDFVDAARRARDAGFEWIELHFAHGYLGQSFFSEHSNKRTDAYGGSFDNRSRFLLETLAAVREVWPENLPLTAR
FGVLEYDGRDEQTLEESIELARRFKAGGLDLLSVSVGFTIPETNIPWGPAFMGPIAERVRREAKLPVTSAWGFGTPQ
LAEAALQANQLDLVSVGRAHLADPHWAYFAAKELGVEKASWTLPAPYAHWLERYR

SEQ ID No. 87
MSALFEPFRLRDTTIPNRIWMPPMCQYSAAPEGPSAGVPGDWHFAHYGARAVGGTGLIVVEATGVSPEGRISPQDLG
LWNDTQVEAFRRITGFLRSQGTVPAVQLAHAGRKASTAQPWRGGAPVGADAYGWQPLAPSALAFDERHPVPTELTVP
QIQEAVGRFADAARRALAAGFEIAEIHGAHGYLIHEFLSPHSNQRTDAYGGSYANRTRFALEVVDAVREVWPDDKPL
FFRVSATDWLEEGGWTPDDTVRFARDLEAHGIDLLDVSTGGNVPRVRIPTGPGYQVPFAARVKAGSTLPVAAVGLIT
EPGQAEKILANGEADAVLLGRELLRNPSWAQHAARELGVDARMPDQYGWGM

SEQ ID No. 88
MTVSSAAAPQPASPAAPLLFTPLKLRSLELPNRVVVSPMCTYSATDGVANEFHLVHLGQYALGGAGLILAEATAVSP
EGRITPEDLGLWDDRQIVPLGHITDFVHQHGGHIGVQLAHAGRKASTYAPWRGKGAVPAELGGWQVIGPDENSFHDL
FPTPAMMGADELRGVVDAFSAAARRAQVAGFDAVEVHAAHGYLLHQFLSPLANTRTDDYGGSFENRTRLLLEVVRAV
RHVWPAHLPLFVRLSATDWAEGGWDLEQTVQLSKLLKYEGVDVLDISSGGLTAAQQIEVGPGYQVPFAAAVSRAETE
ISVMAVGLIETGAQAEAILQAGDADLIALGRPFLRDPHWAQRAARELGLRPVSIDQYARAGW

SEQ ID No. 89
MRIVCIGGGPAGLYFAILMKKLNPAHEIRVIERNRPYDTFGWGVVFSDATMDNMREWDSETADAIQVAFNHWDDIEL
HFKGRTIRSGGHGFVGIGRKMMLNILQARCEELGVELVFDREVESDAEFPDADLVIASDGINSRIRNKYAEVFKPDI
VTRPNRYIWLGTTKLFDAFTFFFEKTEHGWFQAHIYKFDDKTTTFIVECPEHVWKAHGLDTADQEQSIAFCEQLFGK
HLDGHRLMTNSRHLRGSAWLNFQRVKCEQWHHYNGKSHVVLMGDAVHTAHFAIGSGTKLALEDAIELTRLFRDEGDT
REHIPAVLERYQAARNIDVLRLQNAAWNAMEWFEVCGARYCDTLEPEQFMYSMLTRSQRISHENLRLRDAGWLEGYE
RWLARKAGMTVRDDETPPPPMFTPFKLRGLTLANRIVMSPMAMYSAEDGAPTDFHLVHFGSRALGGAGLLYTEMTCV
SPDARITPGCAGMYKPEHVNAWKRIVDFVHGNSDAKIGMQLGHAGRKGATKLAWEGIDEPLEAGAWELISASPLPYL
PHSQVPRAMTRDDMERVRNDFVRATRMAAEAGFDILELHCAHGYLLSSFLSPLTNRRTDEFGGDLENRARFPLEVFK
AMRAMWPTNRPMSVRLSCHDWFPGGNTADDAVAIARLFKEAGADIIDCSSGQVWKGDQPVYGRMYQTPFADRIRNEV
GIPTLAVGAISEADHANSIIAAGRADLCAIARPHLADPAWTLHEAAKIGFGEVAWPKQYRSARGQYETNLQRAAAAV
AGK

SEQ ID No. 90
MREEPSSAQLFKPLKVGRCHLQHRMIMAPTTRFRADGQGVPLPFVQEYYGQRASVPGTLLITEATDITPKAMGYKHV
PGIWSEPQREAWREIVSRVHSKKCFIFCQLWATGRAADPDVLADMKDLISSSAVPVEEKGPLPRALTEDEIQQCIAD
FAQAARNAINAGFDGVEIHGANGYLIDQFTQKSCNHRQDRWGGSIENRARFAVEVTRAVIEAVGADRVGVKLSPYSQ
YLGMGTMDELVPQFEYLIAQMRRLDVAYLHLANSRWLDEEKPHPDPNHEVFVRVWGQSSPILLAGGYDAASAEKVTE
QMAAATYTNVAIAFGRYFISTPDLPFRVMAGIQLQKYDRASFYSTLSREGYLDYPFSAEYMALHNFPV

SEQ ID No. 91
MTIRKLDGEESMLFQPLEIANGRIRLSHRVVHAPMTRNRGVPLNPTSTPEQPNRIWYPGDLMVQYYRQRATPGGLII
SEGVPPSLESNGMPGVPGLWTPEQAAGWKRVVDAVHEQGGYIYCQLWHAGRATIPQMTGSPAVSASATVWDSPTECY
SHPPVGSTEPVRYADHPPIELTIPHLKQTIRDYCNAAKTAMEIGFDGVELHAGNGYLPEQFLSSNVNKRTDEYGGSP
EKRCRFVLELMDELAATVGEDNLAIRLSPFGLFNQARGEQRVETWTFLCESLKKAHPNLSYVSFIEPRYEQIFSYEE
KDNFLRSWGLSDVDLSSFRKIFGTTPFFSAGGWDQSNSWGVLEEGRYDALLYGRYFTSNPDLVERLRKGIPFTPYDR
SRFYGPFEDNAKCYVDYPPATASS

SEQ ID No. 92
MTVESTNSFVVPAGTKQIEIAPLGSTKLFQPIKVGKNILPHRVAHAPTTRFRAAKNHTPSDLQLEYYKTHSQYPGTL
IITEATFTSEQGGMDLHVPGIYNDAQTKAWKKINDEIHANGSFSSMQLWYLGRVANPKDLKDAGLPLIGPSAVYWDE
ESEKLAKSVGNELRELTEKEIDHIVEVEYPNAAKRAIEAGFDYIEVHSAPGYFLDQFLNPASNKRTDKYGGSIENRA
RLLLRIIDKLIGIVGAEKLAVRLAPWSSFLGMEIEGEEIHSYILQQLQQRADNGQQLAYVSLIEPRVIGIFDASLED
QKGRSNEFAYKYWKGNFVRAGNYTYDAPEFKTLLHDLDNDRTIVGFARFFTSNPDLVEKLKLGKPLNHYDREEFYKY
YNYGYNSYDESEKQVIGKPLV

SEQ ID No.
MTIESTNSFVVPSDTKLIDVTPLGSTKLFQPIKVGNNVLPQRIAYVPTTRFRASKDHIPSDLQLNYYNARSQYPGTL
IITEATFASERGGIDLHVPGIYNDAQAKSWKKINEAIHGNGSFSSVQLWYLGRVANAKDLKDSGLPLIAPSAVYWDE
NSEKLAKEAGNELRALTEEEIDHIVEVEYPNAAKHALEAGFDYVEIHGAHGYLLDQFLNLASNKRTDKYGCGSIENR
ARLLLRVVDKLIEVVGANRLALRLSPWASFQGMEIEGEEIHSYILQQLQQRADNGQQLAYISLVEPRVTGIYDVSLK
DQQGRSNEFAYKIWKGNFIRAGNYTYDAPEFKTLINDLKNDRSIIGFSRFFTSNPDLVEKLKLGKPLNYYNREEFYK
YYNYGYNSYDESEKQVIGKPL

SEQ ID No. 94
MAATAAESRLFQPLKLTPKITLGHRLAMAPLTRFRSDDEHVPIVPLMTTYYSQRASVPGTLLVTEATFISPAAGGYD
NVPGIYNAAQIAAWKKITDAVHAKGSFIFCQLWSLGRAANPEVLAKEGGLKLKSSSAVPMEEGAPVPEEMTVAEIKE
RVAEYAAAAKNAVEAGFDGVEIHGANGYLIDQFLQDTCNQRTDEYGGSIENRSRFAHEVVKAVVEAVGAEKTGIRLS
PYSTFQGMKMKKDLIPQFEDVIRKINGFGLAYLHLTQSRVAGNMDVQPEEDEENLAFAAKLWDGPLLIAGGLTPETA
KHLVDREFPEKDVVATFGRHFISTPDLPFRIKEGIELNPYDRDTFYKAKSPDGYIDQPFSKEFEKVYGAQA

SEQ ID No. 95
MSFVKDFKPQALGDTNLFKPIKIGNNELLHRAVIPPLTRMRALHPGNIPNRDWAVEYYTQRAQRPGTMIITEGAFIS
PQAGGYDNAPGVWSEEQMVEWTKIFNAIHEKKSFVWVQLWVLGWAAFPDNLARDGLRYDSASDNVFMDAEQEAKAKK
ANNPQHSLTKDEIKQYIKEYVQAAKNSIAAGADGVEIHSANGYLLNQFLDPHSNTRTDEYGGSIENRARFTLEVVDA
LVEAIGHEKVGLRLSPYGVFNSMSGGAETGIVAQYAYVAGELEKRAKAGKRLAFVHLVEPRVTNPFLTEGEGEYEGG
SNDFVYSIWKGPVIRAGNFALHPEVVREEVKDKRTLIGYGRFFISNPDLVDRLEKGLPLNKYDRDTFYQMSAHGYID
YPTYEEALKLGWDKK

SEQ ID No. 96
MPFVKDFKPQALGDTNLFKPIKIGNNELLHRAVIPPLTRMRAQHPGNIPNRDWAVEYYAQRAQRPGTLIITEGTFPS
PQSGGYDNAPGIWSEEQIKEWTKIFKAIHENKSFAWVQLWVLGWAAFPDTLARDGLRYDSASDNVYMNAEQEEKAKK
ANNPQHSITKDEIKQYVKEYVQAAKNSIAAGADGVEIHSANGYLLNQFLDPHSNNRTDEYGGSIENRARFTLEVVDA
VVDAIGPEKVGLRLSPYGVFNSMSGGAETGIVAQYAYVLGELERRAKAGKRLAFVHLVEPRVTNPFLTEGEGEYNGG
SNKFAYSIWKGPIIRAGNFALHPEVVREEVKDPRTLIGYGRFFISNPDLVDRLEKGLPLNKYDRDTFYKMSAEGYID
YPTYEEALKLGWDKN

SEQ ID No. 97.
MPFVKGFEPISLRDTNLFEPIKIGNTQLAHRAVMPPLTRMRATHPGNIPNKEWAAVYYGQRAQRPGTMIITEGTFIS
PQAGGYDNAPGIWSDEQVAEWKNIFLAIHDCQSFAWVQLWSLGWASFPDVLARDGLRYDCASDRVYMNATLQEKAKD
ANNLEHSLTKDDIKQYIKDYIHAAKNSIAAGADGVEIHSANGYLLNQFLDPHSNKRTDEYGGTIENRARFTLEVVDA
LIETIGPERVGLRLSPYGTFNSMSGGAEPGIIAQYSYVLGELEKRAKAGKRLAFVHLVEPRVTDPSLVEGEGEYSEG
TNDFAYSIWKGPIIRAGNYALHPEVVREQVKDPRTLIGYGRFFISNPDLVYRLEEGLPLNKYDRSTFYTMSAEGYTD
YPTYEEAVDLGWNKN

SEQ ID No. 98
GCTAGCATGACTGTCGCCGATATCGA

SEQ ID No. 99
GCTAGCCTATACATCGAAAATAGACTGC

SEQ ID No. 100
ACTAGTCCAGGGGACTGTCGTGGTCAA

SEQ ID No. 101
CAATTGCCCAGGCCTAATGCATGCTG

CLAIMS

1. Method of identifying an anti-fungal agent which targets an essential protein or gene of a fungus comprising contacting a candidate substance with

(i) a NADH:flavin oxidoreductase protein which comprises the sequence shown by SEQ ID NO:3,

(ii) a NADH:flavin oxidoreductase protein which is a homologue of (i) and which comprises the sequence shown by SEQ ID NO: 8, 12, 14, 19, 24, 42, 44, 83 or 85,

(iii) a protein which has 50% identity with (i) or (ii),

(iv) a protein comprising a fragment of (i), (ii) or (iii) which fragment has a length of at least 50 amino acids,

(v) a polynucleotide that comprises sequence which encodes (i), (ii), (iii) or (iv),

(vi) a polynucleotide comprising sequence which has at least 70% identity with the coding sequence of (v),

and determining whether the candidate substance binds or modulates (i), (ii), (iii), (iv), (v) or (vi), wherein binding or modulation of (i), (ii), (iii), (iv), (v) or (vi) indicates that the candidate substance is an anti-fungal agent.

2. Method according to claim 1 wherein (iii) or (iv) have an oxidoreductase activity.

3. Method according to claim 1 or 2 wherein (i), (ii), (iii) or (iv) comprise one or more of the motifs defined by regions 1 to 11 in Figures 1 and 2.

4. Method according to any one of the preceding claims comprising carrying out a redox reaction in the presence and absence of the candidate substance to determine whether the candidate substance inhibits the oxidoreductase activity of a protein as defined in any one of the preceding claims, wherein the redox reaction is carried out by contacting said protein with NADH or NADPH; and an electron acceptor, under conditions in which in the absence of the candidate substance the protein catalyses reduction of the electron acceptor.

5. Method according to any one of the preceding claims wherein (iii) is a protein comprising the sequence of any of the following: SEQ ID NO: 6, 10, 16, 22, 27, 30, 33, 35, 38, 40.

6. Method according to any one of the preceding claims wherein the (i) or (ii) is an oxidoreductase of *Aspergillus flavus; Aspergillus fumigatus; Aspergillus nidulans; Aspergillus niger; Aspergillus parasiticus*; *Aspergillus terreus; Blumeria graminis; Candida albicans; Candida cruzei; Candida glabrata; Candida parapsilosis; Candida tropicalis; Colletotrichium trifolii; Cryptococcus neoformans; Encephalitozoon cuniculi*; *Fusarium graminarium; Fusarium solani; Fusarium sporotrichoides; Leptosphaeria nodorum; Magnaporthe grisea; Mycosphaerella graminicola; Neurospora crassa; Phytophthora capsici; Phytophthora infestans; Plasmopara viticola; Pneumocystis jiroveci; Puccinia coronata; Puccinia graminis; Pyricularia oryzae; Pythium ultimum; Rhizoctonia solani*; *Schizzosaccharomyces pombe; Trichophyton interdigitale; Trichophyton rubrum;* or *Ustilago maydis*.

7. Method according to any one of the preceding claims which further comprises formulating the identified anti-fungal agent into a agricultural or pharmaceutical composition.

8. Method according to any one of claims 1 to 6 which further comprises killing or impairing the growth of a fungus by contacting the fungus with the identified anti-fungal agent.

9. Use of (i), (ii), (iii), (iv), (v) or (vi) as defined in any one of claims 1 to 6 to identify or obtain an anti-fungal agent.

10. Use of an anti-fungal agent identified by the method of any one of claims 1 to 6 in the manufacture of a medicament for prevention or treatment of fungal infection.

11. Method of detecting the presence of a fungus in a sample comprising detecting the presence in the said sample of a protein or polynucleotide as defined in any one of claims 1 to 3, 5 or 6.

12. Method according to claim 11 wherein the sample is from an human, animal or plant individual who is suspected of having a fungal infection.

13. An isolated protein or polynucleotide as defined in any one of claims 1 to 3, 5 or 6.

14. A vector comprising a polynucleotide as defined in any one of claims 1 to 3, 5 or 6.

15. A recombinant cell comprising a polynucleotide as defined in any one of claims 1 to 3, 5 or 6 or a vector according to claim 14.

16. A method of obtaining a protein as defined in any one of claims 1 to 3, 5 or 6 comprising expressing the protein from a polynucleotide as defined in any one of claims 1 to 3, 5 or 6 or a vector according to claim 14.

17. A method of obtaining a polynucleotide as defined in claim 1 to 3, 5 or 6 comprising replication of a vector as defined in claim 14 or synthesis of the polynucleotide by condensation of nucleotides.

18. An organism which is transgenic for a polynucleotide as defined in any one of claims 1 to 3, 5 or 6.

19. An organism which has been genetically engineered to render a polynucleotide or protein as defined in any one of claims 1 to 3, 5 or 6 non-functional or inhibited.

20. An antibody which is specific for a protein as defined in any one of claims 1 to 3, 5 or 6.

21. A method for preventing or treating a fungal infection comprising administering an anti-fungal agent identified by the method of any one of claims 1 to 6.

22. A method for preventing or treating a fungal infection comprising administering a protein or polynucleotide as defined in any one of claims 1 to 3, 5 or 6.

23. A method of killing, or impairing the growth of, a fungus comprising inhibiting the expression or activity of a polynucleotide or protein as defined in any one of claims 1 to 3, 5 or 6.

24. A method according to claim 23 wherein the fungus has infected a human, animal or plant individual.

25. A fungus which has been killed, or whose growth has been impaired, by inhibition of the expression or activity of a protein or polynucleotide as defined in any one of claims 1 to 3, 5 or 6.


1 11 21 31 41 51 61 71 81 91
101 111 121 131 141 151 161 171 181 191
SEQ 3
SEQ 6
SEQ 8
SEQ 10
SEQ 12
SEQ 14
SEQ 16
SEQ 19
SEQ 22
SEQ 24
SEQ 27
SEQ 30
SEQ 33
SEQ 35
SEQ 38
SEQ 40
SEQ 42
SEQ 44
SEQ 83
SEQ 85
Bacteria
T44612
NP_625402
NP_295913
AF320254
OYE family
Af4875
Af4961
Ca2460
Nc4452
ScOYE1
ScOYE2
ScOYE3
A36990



```
                401        411        421        431        441        451        461        471        481        491
                ---------- ---------- -------9--- ---------- 10-------- ---------- ---------- ---------- ---------- ----------
                ---------- ---------- ---******* ########## ########## ##-------- ---------- ---------- ---------- ----------
SEQ 3 .         SWKSEDTVR- FAQELVK--Q GAVDLIDISS GGVLAQQ--- ---------KI KSGPAFQVPF AVAVKKAVGD ---KLLVAAV GAIT------ ----------
SEQ 6           SWRGVDTVR- -FAKILR-ET GYVDVLDVSS GGTHSEQ--- ---------HI HAKPGFQAPF AIAVKNAVGD ---KLAVASV GMIA------ ----------
SEQ 8           SWDM-QSSL- ELVKKLP--E WGIDLVDVSS AANHKDQ--- ---------KI NLHTAYQTDL AGQIRQAI-- ----RARGAST LVGAVGLITD SEQARGLVQG
SEQ 10          SWKLSDSVR- FAEALAA--Q GAIDLIDVSS GGVHAAQ--- ---------KI KSGPAFQAPF AVAIKKAVGD ---KLLVAEV GTIT------ ----------
SEQ 12          AWTIEDSKK- -LADILV--E KGIALVDVSS GGNDYRQPP- -----RSGISK ELREPIHVPL SRAIKQHVGD ----KLLVSCV GGLE------ ----------
SEQ 14          AWSTEDALK- -LADLVI--D LGVKVIDVTS GGNVAHCKS- -----RYLLND DKQLPSQVPL ARKLKSHIRN ----RCLIACS GGLD------ ----------
SEQ 16          SWDLQQTI-- ELAKILP---D LGVDLLDVSS GGNNKDQ--- ---------KI NVHTYYQIDM AEQIRAAVHE AGKQLLVGAV GLVT----SA EIAKETVQEK
SEQ 19          TDTAEEVLK- -QIELFE--Q WGIDFVEVSG GSYEDPQMAN GPKPEKSERT MAREAFFLEF AKIIRTK--- -FPKLPIMVT GGFR------ ----------
SEQ 22          SWDLEQSTQ- -LAKLLP---D LGVDLLDVSS GGNSVAQ--- ---------KI ELTPYYQIDL AAKIREAVGD ----RLLIGAV GNIN------ ----------
SEQ 24          GWEIEDTVAF TLAARLR---D GGVDLIDVSS GGNHKDQ--- ---------RI EVKDCYQVPF AEKIKDQVNG -----ILLGAV GMIR------ ----------
SEQ 27          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 30          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 33          SWTVEQTC-- QLARILP---K HGVDLVDVSS GGIHPKS--- -------AIAI KSGPAYQVDL AKQVKKAVGD ----SVLVSAV GGIK------ ----------
SEQ 35          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 38          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 40          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 42          SWDVESTIK- -ISKILA---D LGVDLLDVSS GGNHPQQ--- ---------KI NMENT----- ---------- ---------- ---------- ----------
SEQ 44          FKP-EEAVQ- LCEALEAAGM ----DFVETSG GTYESFG--- ---FAHRKESS RKRENYTIEF AEVIRKAVKH ----MVVYTTG GFKT------ ----------
SEQ 83          TWTLEQSIK- -LAHQLA---D RGVDVLDVSS GGIHKMQ--- ---------KV AAGPGYQAPL AKAIKKSVGD ----KMLISTV GSIK------ ----------
SEQ 85          SWTVDQTVE- LAKMLQE--- ARVDLLDVSS GGLVPFQ--- ---------KI TVGAGYQLEG AKAVRDALAK ---IEPDASKR MLVGA------ ----------
Bacteria        ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
T44612          EQTLEESI-- ELARRFK---A GGLDLLLSVSV GFTIPET--- ---------NI FWGPAFMGPI AERVRREAKL ----PVTSAW GFGT------ ----------
NP_625402       GWTPDDTVR- -FARDLE---A HGIDLLDVST GGNVPRV--- ---------RI PTGPGYQVPF AARVKAGST- ----LPVAAV GLIT------ ----------
NP_295913       GWDLEQTVQ- -LSKLLK---Y EGVDVLDISS GGLTAAQ--- ---------QI EVGPGYQVPF AAAVSRAETE ----ISVMAV GLIE------ ----------
AF320254        GNTADDAVA- -IARLFK---E AGADIIDCSS GQVWKGD--- ---------QP VYGRMYQTPF ADRIRNEVGI ----PTLAVG AISE------ ----------
OYE family      ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Af4875          EL---VPQFEY LIA-----QM RRLDVAYLHL ANSRWL---- ---------DE EKPHPDPNHE VFVRVWG-Q- ---SS-PILLA GGYD------ ----------
Af4961          EQR-VETWTF LCESLKKAHP ----NLSYVSF IEPRYE---- ---------- -QIFSYEEKD NFLRSWG--- LSDVDLSSFR KIFGTTPFFS ----------
Ca2460          EE-----IHSY ILQQLQQRAD NGQQLAYVSL IEPRVIG--- ----IFDASL EDQKGRSNEF AYKYWKG--- -----NEVRA GNYT------ ----------
Nc4452          DLIP---QFED VIRKIN----- -GFGLAYLHL TQSRVAGN-- -----MDVQP EEDEE-NLAF AAKLWDG--- -----PLLIA GGLT------ ----------
ScOYE1          ETGIVAQYAY VAGELEKRAK AGKRLAFVHL VEPRVTNP-- ----FLTEGE GEYEGGSNDF VYSIWKG--- ------PVIRA GNFA------ ----------
ScOYE2          ETGIVAQYAY VLGELERRAK AGKRLAFVHL VEPRVTNP-- ----FLTEGE GEYNGGSNKF AYSIWKG--- ------PIIRA GNFA------ ----------
ScOYE3          EPGIIAQYSY VLGELEKRAK AGKRLAFVHL VEPRVTDP-- ----SLVEGE GEYSEGTNDF AYSIWKG--- ------PIIRA GNYA------ ----------
A36990          EE----IHSY ILQQLQQRAD NGQQLAYISL VEPRVTG---- ----IYDVSL KDQQGRSNEF AYKIWKG--- -----NFIRA GNYT------ ----------

                501        511        521        531        541        551        561        571        581        591
                ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------1 1---------
                ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------**** ***---------
                ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 3           --NGKQ--AN QILEEQD--- ---------- ---------- ---IDVALVG RGFQKDPGLA WTFAQHLGV- ---------- ----EISMAN QIRWGFTRRG
SEQ 6           ---SAHLANS LLEKDG---- ---------- ---------- ---LDLVLVG RGFQKNPGLV WAWADELNV- ---------- ----EISMAN QIRWGFSRRG
SEQ 8           ADEATAAEAM LSGPEPK--- ---------- ---------- ---ADRILLA RQFLREPEWV FSTARKLGV- ---------- ----PVTVPV QFGRAI----
SEQ 10          --NGKQ--AN KLLEEEG--- ---------- ---------- ---LDVALVG RGFQKDPGLA WTFAQHLDV- ---------- ----EIAMAS QIRWGFTRRG
SEQ 12          ---KDPELLN KYLEEGT--- ---------- ---------- ---FDLALIG RGFLRNPGLV WEFADKLGV- ---------- ----RLHQAL QLGWGFWPNK
SEQ 14          ---RDIFKLD EFIANGD--- ---------- ---------- ---FDIALIG KGFLKNTGLI SRIADQLQA- ---------- ----QFRTAP QYKLALS----
SEQ 16          E-DGRVTIQR ENGAKTR--- ---------- ---------- ---CDMIGIG RPAIINPSLP ANLILNPEV- ---------- ----PDADAR LFDKKRAEPH
SEQ 19          -----TRQGME AALESDD--- ---------- ---------- ---ADMVLVA RQFLKEPEFV LTVADELGV- ---------- ----NVQWPH QYHRAVWRKG
SEQ 22          --TADI--AR DVVDEQGAEK VAEAKQTHDT IEVVSESHGG KTKADLVLIA RQFLREPEFV LRTAHNLGV- ---------- ----NVAWPV QYDYAVKGHR
SEQ 24          --DGLETTAN EILESGK--- ---------- ---------- ---ADVTFVA REFLRNPSLV LDSANQLGE- ---------- ---------- ----------
SEQ 27          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 30          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 33          --TGHL--AE EVLQSG---- ---------- ---------- ---IDIVRAG RWFQQNPGLV RAFANELGV- ---------- ----EVKMAN QIDWSFKGRG
SEQ 35          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 38          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 40          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 42          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 44          --VGAM-VDA LQGVDG---- ---------- ---------- ------IGIG RAAGSEPDLA KDIIAGKVSS IIKYAMGEDE FVLQLTACSA QIRLMAKGEE
SEQ 83          --IGTL--AE EIIAGG---- ---------- ---------- ---ED DTPLDLVASG RLFQKNTGLV WSWADDLNT- ---------- ----SIQIAH QIAWGFGGRA
SEQ 85          --VGMM--EG SYDSPNG--- ---------- ---------- ---QDRSQIG KLAEQSIQSG ECDAVLLAR- ---GLMSYPS WTEDASVALM GTRAAGNPQY
Bacteria        ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
T44612          -PQLAE---- AALQANQ--- ---------- ---------- ---LDLVSVG RAHLADPHWA YFAAKELGV- ---------- ----EKASWT LPAPYAHWLE
NP_625402       -EPG---QAE KILANGE--- ---------- ---------- ---ADAVLLG RELLRNPSWA QHAARELGV- ---------- ----DARMPD QYGWGM-----
NP_295913       --TGA--QAE AILQAGD--- ---------- ---------- ---ADLIALG RPFLRDPHWA QRAARELGL- ---------- ----RPVSID QYARAGW----
AF320254        ----AD--HAN SIIAAGR--- ---------- ---------- ---ADLCAIA RPHLADPAWT LHEAAKIGF- ---------- ----GEVAWP KQYRSARGQY
OYE family      ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Af4875          AASAEKVTEQ MAARTYT--- ---------- ---------- ---NVAIAFG RYFISTPDLP FRVMAGIQL- ---------- ----QKYDRA SFYSTLSREG
Af4961          AGGWDQSNSW GVLEEGR--- ---------- ---------- ---YDALLYG RYFTSNPDLV ERLRKGIPF- ---------- ----TPYDRS RFYGPFEDNA
Ca2460          -YDAPEEFKTL LHDLDND--- ---------- ---------- ---RTIVGFA RFFTSNPDLV EKLKLGKPL- ---------- ----NHYDRE EFYKYYNY-G
Nc4452          -PETAK-HLV DREFPEK--- ---------- ---------- ---DVVATFG RHFISTPDLP FRIKEGIEL- ---------- ----NPYDRD TFYKAKSPDG
ScOYE1          -LHP---EVV REEVKDK--- ---------- ---------- ---RTLIGYG RFFISNPDLV DRLEKGLPL- ---------- ----NKYDRD TFYQMSAH-G
ScOYE2          -LHP---EVV REEVKDP--- ---------- ---------- ---RTLIGYG RFFISNPDLV DRLEKGLPL- ---------- ----NKYDRD TFYKMSAE-G
ScOYE3          -LHP---EVV REQVKDP--- ---------- ---------- ---RTLIGYG RFFISNPDLV YRLEEGLPL- ---------- ----NKYDRS TFYTMSAE-G
A36990          -YDAPEEFKTL INDLKND--- ---------- ---------- ---RSIIGFS RFFTSNPDLV EKLKLGKPL- ---------- ----NYYNRE EFYKYYNY-G
```



Figure 1. A multiple alignment of the 2031 OR amino acid sequence from *A. fumigatus* (SEQ ID No3) along with related 2031 ORs from other fungi and bacteria (see Example 4) and OYEs. Regions 1-11, marked with * or #, refer to amino acids conserved between ORs but not OYEs.

Fungal 2031 ORs are given by the following SEQ ID No.: *A. fumigatus*, SEQ ID Nos. 3, 6 and 8; *A. nidulans*, SEQ ID No. 10; *C. albicans* SEQ ID Nos. 12 and 14; *N. crassa*, SEQ ID Nos. 16 and 19; *M. grisea* SEQ ID Nos. 22 and 44; *S. pombe* SEQ ID No. 24 (NP_595868); *C. trifolii* SEQ ID No. 27; *F. sporotrichioides* SEQ ID Nos. 30, 33 and 35; *F. graminearum* SEQ ID Nos. 38 and 83; *M. graminicola* SEQ ID Nos. 40 and 42; *U. maydis* SEQ ID No 85.

Bacterial ORs resembling 2031 are:
T44612 (*Pseudomonas putida*), SEQ ID No. 86; NP_625402 (*Streptomyces coelicolor*), SEQ ID No. 87; NP_295913 (*Deinococcus radiodurans*), SEQ ID No. 88; AF320254 (*Azoarcus evansii*, SEQ ID No. 89.

Fungal ORs similar to the Old Yellow Enzyme family (originally identified in *S. cerevisiae*):
A. fumigatus, Af4875 and Af4961, SEQ ID Nos. 90 and 91 respectively; *C. albicans*, Ca2460 and A36990, SEQ ID Nos. 92 and 93 respectively; *N. crassa*, Nc4452, SEQ ID No. 94; *S. cerevisiae*, OYE1, OYE2 and OYE3, SEQ ID Nos. 95-97 respectively.

Details of the sequence searches that identified the ORs other than SEQ ID No. 3, and methods for the construction of multiple alignments are given in Example 4 hereinafter.

```
                1          11         21         31         41         51         61         71         81         91
                ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
                ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 1           GTTCGACGTC ATTGCCACGT TTCGACCCAA GGGCAGACGC CATGTCGCCG AGCGATCGCC GCGATATGCC TCGAATTTGC GCCATTCGGC ATCCAGTTTC
SEQ 2           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 4           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 5           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 7           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 9           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 11          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 13          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 15          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 17          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 18          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 20          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 21          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 23          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 25          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 26          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 28          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 29          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 32          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 36          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 37          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 39          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 41          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 82          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 84          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------

                101        111        121        131        141        151        161        171        181        191
                ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
                ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 1           CAGTGCCCTT CCCCGAATGA CTGTCTCCAC TATTCGGCAA GATTGTAAAT CAAGCCTGAA GAAGCGGAGC AATTCTTGGA AGTCGTATGT TCTACTGATT
SEQ 2           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----GTATGT TCTACTGATT
SEQ 4           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 5           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 7           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 9           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 11          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 13          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 15          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 17          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 18          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 20          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 21          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 23          ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----CGAAA CCTCGACCCA AACAAACAGC
SEQ 25          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 26          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------GAAC
SEQ 28          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 29          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 32          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34          ----AGGAAG TTGCATGTCA CTTGTAGTGA CAGGGCGTCG TGTAAATTTT ATAAATACCT ATACTTGTTT GTTCACTTCT ATGCTACTCA TATCAATCCG
SEQ 36          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 37          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 39          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 41          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 82          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 84          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------

                201        211        221        231        241        251        261        271        281        291
                ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
                ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 1           TCTGTGCCTG GCGCAGACGG GTATATAAAT AAAGATCACC GCACCGAGGA GTTTCTTACC AACCCATCAA TAACCATCCA CAATCTCCTA CAACAAAAAT
SEQ 2           TCTGTGCCTG GCGCAGACGG GTATATAAAT AAAGATCACC GCACCGAGGA GTTTCTTACC AACCCATCAA TAACCATCCA CAATCTCCTA CAACAAAAAT
SEQ 4           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------A TGTCGCAACC
SEQ 5           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------A TGTCGCAACC
SEQ 7           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------A TGGGTTCCAA
SEQ 9           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------AT
SEQ 11          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---ATGACAG TTCCATACCA
SEQ 13          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------A TGGCCGACTT
SEQ 15          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 17          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 18          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----ATGTC
SEQ 20          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----ATGTC
SEQ 21          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 23          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 25          TGACCCTCTC CTTGACAACA AAGCCGGCCA TCCTCGCCGA CGATTGCCTC TACCCCCGCA TAGTCACACT CGCACGTCCG TTCTCCCACC GTCAAACAGA
SEQ 26          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 28          TGCTGTAGAT GTGGTTGAAT TGGTATATTA GACCGGAGTA CTCTATATGC GAGAGACTAT ACATTGAAGT TGCCAACGTT CTTCCAGATT GATTAATCAT
SEQ 29          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------AT
SEQ 32          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34          AGAAGATCAA ACAGTCCCCT ATACACACTT GTCAAGACCT ATCTATTATT TCAAAAATCA GCAATATGGC TGAGACAATG CCTAAGTGTG AGGCAAATGG
SEQ 36          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 37          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 39          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 41          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 82          ---------- ---------- ---ATGACAG TTCAATCACA GCAACAATCC CAGGCTATTC CCGTCCTTTC TTCCCAGAAT GGCACTGAAC CCCAAGACGC
SEQ 84          ---------- ---------- ---------- ---------- ---------- ---------- --------AT GGACACGTCT CGATTCGTGT CTGGTCTCAC
```

```
                301        311        321        331        341        351        361        371        381        391
                ---------- ---------- ---------- ---------- ---------- ---------- -1-------- ---------- ---------- ----------
                ---------- ---------- ---------- ---------- ---******* ********** ********** ********** **-------- ----------
SEQ 1           GACTGTCGCC GATATCGACG TTCCTCCTGC CGAGGGCATC CCCTACTTCA CTCCGGCCCA GAACCCTCCT GCCGGTACGG CAGCTAACCC CCAGACCAAT
SEQ 2           GACTGTCGCC GATATCGACG TTCCTCCTGC CGAGGGCATC CCCTACTTCA CTCCGGCCCA GAACCCTCCT GCCGGTACGG CAGCTAACCC CCAGACCAAT
SEQ 4           TGTTGTGCCT GACATCGAGA ACAAACCCGC GCCGGGTATC TCGTACTTTA CTCCGGCGCA AGAGCCGCCT GCTGGCACCG CTGCTAATCC TCAGTCTGAT
SEQ 5           TGTTGTGCCT GACATCGAGA ACAAACCCGC GCCGGGTATC TCGTACTTTA CTCCGGCGCA AGAGCCGCCT GCTGGCACCG CTGCTAATCC TCAGTCTGAT
SEQ 7           CGCCTTCCGG TCCCCCGCCG TCACCAAGTC CTCCTCCACC CCCTACTACA CTCCCGCCAA CAATGGAGGC GCCGCCCTGC ACCCCGACGA CCCCAC----
SEQ 9           GGCTCTCCCT GACGTCGAAA ACACCCCCGC CGCCGGCATC CCCTACTTTA CACCAGCACA GAACCCTCCT GCTGGAACAG CTGCCAACCC GCAAACCAGC
SEQ 11          AGTAAAACCA TCAGATGAAA TCAAAGGTGC TCCTGAGGTT TCCTATTACA CTCCAGAACA GCCTGTTCCG GCTGGTACTT TTTATCCCCA ATCGTC---A
SEQ 13          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---ATGGAAA ACAACAATAC TATACCG---
SEQ 15          CACCCAGAAG AAGACCTCCT CCCCCGCGGC CCCGGGTGTT CCCTTCTACA CCCCGGCCCA GGTCCCCGCC GCCGGCACTC CCCTCCCCTC CACCCCC---
SEQ 17          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ATGGCTACTT CCACTACCTC CGACCTC---
SEQ 18          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ATGGCTACTT CCACTACCTC CGACCTC---
SEQ 20          GGCAGAAAAG AAGACTTTGA GCAAACCGGC CGCCGGGGTG CCTTACTACA CCCCAGCCCA GGAGCCGCCG GCAGGGACCC CTTTGCAGCA GCAGGACG--
SEQ 21          GGCAGAAAAG AAGACTTTGA GCAAACCGGC CGCCGGGGTG CCTTACTACA CCCCAGCCCA GGAGCCGCCG GCAGGGACCC CTTTGCAGCA GCAGGACG--
SEQ 23          -----ATGAC TATTGTTAAT GAAGGAGCCG AAAATGTTGG TTATTTTACA CCTGCGCAAA AAATACCAGC TGGAGCGGCG ATAGGTGTAC CGCAAA----
SEQ 25          CAGCATGACG GGCACCGCGA ACAAGGCCGC CCCCGGTGTG CCGTTTTACA CCCCGGCCCA GGAGCCTCCC GCGGGAACGC CAGTCGACGC CAGCACGG--
SEQ 26          ----ATGACG GGCACCGCGA ACAAGGCCGC CCCCGGTGTG CCGTTTTACA CCCCGGCCCA GGAGCCTCCC GCGGGAACGC CAGTCGACGC CAGCACGG--
SEQ 28          GGCTTACGAG ATAATCGACA ACGTTGCGGC TGAAGGGGTT CCATATTACA CACCGGCTCA AGACCCGCCA GCTGGTACGC AGACAAGCGG CTCAACG---
SEQ 29          GGCTTACGAG ATAATCGACA ACGTTGCGGC TGAAGGGGTT CCATATTACA CACCGGCTCA AGACCCGCCA GCTGGTACGC AGACAAGCGG CTCAACG---
SEQ 32          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34          CCATCACAAA ATCATCATCA ATAAGGAAGC TCCGAATGTT CCTTTCTATA CTCCAGTGCA AGATCCACCA GCAGGAACGT CTTACGATGT TCAGCCTGAA
SEQ 36          -GCACGAGGG ATTATTGACA ACATCGCGGC TGAAGGGGCT CCCTACTACA CGCCTGCTCA AGACYCTCCA GCAGGCACAC AGACCAGCGG CTCAACCA--
SEQ 37          -GCACGAGGG ATTATTGACA ACATCGCGGC TGAAGGGGCT CCCTACTACA CGCCTGCTCA AGACYCTCCA GCAGGCACAC AGACCAGCGG CTCAACCA--
SEQ 39          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 41          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43          ---------- ---------- ---------- ---------- ------ATGT CCCCACCACG CTTCGAAGCG GCCCCTGCCG ACCCCTCACC GCTCGGC---
SEQ 82          AAACAAGGAG GTTGTTCAGA ATGTCGCTGC CAAAGGAGTG CAATACTTCA ACCCTGAGCA ACTTCCTGCA CCAGGTCTCG GTATAAACGG TCCCAAT---
SEQ 84          ACCGCCTCTC GTCGACTCGA TCGATGCACT CAAGATCAGC AACTTTGTCC CCACTCGAAG TGGCCACCCT CCTCCTGGCT CGGTCCCGGA ATCCATCCTG

                401        411        421        431        441        451        461        471        481        491
                ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
                ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 1           GG------CC AGAAGATCCC CAAGCTCTTC ACGCCCTTGA CCATCCGTGG CGTCACC--- ---------- ---------- -TTCCAGAAC CGCCTTGGTG
SEQ 2           GG------CC AGAAGATCCC CAAGCTCTTC ACGCCCTTGA CCATCCGTGG CGTCACC--- ---------- ---------- -TTCCAGAAC CGCCTTGGT-
SEQ 4           GG------AT CGGCACCTCC CAAGCTCTTC CGGCCGCTTT CGGTGCGGGG TCTGACC--- ---------- ---------- -TTTCACAAT CGCATTGGCG
SEQ 5           GG------AT CGGCACCTCC CAAGCTCTTC CGGCCGCTTT CGGTGCGGGG TCTGACC--- ---------- ---------- -TTTCACAAT CGCATTGGC-
SEQ 7           ---------- -----GACCCC TACGCTCTTC CGGCCCTTAC AAATCCGCAA TGTGACG--- ---------- ---------- -CTCAAGAAC CGCATCATG-
SEQ 9           GG------CA ATGCCGTCCC CAAGCTGTAC ACACCTCTGA CGGTGCGTGG GGTGACC--- ---------- ---------- -TTCCACAAC AGACTTGGC-
SEQ 11          GA------TG AAGTTGCTCC CAAAATTTTT CAACCTTTAA AGATTGGTAA GCTTGCT--- ---------- ---------- -TTGCCAAAC AGAATTGGG-
SEQ 13          ---------- ---------- -GCATTATTT CAACCCATAA AGATCAGTGA CTCGATC--- ---------- --------AC ATTACCTAAT AGAATTGGT-
SEQ 15          ---------G GCGATGTCCC TACTCTCTTC ACCCCTCTCA AGATCCGTGG TGTTGAG--- ---------- ---------- -CTCCAGAAC CGCTTCGCC-
SEQ 17          ---------- ---------- -AAACTCTCC CAACCCCTCA CCCTCCCCAA TGGCCTT--- ---------- --------AC CCTCCCCAAC CGCCTCGTC-
SEQ 18          ---------- ---------- -AAACTCTCC CAACCCCTCA CCCTCCCCAA TGGCCTT--- ---------- --------AC CCTCCCCAAC CGCCTCGTC-
SEQ 20          ---------- ---CCATCCC AACGCTGTTC AAGCCTCTGA AGATCCGTGG CGTCGAG--- ---------- ---------- -CTCTCCAAC CGCTTTGGC-
SEQ 21          ---------- ---CCATCCC AACGCTGTTC AAGCCTCTGA AGATCCGTGG CGTCGAG--- ---------- ---------- -CTCTCCAAC CGCTTTGGC-
SEQ 23          ---------- ---------C AAAATTATTT ACTCCTCTTA AAATTAGAGG AGTGGAG--- ---------- ---------- -TTCCATAAC AGAATGTTT-
SEQ 25          ---------- ------CTCC GACGCTCTTC AAGCCCCTCC GCATCCGCGA CCTCACC--- ---------- ---------- -ATCAACAAC CGCATCTGG-
SEQ 26          ---------- ------CTCC GACGCTCTTC AAGCCCCTCC GCATCCGCGA CCTCACC--- ---------- ---------- -ATCAACAAC CGCATCTGG-
SEQ 28          ---------- ---------- -AAGCTATTC ACACCCATCA CCATCCGCGG CGTCACA--- ---------- ---------- -TTCCCAAAC CGCCTCTTC-
SEQ 29          ---------- ---------- -AAGCTATTC ACACCCATCA CCATCCGCGG CGTCACA--- ---------- ---------- -TTCCCAAAC CGCCTCTTC-
SEQ 32          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34          GG-------- ---------- AAGCCTATTC TCTCTTATTA AAATAAGAAA CCTGACT--- ---------- ---------- -CTTCAAAAC CGGATTTTT-
SEQ 36          ---------- ---------- --AGGTTTTC ACACBCATCA CCATCCGAGG CGTCACA--- ---------- ---------- -TTCCCAAAC CGTCTCTTT-
SEQ 37          ---------- ---------- --AGGTTTTC ACACBCATCA CCATCCGAGG CGTCACA--- ---------- ---------- -TTCCCAAAC CGTCTCTTT-
SEQ 39          ---------- ---------- ---------- -----CCTCA AGATCCGAGG TCTTACC--- ---------- ---------- -CTCCAGAAC CGTATTATG-
SEQ 41          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43          ---------- ------ACGC CGCTCAAATA CCCCGTCTCG GGGCGGTCG- ---------- ---------- ---------- -GCGCCCAAC CGGTTCCTC-
SEQ 82          ---------A ATACTCTACC AAAGGTCTTT ACACCCATCA AGATTCGCGG CATGACC--- ---------- ---------- -ATGCCCAAC CGTATCTGG-
SEQ 84          CCAGAGGGTG TCAAAAAACC GGCTTTGTTC CAAACGTTGA CATTGCCCTT TGCTGCACCG GAACAGGCGG GTAAGATGAC CTTCAAGAAC CGCATCATT-

                501        511        521        531        541        551        561        571        581        591
                ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
                ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- --------***
SEQ 1           TAAGTCCGTT TGCCCTTGCT CATATCGACG AAAGCTAATC CCCCGTCAG- ---------- ---------- ---------- -----CTCGC GCCCCTCTGC
SEQ 2           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----CTCGC GCCCCTCTGC
SEQ 4           TGAGTGCAGT CCAGGCAATT ATGCTATCCA TCCTATGCGA GCCCTTGCAT TGGAACAGCC GCTTACAGGG AATGATAATG AGTAGCTATC GCCACTCTGC
SEQ 5           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----CTATC GCCACTCTGC
SEQ 7           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----GTGTC GCCCATGTGC
SEQ 9           ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----CTCGC GCCGCTCTGC
SEQ 11          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----GTATC TCCAATGTGT
SEQ 13          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----GTTTC ACCAATGTGC
SEQ 15          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----GTTGC GCCCATGTGC
SEQ 17          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----AAAGC CGCCATGGCC
SEQ 18          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----AAAGC CGCCATGGCC
SEQ 20          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----GTCTC GCCCATGTGC
SEQ 21          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----GTCTC GCCCATGTGC
SEQ 23          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----GTTTC GCCGATGTGC
SEQ 25          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----GTCAG CCCCATGTGC
SEQ 26          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----GTCAG CCCCATGTGC
SEQ 28          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----CTTGC CCCTCTCTGC
SEQ 29          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----CTTGC CCCTCTCTGC
SEQ 32          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----GTCTC CCCAATGTGT
SEQ 36          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----CTTGC CCCTCTCTGT
SEQ 37          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----CTTGC CCCTCTCTGT
SEQ 39          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----TTGAG GGGGCTCTGC
SEQ 41          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----AACGC GGCCATGTCG
SEQ 82          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----GTCAG CCCCATGTGC
SEQ 84          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----GTCTC TCCCATGTGC
```

```
                601        611        621        631        641        651        661        671        681        691
                --2------- ---------- ---------- ---------- ---------- ---------- ---------- 3--------- ---------- ----------
                *********- ---------- ---------- ---------- ---------- ---------- ********** ********** *--------- ----------
SEQ 1           CAATACTCCG CC-------- ---------- ---CAGGACG GCCACATGAC CGAC------ TACCACATCG CCCATCTGGG TGGGATCGCC CAACGCGGAC
SEQ 2           CAATACTCCG CC-------- ---------- ---CAGGACG GCCACATGAC CGAC------ TACCACATCG CCCATCTGGG TGGGATCGCC CAACGCGGAC
SEQ 4           CAATACTCAG CC-------- ---------- ---GACGATG GACACATGAC TCCC------ TGGCATATGG CACATCTTGG AGGGATTGCC CAGCGAGGGC
SEQ 5           CAATACTCAG CC-------- ---------- ---GACGATG GACACATGAC TCCC------ TGGCATATGG CACATCTTGG AGGGATTGCC CAGCGAGGGC
SEQ 7           ATGTACTCCT GCGAGTCGGA CCCGTCGTCT CCCCACGTCG GCGCCCTAAC AAAC------ TACCACCTGG CGCATCTGGG CCACCTCGCC CTCAAAGGCG
SEQ 9           CAGTACTCCG CA-------- ---------- ---GAAGACG GCCACATGAC AGAC------ TACCACATCG CGCACTTGGG AGGTATTGCC CAGCGCGGCC
SEQ 11          CAATATTCTG CT-------- ---------- GATTATAATT TTGAAGCAAC TCCA------ TACCATTTAA TCCATTATGG TTCATTAGTG AATCGTGGGC
SEQ 13          ATGTATTCAT CG-------- --------TCA CCAACTGACA ATCAAGCCAC TCTG------ TTTCATTTTG TTCATTATGG ATCATTTGCT GTACGTGGAC
SEQ 15          ACCTACTCTG CC-------- ---------- ---GACGATG GCCACATGAC CGAC------ TGGCACCTTG TCCACCTGGG CTCCTTCGCC CTCCGCGGTG
SEQ 17          GAACAAATGG GC-------- ---------- ---TTCGGCA ACCACCTGCC CAAC------ CCCGAACTCG CCGCCGTCTA CGCCACCTGG GCCCGCGGCG
SEQ 18          GAACAAATGG GC-------- ---------- ---TTCGGCA ACCACCTGCC CAAC------ CCCGAACTCG CCGCCGTCTA CGCCACCTGG GCCCGCGGCG
SEQ 20          ACCTACTCAG CC-------- ---------- ---GACGATG GCCACCTGAC CGAC------ TTCCACTTGG TGCACCTGGG CCAGTTCGCC CTGCACGGCA
SEQ 21          ACCTACTCAG CC-------- ---------- ---GACGATG GCCACCTGAC CGAC------ TTCCACTTGG TGCACCTGGG CCAGTTCGCC CTGCACGGCA
SEQ 23          ACTTATTCCG CT-------- ---------- GACCAAGAAG GGCATTTGAC AGAT------ TTTCACCTAG TACATCTTGG AGCGATGGGA ATGCGTGGGC
SEQ 25          CAGTACTCCG CC-------- ---------- ---GACAATG GCCACGCGAC CGAC------ TACCACCTCG TCCACCTGGG CCAGTTCGCC CTGCACGGCG
SEQ 26          CAGTACTCCG CC-------- ---------- ---GACAATG GCCACGCGAC CGAC------ TACCACCTCG TCCACCTGGG CCAGTTCGCC CTGCACGGCG
SEQ 28          CAATACTCCG CC-------- ---------- ---AAAGATG GTTATGCCAC TGAT------ TGGCACTTGA CTCACCTCGG GGGAATAATC CAAAGAGGCC
SEQ 29          CAATACTCCG CC-------- ---------- ---AAAGATG GTTATGCCAC TGAT------ TGGCACTTGA CTCACCTCGG GGGAATAATC CAAAGAGGCC
SEQ 32          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34          CAATATTCAG CA-------- ---------- ---AAGGATG GTGTCATGAC CCCC------ TGGCACAAAC AACACCTGGG CAGCTTCGCA GCACGAGGTC
SEQ 36          CAATACTCCG CC-------- ---------- ---AAAGATG GATATGCTAC TGAT------ TGGCACTTGA CTCATCTCGG AGGCATTATC CAACGAGGCC
SEQ 37          CAATACTCCG CC-------- ---------- ---AAAGATG GATATGCTAC TGAT------ TGGCACTTGA CTCATCTCGG AGGCATTATC CAACGAGGCC
SEQ 39          CAGTACTCTG CT-------- ---------- ---CCCGACG GACACTACAC AATG------ TGGCATCACA CCCACATGGG CGGCATCATC CAACGCGGTC
SEQ 41          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43          GAGGGCCTGG CG---ACGTT TGACGAGGCG GACCCGTCCA AGCGCGGCAT CCCGACGGAG CAGCTGGTGC AGCTGTACCG GCGCTGGGGC CAGGGCGAGT
SEQ 82          CAATACAGTG CC-------- ---------- ---CGTGACG GCTTTCAGCA GCCT------ TGGCACTTTG CCCACTACGG CGGACTGGCC CAACGTGGCC
SEQ 84          CAGTACTCTG CG-------- ---------- ---AACAATG GTCTTCCTAC TCCG------ TACCACATTG CGCATTTGGG ATCGTTTGCC CTGCACGGTG

                701        711        721        731        741        751        761        771        781        791
                ---------- ---------- ---------- ---------- ------4--- ---------- ---------- ---------- ---------- ----------
                ---------- ---------- ---------- ---------- -------*** ********** *****----- ---------- ---------- ----------
SEQ 1           CCGGCCTGAT GCTGATTGAG GCGACCGCCG TCCAGCCCGA A---GGCCGC ATCACCCCTC AGGATGTCGG TCTGTGGAAG GACTCC---- ---------CA
SEQ 2           CCGGCCTGAT GCTGATTGAG GCGACCGCCG TCCAGCCCGA A---GGCCGC ATCACCCCTC AGGATGTCGG TCTGTGGAAG GACTCC---- ---------CA
SEQ 4           CAGGATTCTT GATGGTCGAG GCAACAGCAG TCGAACCGGA A---GGCAGG ATCACCCCGC AGGACCTGGG ACTATGGAAA GACTCG---- ---------CA
SEQ 5           CAGGATTCTT GATGGTCGAG GCAACAGCAG TCGAACCGGA A---GGCAGG ATCACCCCGC AGGACCTGGG ACTATGGAAA GACTCG---- ---------CA
SEQ 7           CAGGCCTCGT CTTCATCGAA GCCACCGCCG TGCAGCCCAA C---GGGCGC ATCTCCCCCA ACGACTCGGG CCTCTGGCAG GACGGCACCA CCTCGGAACA
SEQ 9           CCGGTCTCAT GATGATCGAG GCAACCTCCG TCTCACCTGA A---GGCAGA ATCACGCCGC AGGACGTCGG TTTATGGAAG GACTCG---- ---------CA
SEQ 11          CAGGTATCAC CATTGTTGAA AGCACGGCTG TTTCTCCTGA G---GGTGGA TTATCACCTC ATGATTTAGG AATCTGGAAG GATGAA---- ---------CA
SEQ 13          CAGCATTAAT CATTTTAGAG AGTATCTTTG TGTCCGAAAA T---TCCGGA TTATCCATTC ATGATTTAGG TCTTTGGAAT GATGAT---- ---------CA
SEQ 15          TCCCCCTCAC CATCTTCGAG GCCACCGGCG TCCTCCCCAA C---GGCCGC ATCACCCCCG AGTGCTCTGG TCTCTGGCAG GACTCC---- ---------CA
SEQ 17          ACTGGGGCCT GATTCTCACC GGCAACGTCC AAGTCGACCA CGCGCACAAG GGCGACGCCC ACGACATCAG CCCCAACCAC CCCGGCACCA CGCCCGAGCA
SEQ 18          ACTGGGGCCT GATTCTCACC GGCAACGTCC AAGTCGACCA CGCGCACAAG GGCGACGCCC ACGACATCAG CCCCAACCAC CCCGGCACCA CGCCCGAGCA
SEQ 20          CGGCCCTGAC CATTGTCGAG GCCACATCCG TCACGCCCAA C---GGACGC ATCTCGCCCG AGGACAGCGG CCTGTGGCAA GACAGC---- ---------CA
SEQ 21          CGGCCCTGAC CATTGTCGAG GCCACATCCG TCACGCCCAA C---GGACGC ATCTCGCCCG AGGACAGCGG CCTGTGGCAA GACAGC---- ---------CA
SEQ 23          CTGGCCTTGT AATGGTAGAA GCGACAGCGG TTTCCCCAGA G---GGACGA ATTTCACCTA ATGATTCAGG ATTATGGATG GAGTCG---- ---------CA
SEQ 25          CCGCCCTGTC CATGGTCGAG GCCACCGCCG TCGAGGCTCG T---GGCCGC ATCTCCCCCG AGGATGTCGG TTTGTGGCAG GACTCG---- ---------CA
SEQ 26          CCGCCCTGTC CATGGTCGAG GCCACCGCCG TCGAGGCTCG T---GGCCGC ATCTCCCCCG AGGATGTCGG TTTGTGGCAG GACTCG---- ---------CA
SEQ 28          CCGGATTGTC CATGGTGGAG GCTACCGCTG TACAAAACCA C---GGTCGC ATCACACCTC AGGATGTTGG TCTGTGGGAA GACGGC---- ---------CA
SEQ 29          CCGGATTGTC CATGGTGGAG GCTACCGCTG TACAAAACCA C---GGTCGC ATCACACCTC AGGATGTTGG TCTGTGGGAA GACGGC---- ---------CA
SEQ 32          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34          CGGGTCTCAT TGTCACAGAA GTCAACGCAG TTTCACCAGA G---GGACGA ATCAGTCCTG AGGATGCAGG CATCTACGAT GATGGG---- ---------CA
SEQ 36          CGGGACTGTC CATGGTAGAG GCCACCGCTG TTCAAAACCA C---GGTCGC ATCACGCCTC AGGACGTTGG TCTCTGGGAA GATGGA---- ---------CA
SEQ 37          CGGGACTGTC CATGGTAGAG GCCACCGCTG TTCAAAACCA C---GGTCGC ATCACGCCTC AGGACGTTGG TCTCTGGGAA GATGGA---- ---------CA
SEQ 39          CCGGACTCAC CTGCGTTGAA GCCACAGCCG TGACTCCTCA A---GGTCGC ATCACGCCTG AAGACGTCGG TATCTGGCAA GATTCT---- ---------CA
SEQ 41          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43          GGGGCCAGAT CCAGACGGGC AACGTCATGA TCGACCCGGA GCACCTCGAG GCCCCGGGCA ACATGGTGGT GCCGCGCGAC GCCGAGCCCT CGGGCGAGCG
SEQ 82          CTGGCCTCAT CATGCTAGAA GCTACCGCAG TTCAAGCACG T---GGCCGT ATCACACCTG AAGATTCTGG CATCTGGCTA GACTCT---- ---------CA
SEQ 84          TGGGAAACGT CATGGTCGAA GCATCTGGTG TTGAGCCAGA G---GGGAGG ATCACGCCTC AGGACCTGGG TATTTGGTCG GAACAG---- ---------CA

                801        811        821        831        841        851        861        871        881        891
                ---------- ---------- ---------- ---------- --------5-- ---------- ---------- ---------- ---------- ---------6
                ---------- ---------- ---------- ---------- *********- ******---- ---------- ---------- ---******* **********
SEQ 1           GATCGCCCCG ---ATGCGCC GGGTCATCGA CTTCGTGCAC AGCCAGGGC- CAGAAGATCG GCGTG----- ----CAGCTT GCCCATGCCG GCCGGAAAGC
SEQ 2           GATCGCCCCG ---ATGCGCC GGGTCATCGA CTTCGTGCAC AGCCAGGGC- CAGAAGATCG GCGTG----- ----CAGCTT GCCCATGCCG GCCGGAAAGC
SEQ 4           GATTGAGCCA ---TTGAGCC GCGTGATCGA GTTTGTCCAC AGTCAGAAC- CAGCTTATCG GCGTG----- ----CAGATC GCACACGCAG GTCGCAAGGC
SEQ 5           GATTGAGCCA ---TTGAGCC GCGTGATCGA GTTTGTCCAC AGTCAGAAC- CAGCTTATCG GCGTG----- ----CAGATC GCACACGCAG GTCGCAAGGC
SEQ 7           ATTCCTGGGG ---CTGAAGC GGGTCGTCGA GTTCATGCAC GCACAGGGC- GCCAAGGTCG GGATC----- ----CAGCTT GCGCATGCGG GCCGGAAAGC
SEQ 9           GATTGCGCCC ---ATGAAGC GCGTCATCGA CTTCGTGCAC TCGCAGTCC- CAGAAGATTG GCGTG----- ----CAGATT GCCCACGCCG GCCGCAAGGC
SEQ 11          AGCAGAGAAA ---TTGAAAC CAATTGTCGA TTACGCTCAT TCTCAAAAG- CAATTAATTG CCATC----- ----CAATTG GGCCATGGTG GTAGAAAAGC
SEQ 13          AGCTCACAGT ---TTACGGA AAATTGTTGA TTTTATTCAT GATCAAGAC- GGAATTTGCT GTATA----- ----CAATTG AATCACGCTG GGCGAAAGAT
SEQ 15          GATTGCGCCC ---CTCAAGC GCATCGTCGA CTACATCCAC TCCCAGGGC- CAGAAGGCCG GTATC----- ----CAGCTT GCCCACGCCG GCCGCAAGGC
SEQ 17          GACCGTCACG GCCTTCAAGG CCTGGGCGGA CGCCGCGCGC CTGAATGGC- CAGTCCAAAA CGCCTGTGGT CGTGCAGATC AACCACCCTG GTCGCCAGAG
SEQ 18          GACCGTCACG GCCTTCAAGG CCTGGGCGGA CGCCGCGCGC CTGAATGGC- CAGTCCAAAA CGCCTGTGGT CGTGCAGATC AACCACCCTG GTCGCCAGAG
SEQ 20          GATCGCTCCT ---CTGCGCC GCATCGTCGA CTACGTGCAC AGCCAGGGC- CAAAAGATCG CCATC----- ----CAACTG GCTCATGCCG GCCGCAAGGC
SEQ 21          GATCGCTCCT ---CTGCGCC GCATCGTCGA CTACGTGCAC AGCCAGGGC- CAAAAGATCG CCATC----- ----CAACTG GCTCATGCCG GCCGCAAGGC
SEQ 23          AATGAAGCCG ---TTACGAA GAATTGTTGA ATTTGCTCAT TCGCAAAAT- CAAAAAATTG GGATT----- ----CAATTG GCGCATGCTG GTAGAAAGGC
SEQ 25          GATTGCGCCG ---CTGAAGC GCATCGTCGA CTTTATCCAC TCGCAGAAC- CAGGTCGCGG CCATC----- ----CAGCTC GCCCACGCCG GTCGCAAGGC
SEQ 26          GATTGCGCCG ---CTGAAGC GCATCGTCGA CTTTATCCAC TCGCAGAAC- CAGGTCGCGG CCATC----- ----CAGCTC GCCCACGCCG GTCGCAAGGC
SEQ 28          GATCGAGCCT ---CTGAAGC GCATCACCAC TTTCGCGCAC AGTCAGAGC- CAGAAAATTG GTATC----- ----CAGCTG TCGCATGCGG GTCGCAAGGC
SEQ 29          GATCGAGCCT ---CTGAAGC GCATCACCAC TTTCGCGCAC AGTCAGAGC- CAGAAAATTG GTATC----- ----CAGCTG TCGCATGCGG GTCGCAAGGC
SEQ 32          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34          GCTTGGACCT ---CTCCGGG ATATTGTGGA CTTTGTACAC AGCCAGGGC- GCCAAGATTG CTATT----- ----CAGATA GGTCATGCTG GGAGAAAAGC
SEQ 36          AATCGAGCCC T---TTGAAGC GCATCACTAC TTTTGCCCAC AGCCAAAGCW CAGAAGATTG GTAT------ ---TCAGCTC TCGCACGCTG GTCGTAAGGC
SEQ 37          AATCGAGCCC ---TTGAAGC GCATCACTAC TTTTGCCCAC AGCCAAAGC- CAGAAGATTG GTAT------ ---TCAGCTC TCGCACGCTG GTCGTAAGGC
SEQ 39          GATCGAGCCT C---TTGCCAA GGTCGTC-GA GTTTGCCCAC TCCCAGAAC- CAGAAGATCA TGATT----- ----CAGTTG GCGCATGCGG GCCGCAAAGC
SEQ 41          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43          CTTCGACATG TTTTCCAAGC TCGCCGCCGC CGCCAAGGAG CACGGCAGC- CTC-ATCGTC GCG------- ----CAGGTC GGACACCCCG GTCGCCAGGC
SEQ 82          TGTTGAGGGA ---CTGCGAA AGCACGTCGA GTTTGCCCAT GCCAACAAC- TCTCTTATCG GTATC----- ----CAGATT GGCCATGCTG GTCGCAAGGC
SEQ 84          TCGGGATGCA ---CACAAGG CGCTGGTGTC GGTGCTCAAG TCCTTCACG- GATGGTCTGG GTGTA----- ----GGGCTG CAACTGGCGC ATGCGGGAAG
```

```
        901        911        921        931        941        951        961        971        981        991
        ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
        ********** *********_ ---------- ---------- ---------- ---------- ---------- ---------- **********
SEQ 1   CACCACCGTT GCGCCCTGGA TCTCA----- ---------- ---------- ---------- -TTCTCGGCC ATCGCGACGG AGAAGGTCGG CGGATGGCCG
SEQ 2   CACCACCGTT GCGCCCTGGA TCTCA----- ---------- ---------- ---------- -TTCTCGGCC ATCGCGACGG AGAAGGTCGG CGGATGGCCG
SEQ 4   CAGCACCGTC GCGCCATGGC TCTCG----- ---------- ---------- ---------- -GCCAACGAT ACCGCCTCCG AGAAGATGGG CGGCTGGCCA
SEQ 5   CAGCACCGTC GCGCCATGGC TCTCG----- ---------- ---------- ---------- -GCCAACGAT ACCGCCTCCG AGAAGATGGG CGGCTGGCCA
SEQ 7   GAGTGCCGTT GCGCCGTGGC TGGCG----- ---------- ------GCGC AGGCGGGCAA GTCGAGTCTG AAGGCGGATG AGAGCGTTGG CGGGTGGCCC
SEQ 9   TTCGAACATC GCCCCCTGGC TCATG----- ---------- ---------- --------AA CAAGGGCATC GTCGCGACGG AGAAGGTCGG TGGCTGGCCG
SEQ 11  TTCTGGTCAG CCCTTATTTT TGCAC----- ---------- ---------- ---------- -TTGGAACAA GTTGCAGATA AATCTGTCAA TGGGTTTGCC
SEQ 13  TGTTGAAGGG GTACCATTCC AACAA----- ---------- ---------- ---------- ---------- ---------- --ATACAACA TGGTTGGCAA
SEQ 15  CTCCACCAAG GCCCCCTGGC ACTAC----- ---------- ---------- --CAGCGCGG CAAGAGCGAG CTTGCCGGCC CCGAGCAGGG TGGCTGGCCC
SEQ 17  TCCGATGGGC GCGGGCACGC GGGGA----- ---------- ------CTGT GGGAGAAGGC GGTGGCGCCC TCGCCGGTGC CGTTGGTGTT GGGAGAGGCG
SEQ 18  TCCGATGGGC GCGGGCACGC GGGGA----- ---------- ------CTGT GGGAGAAGGC GGTGGCGCCC TCGCCGGTGC CGTTGGTGTT GGGAGAGGCG
SEQ 20  CAGCACAAAG GCCCCCTGGC ACGACTCCTT CACCCCCAGC GGCGAGTATA AGCCGAGAGA GGGCTTACAG GTCGTCGGAC CCGAGTATGG CGGCTGGCCT
SEQ 21  CAGCACAAAG GCCCCCTGGC ACGACTCCTT CACCCCCAGC GGCGAGTATA AGCCGAGAGA GGGCTTACAG GTCGTCGGAC CCGAGTATGG CGGCTGGCCT
SEQ 23  TAGCACCACT GCTCCTTATC GAGGA----- ---------- ---------- ---------- ----TACACA GTTGCGACTG AAGCTCAAGG TGGGTGGGAG
SEQ 25  TAGCACCCTG GCACCGTGGA TCACC----- ---------- ---------- --GAGGCTCG CGGCAAGGCG CTGGCTCAGG AGAGCGAGAA CGGCTGGCCC
SEQ 26  TAGCACCCTG GCACCGTGGA TCACC----- ---------- ---------- --GAGGCTCG CGGCAAGGCG CTGGCTCAGG AGAGCGAGAA CGGCTGGCCC
SEQ 28  CAGTTGCGTA TCTCCCTGGC TAAGC----- ---------- ---------- ---------- -GTAAATGCT GTCGCGGCGG AAGAAGTGGG TGGCTGGCCA
SEQ 29  CAGTTGCGTA TCTCCCTGGC TAAGC----- ---------- ---------- ---------- -GTAAATGCT GTCGCGGCGG AAGAAGTGGG TGGCTGGCCA
SEQ 32  ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34  GAGCACAGTC GTACCGTGGC TGGAC----- ---------- ---------- ---------- -CGCAAGAAC ACTGCTTTTA ---------- ----------
SEQ 36  TAGTTGTGTA TCTCCGTGGT TGAGC----- ---------- ---------- ---------- -ATCAACGCT GTTGCCGCTA AGGAAGTCGG TGGCTGGCCA
SEQ 37  TAGTTGTGTA TCTCCGTGGT TGAGC----- ---------- ---------- ---------- -ATCAACGCT GTTGCCGCTA AGGAAGTCGG TGGCTGGCCA
SEQ 39  GAGCACTGTG GCACCATGGT TAAGC----- ---------- ---------- ---------- -GGCGGCGAT GTTGCTGGTG AGGACGTCAA CGGATGGCCA
SEQ 41  ---------- ---------- ---------- ---------- ---------- ------GACT GCCGAGTAAA CGCCCGGCA AGGAGGCGGG AGGATGGCCG
SEQ 43  CCGCGGCAGC GTCCAGCAGC ACCCC----- ---------- ---------- --ATTAGCGC CAGCGACGTG CAGCTTAAGC AGGAGATG-- ----------
SEQ 82  CTCCTGCGTT GCTCCTTGGT TAGAC----- ---------- ---------- ---------- -GCCGGACTT GCCGCTGAAA AGGCCGCTGG TGGATGGCCC
SEQ 84  GAAGGCCTCG GACTGGTCAC CTTTC----- ---------- ---------- ------TACC GCGGAGAAAA GAAGCAAAAG TTTGTGACGC AGGAGGAAGG TGGCTGGCCG

        1001       1011       1021       1031       1041       1051       1061       1071       1081       1091
        ---------- ---------- -7-------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
        ********** ********** ********-- ---------- ---------- ---------- -********* ********** *****----- ----------
SEQ 1   GACCCGCGTC AAAGGGCCCG GCGATATC-- ---------- ---------- ---------- -CCCTTTGCG GAGCCCTTCG CCAAGCCCAA GGCCATGACG
SEQ 2   GAC-CGCGTC AAAGGGCCCG GCGATATC-- ---------- ---------- ---------- -CCCTTTGCG GAGCCCTTCG CCAAGCCCAA GGCCATGACG
SEQ 4   GGC-CGCGTC AAAGGCCCGA CAAATGTG-- ---------- ---------- ---------- -CCCTTCACC GTTAAGAACC CTGTGCCGAA GGAGATGACC
SEQ 5   GGC-CGCGTC AAAGGCCCGA CAAATGTG-- ---------- ---------- ---------- -CCCTTCACC GTTAAGAACC CTGTGCCGAA GGAGATGACC
SEQ 7   GCG-GATGTG GTGGGTCCGT CGGGCGGG-- ---------- ---GAGGAGC ATATCTTTAG TCCCGAGGAG GATGCGTATT GGGTGCCGCG GGCGCTGAGC
SEQ 9   GAT-CGTGTG ATCGGCCCGT CCACCGTG-- ---------- ---------- ---------- -CCCTTCCAC GAGACTTTCC CCACCCCCAA GGCCATGACC
SEQ 11  GAC-AAAGCA GTTGCTCCTT CTGCATTG-- ---------- ---------- ---GCATTC- ---------- -AGACCAAAT GGTAATTTAC CTGTTCCTAA TGAGTTGACC
SEQ 13  GAA-CATTGT GTGGGGCCAT CTACTGAG-- ---------- ---------- ---------- -CCATTTAGT GATTCACACA ATACACCACG AGAATTGACT
SEQ 15  GAG-AACGTC TGGGCCCCCA GCGCCATC-- ---------- ---------- ---------- --------AG CTACAACGAG GAGACCTTCC CCTTCCCCAA GGAGATGACC
SEQ 17  TTT-GTGCCT CGCTTGTTGT CGAAAGTG-- ---------- ---------- ---------- ---------- ---CTTTTCG GCACGCCGCG GGAGCTGACG
SEQ 18  TTT-GTGCCT CGCTTGTTGT CGAAAGTG-- ---------- ---------- ---------- ---------- ---CTTTTCG GCACGCCGCG GGAGCTGACG
SEQ 20  GAT-GACGTC TGGGCCCCGA GCGCCATC-- ---------- ---------- ---------- -CCGTTCTCG GAGGACTTTC CGAACCCCAA GGAGATGACC
SEQ 21  GAT-GACGTC TGGGCCCCGA GCGCCATC-- ---------- ---------- ---------- -CCGTTCTCG GAGGACTTTC CGAACCCCAA GGAGATGACC
SEQ 23  AAT-GATGTT TATGGACCAA ATGAAGAC-- ---------- ---------- ---------- -AGGTGGGAC GAAAACCACG CTCAACCTCA TAAGTTAACT
SEQ 25  GAC-GACGTT GTGGCTCCCA GCGCGATT-- ---------- ---------- ---------- -CCTTACACC AAGGACTGGG CCACACCGCG TGAGTTGACT
SEQ 26  GAC-GACGTT GTGGCTCCCA GCGCGATT-- ---------- ---------- ---------- -CCTTACACC AAGGACTGGG CCACACCGCG TGAGTTGACT
SEQ 28  GAC-AATATC GTTGCTCCCT CGGCCATC-- ---------- ---------- ---------- --------GC ACAAGAAAAT GGTGTGAACC CAGTTCCCAA GGCTTTCACG
SEQ 29  GAC-AATATC GTTGCTCCCT CGGCCATC-- ---------- ---------- ---------- --------GC ACAAGAAAAT GGTGTGAACC CAGTTCCCAA GGCTTTCACG
SEQ 32  ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34  ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 36  GAC-AACATT GTTGCTCCTT CTGCCATC-- ---------- ---------- ---------- --------GC ACAAGAAGCT GGCGTGAACC CTGTTCCCAA GGCCTTCACC
SEQ 37  GAC-AACATT GTTGCTCCTT CTGCCATC-- ---------- ---------- ---------- --------GC ACAAGAAGCT GGCGTGAACC CTGTTCCCAA GGCCTTCACC
SEQ 39  CAG-GATGTC TGGGCGCCCA GTGCGATT-- ---------- ---------- ---------- ---------- -CCATGGAAC GAGAAGCACG CTGTCCCAAA GGAGATGTCG
SEQ 41  GAG-GATGTT GTGGGTCCGT CGGGTGGGGA GGACTTTACG TGGGATGAGA GGTCCTCGAG CGACCCTAGT GGAGGCTACT ATGCGCCGAG AGAGTTGTCG
SEQ 43  ---------- ---------- ---------- ---------- ---------- ---------- ----TTTGGG TCAAAGTTTG GCGTGCCCAG GCCCGCTACC
SEQ 82  GAT-GACGTT GTCGGACCTA GCAACGAG-- ---------- ---------- ---------- -CCTTTTGCT CCTGGCTACC CTACCCCCCG TGCTATTACT
SEQ 84  GAT-CGTGTC GTCGCTCCTT CGGCCATC-- ---------- ---------- ---------- -GCATATGCG CAAGGTCACG TTACCCCTCG AGCTCTCACG

        1101       1111       1121       1131       1141       1151       1161       1171       1181       1191
        ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
        ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 1   CTGGATGA-G ATCGAGCAGT TCAAGAAGGA CTGGGTGGCG GCCACGAAGC GCGCCATCGC CG---CCGGT GCGGACTTTG TCGAGATTCA CAATGCGCAT
SEQ 2   CTGGATGA-G ATCGAGCAGT TCAAGAAGGA CTGGGTGGCG GCCACGAAGC GCGCCATCGC CG---CCGGT GCGGACTTTG TCGAGATTCA CAATGCGCAT
SEQ 4   AAGCAGGA-T ATCGAGGATC TGAAGACCGC CTGGGTGGCC GCTGTCAAAC GGGCTGTTAA GG---CCGGA GCCGACTTTA TCGAGATCCA CAATGCGCAT
SEQ 5   AAGCAGGA-T ATCGAGGATC TGAAGACCGC CTGGGTGGCC GCTGTCAAAC GGGCTGTTAA GG---CCGGA GCCGACTTTA TCGAGATCCA CAATGCGCAT
SEQ 7   ACGGCCGA-G GTCCGTCAGG TGGTGGCGGC GTTTGCGAAG AGCGCGCGGC TAGCGGTGCA GG---CTGGG GTGGATGTTA TCGAGATCCA TGGGGCGCAT
SEQ 9   AAGGACGA-C ATCGAGCAGT TCAAGCGCGA CTGGTTTGAT GCGTGCAAGC GGGCCATTGC CG---CTGGC GCGGACTTCA TCGAGATCCA CAATGCCCAC
SEQ 11  AAAGATGA-A ATCAAACGTG TTGTTAAGGA TTTTGGTGCT GCTGCTAGAA GAGCTGTTGA AATCAGTGGC TTTGATGCAG TTGAGATTCA TGGTGCTCAT
SEQ 13  GTTAATGA-A ATAAATTCAA TTGTGGAAGA CTTTGCCAAT GCAGCTTGGC GGGCTGTGGA AATCTCAAAA TTCGATGCCA TTGAAATACA TTGTGCTAAT
SEQ 15  GTCGAGCA-G ATCCACGAGC TCGTCGAGGC CTGGAAGGCG TCTGCCCAGC GTGCCCTCAA GG---CCGGC TTCGACCTCA TTGAGATCCA CGCCGCCCAC
SEQ 17  GTTGCGGA-G ATCAAGGATA TCGTGCAAAA GTTTGCGGTG ACGGCGAGGA TCACGGCCGA GG---CCGGG TTCAATGGCG TGGAGATCCA TGCGGCGCAT
SEQ 18  GTTGCGGA-G ATCAAGGATA TCGTGCAAAA GTTTGCGGTG ACGGCGAGGA TCACGGCCGA GG---CCGGG TTCAATGGCG TGGAGATCCA TGCGGCGCAT
SEQ 20  GTTGAGGA-G ATTGAGGGAC TCGTCACCAG CTTTGTGGAC GCTGCCAAGC GTGCCATCGA GG---CCGGC GTCGACATTA TTGAGATTCA CGGCGCTCAC
SEQ 21  GTTGAGGA-G ATTGAGGGAC TCGTCACCAG CTTTGTGGAC GCTGCCAAGC GTGCCATCGA GG---CCGGC GTCGACATTA TTGAGATTCA CGGCGCTCAC
SEQ 23  GAAAAGCA-A TATGATGAAT TAGTGGATAA GTTTGTTGTT GCTGCGAAGC GTGCAGTTGA AA---TAGGT TTTGATGTAA TTGAAATTCA TGGCGCTCAT
SEQ 25  ACCGAGGRRG TCGAGGGTCT GGGTGAAGAA GTTCGCCGAG TCGGCCAAGA GGTCAAATCG A---GCTGGT TTTGACGTCA TTGAGATCCA CGCCGCTCA-
SEQ 26  ACCGAGGR-G TCGAGGGTCT GGGTGAAGAA GTTCGCCGAG TCGGCCAAGA GGTCAAATCG AG---CTGGT TTTGACGTCA TTGAGATCCA CGCCGCT---
SEQ 28  AAGGAGGA-T ATAGAGCAAC TCAAGAGCGA CTACGTGGAA GCGGCAAAAC GAGCCATCCA TG---CTGGT TTCGATGTTA TCGAAATTCA TGCAGCTCAT
SEQ 29  AAGGAGGA-T ATAGAGCAAC TCAAGAGCGA CTACGTGGAA GCGGCAAAAC GAGCCATCCA TG---CTGGT TTCGATGTTA TCGAAATTCA TGCAGCTCAT
SEQ 32  ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34  ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 36  AAGGAGGA-T ATCGAGGAAC TCAAGAATGA CTTTCTGGCT GCAGCMAAAC GAGCCAWCCG CGC---TGGT TTTGATGTCA TCGAGATCCA TGCAGCTCAT
SEQ 37  AAGGAGGA-T ATCGAGGAAC TCAAGAATGA CTTTCTGGCT GCAGCMAAAC GAGCCAWCCG CGC---TGGT TTTGATGTCA TCGAGATCCA TGCAGCTCAT
SEQ 39  TTGGATGA-T ATCGAGGCTT TCAAGAAGGC GTTTGGAGAG GCGGTCAAGC GGGCATTGAA GGC---TGGA TTTGATGTTA TTGAGATTCA CAATGCTCAC
SEQ 41  GTCAGAGA-G ATCAAGGAGA TGGTCCAAGA CTGGGCGACA GCAGCGAAAA GGGCGGTGAA AGC---GGGC GTGGATGTAA TCGAAATTCA CGGCGCGCAT
SEQ 43  AAGGAGGA-T ATTAAGGCGG TGATTGAGGG TTTTGCCCAC ACGGCCGAGT ACCTTGAAAA GGC---CGGT TTCGACGGTA TCGAATTGCA CGCCGCCCAC
SEQ 82  CTTGAAGA-G ATTGAACAGT TGAAGGAGGA CTTTGTTTCC GGTGTTCGTC GAGCGGTTGA AG---CAGGA TTTGACACTA TCGACTTCCA TTTCGCTCAC
SEQ 84  ACCGAGGA-C ATCAACAAGT TGCAAGACAA ATTCGTTCAG TCGGCACGAT GGGCGTTTGA AG---CTGGG TATGACTACG TCGAACTTCA CAGCGCTCAC
```

```
          1201       1211       1221       1231       1241       1251       1261       1271       1281       1291
          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 1     GGATACCTGC TGTCGTCATT CCTCTCGCCG GCCGCCAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 2     GGATACCTGC TGTCGTCATT CCTCTCGCCG GCCGCCAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 4     GGCTATCTTC TGATGTCGTT CCTCTCCCCT GCGGTCAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 5     GGCTATCTTC TGATGTCGTT CCTCTCCCCT GCGGTCAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 7     GGCTATCTCA TCAACGAGTT CCTGAGCCCG GTCACGAAT- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 9     GGGTATCTTC TCTCGTCTTT CCTATCACCG TCTTCCAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 11    GGTTATTTGA TTAATGAGTT CTATAGTCCT ATTTCAAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 13    GGATGTTTAA TACACCAATT TTTAAGTAAA TTGACAAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 15    GGCTACCTCA TTTCCGAGTT CTTGAGCCCC ATCTCCAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 17    GGATACCTGT TGGCGCAGTT CTTGAGCAAG AAGACAAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 18    GGATACCTGT TGGCGCAGTT CTTGAGCAAG AAGACAAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 20    GGTTACCTGA TCACCGAGTT CCTTTCGCCG CTATCAAACG TAAGTGGAGA TACTTTGTGT GGGGCTGTGC GCATACTCCC TCGGGTGTGA CTTCTATTAA
SEQ 21    GGTTACCTGA TCACCGAGTT CCTTTCGCCG CTATCAAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 23    GGTTATCTTA TATCGTCAAC AGTTAGTCCT GCCACTAAT- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 25    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 26    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 28    GGATATCTAC TGCATCAATT CTTGAGTCCG GTAAGCAAT- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 29    GGATATCTAC TGCATCAATT CTTGAGTCCG GTAAGCAAT- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 32    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 36    GGATACKTGC TTCACCAGTT CTTGAGTCCA GTCAGTAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 37    GGATACKTGC TTCACCAGTT CTTGAGTCCA GTCAGTAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 39    GGATACCTCC TCCACGAATT CATCTGCCTG AGAGCAACA- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 41    GGGTACCTCA TCCACGAATT CCTCTCACCC ATTACCAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43    GGTTACCTGC TGGCCCAATT CCTGTCCGAA ACAACCAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 82    GGTTATCTTG TTTCCAGCTT CCTGTCCCCT GCCACCAAC- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 84    GGATACCTGA TGCACTCGTT CCTCAGCCCG TTGACCAAT- ---------- ---------- ---------- ---------- ---------- ----------

          1301       1311       1321       1331       1341       1351       1361       1371       1381       1391
          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 1     ---------- ---------- --AACCGCAC GGACCAGTAC GGCGGGTCGT TCGAGAACCG CATCCGGCTG TCTCTCGAGA TTGCGCAGTT GACTCGGGAC
SEQ 2     ---------- ---------- --AACCGCAC GGACCAGTAC GGCGGGTCGT TCGAGAACCG CATCCGGCTG TCTCTCGAGA TTGCGCAGTT GACTCGGGAC
SEQ 4     ---------- ---------- --ACGAGAAC AGACGAGTAC GGAGGCAGTT TTGAGAATCG CATCCGGCTC AGTCTGGAGA TCGCCAAGCT CACCCGCGAA
SEQ 5     ---------- ---------- --ACGAGAAC AGACGAGTAC GGAGGCAGTT TTGAGAATCG CATCCGGCTC AGTCTGGAGA TCGCCAAGCT CACCCGCGAA
SEQ 7     ---------- ---------- --AAGCGGAC GGATGCGTAC GGCGGGAGCT TTGAGAACCG GACCCGGATC GTGCGCGAGG TTGCGGCGGC TATTCGTGCG
SEQ 9     ---------- ---------- --ACGCGCAC CGACGAGTAC GGCGGCTCCT TTGAGAACCG CATCCGGCTC TCTCTCGAAA TCGCCCAGGT CACCCGTGAC
SEQ 11    ---------- ---------- --AAGAGAAC AGATGAATAC GGTGGCAGTT TTGAAAATAG AACCAGATTT TTAAAGGAAG TTATCGATAG TGTTAAATCA
SEQ 13    ---------- ---------- --AAGAGAGC TGACCAATAC GGGGGCTCAT TTGAAAACAG AGTTAGATTT CTTTTACAAA TAATTGAGAA TATAAAACGA
SEQ 15    ---------- ---------- --CAGCGTAC CGACCAGTAC GGTGGCTCCT TCGAGAACCG CACCCGCGTT CTCCGCGAGA TCATCTCGGC CGTCCGCTCC
SEQ 17    ---------- ---------- --AGGCGCGG GGATGAGTAT GGCGGGTCGG CTGAGAACAG GGCGAGGATT GTTGGGGAGA TTATTAAGGA GTGCAGGAGG
SEQ 18    ---------- ---------- --AGGCGCGG GGATGAGTAT GGCGGGTCGG CTGAGAACAG GGCGAGGATT GTTGGGGAGA TTATTAAGGA GTGCAGGAGG
SEQ 20    CATTTTATTT CCTGGCACGC AGAAACGGAC AGACAAGTAC GGCGGCAGCT TTGAGAACCG CACCCGGGTC CTGATCGATA TTATCAAGGC CGTCCGGGCA
SEQ 21    ---------- ---------- --AAACGGAC AGACAAGTAC GGCGGCAGCT TTGAGAACCG CACCCGGGTC CTGATCGATA TTATCAAGGC CGTCCGGGCA
SEQ 23    ---------- ---------- --GACCGCAA TGACAAGTAT GGTGGGACAT TTGAGAAACG TATTTTGTTT CCTATGGAAG TTGTCCATTC TGTTCGTAAA
SEQ 25    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 26    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 28    ---------- ---------- --CAAAGAAC CGACGAGTAT GG-------- ---------- ---------- ---------- ---------- ----------
SEQ 29    ---------- ---------- --CAAAGAAC CGACGAGTAT GG-------- ---------- ---------- ---------- ---------- ----------
SEQ 32    ---------- ---------- -------AAC CGACGAGTAT GGTGGCAGTT TCGAGAACCG TATCAGAGTT GTCTTGGAAA TCCTTGACCT CATCCGCGCT
SEQ 34    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 36    ---------- ---------- --CAAAGAAC CGATGAGTAT GGTGGCAGCT TCGAGAACCG TATCAGAGTC GTCTTGGAGA TCATTG---- ----------
SEQ 37    ---------- ---------- --CAAAGAAC CGATGAGTAT GGTGGCAGCT TCGAGAACCG TATCAGAGTC GTCTTGGAGA TCATTG---- ----------
SEQ 39    ---------- ---------- --CCAGGACC GACAAGTACG GGCGGAAGCT GGGAAAACCG CACTCGTCTG ACAATGGAAA GTCGTCGACC TTGTCCGCAG
SEQ 41    ---------- ---------- --CGCCGGAC AGATTCTTAC GGCGGTTCTT TCGAAAACCG TACCCGTCTA CTCATTGAAA TCGTAACAGC CGTCCGAGCC
SEQ 43    ---------- ---------- --CAGCGCAC CGACGAGTAC GGCGGCAGCC TCGAAAACCG CATGCGGCTA ATCCTCGAGG TCACGGCCGA GGTCCGCAGG
SEQ 82    ---------- ---------- --AAGCGTAC CGACAAGTAC GGAGGTAGCT TCGAGAACAG AGTGCGCCTT GCTCTCGAGA TTGTCGAGGC TGCACGAGCT
SEQ 84    ---------- ---------- --CAGCGTAC CGACGAGTAC GGCGGTAGCC TGGAGAACCG CGCTCGATTT CTGCTCAACG TTGCCCGTCG AATCCGCCAA

          1401       1411       1421       1431       1441       1451       1461       1471       1481       1491
          ---------- ---------- ---------- ---------- ---------- ---------- ----------* ********** *---------- ----------
          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---8------ ---------- ----------
SEQ 1     GCCGTCGGCC CTCATGTGCC C--------- ---------- -----GTTTT CCTGCGCATT TCGGCCTCGG ACTGGTGCGA GGAGACCCTG CCGGA-----
SEQ 2     GCCGTCGGCC CTCATGTGCC C--------- ---------- -----GTTTT CCTGCGCATT TCGGCCTCGG ACTGGTGCGA GGAGACCCTG CCGGA-----
SEQ 4     AATGTGCCCA AGGATATGCC T--------- ---------- -----GTCTT CCTGCGGGTC TCCGCCACCG ATTGGCTGGA GGAGGTGCAG CCGAA-----
SEQ 5     AATGTGCCCA AGGATATGCC T--------- ---------- -----GTCTT CCTGCGGGTC TCCGCCACCG ATTGGCTGGA GGAGGTGCAG CCGAA-----
SEQ 7     GTGATTCCCG AGGGGATGCC C--------- ---------- -----CTGTT TCTGCGTATC AGCGCCACGG AGTGGTTGGA GGGTCAGCCG GTGGC-----
SEQ 9     GCCGTCGGCC CCAACGTTCC T--------- ---------- -----GTTTT TCTCCGTGTC TCCGCGACGG ACTGGATCGA GGAGACCCTC CCCGA-----
SEQ 11    AGTATTCCAA ACGATGTTCC A--------- ---------- -----GTGTT TTTGAGAATC TCTGCTGCTG AAAATAGTCC TGATCCA--- ----------
SEQ 13    AAGATAGAAA CA------CC G--------- ---------- -----ATTTT CTTAAAGTTT CCAATGTCAG ATAATTGTAG TGATCCG--- ----------
SEQ 15    GTCATCCCCG AGGACATGCC C--------- ---------- -----CTCTT CGTCCGTGTC TCCGCCACCG AGTGGATGGA GTACACC--- ----------
SEQ 17    CAGGTGACTG AGGCGGTGGG TGAAGAGGAG GCGAAGAAGT TTGTGGTGGG AATCAAGCTG AACAGTGCGG ATTGGCAGGC GGGACGCGAT GGA------A
SEQ 18    CAGGTGACTG AGGCGGTGGG TGAAGAGGAG GCGAAGAAGT TTGTGGTGGG AATCAAGCTG AACAGTGCGG ATTGGCAGGC GGGACGCGAT GGAAAG----
SEQ 20    GTGATTCCCG AGGAGATGCC A--------- ---------- -----CTCTT CGTCCGAATC TCCGCGACCG AATGGATGGA GTACGCCGGC ----------
SEQ 21    GTGATTCCCG AGGAGATGCC A--------- ---------- -----CTCTT CGTCCGAATC TCCGCGACCG AATGGATGGA GTACGCCGGC ----------
SEQ 23    GCAATTCCAG ATAGTATGCC C--------- ---------- -----TTGTT TTATAGAGTA ACGGCTACAG ATTGGTTGCC CAAAGGACAA ----------
SEQ 25    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 26    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 28    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 29    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 32    GCCATCCCCG AAACTACACC T--------- ---------- -----GTCCT CGTTCGTGTC AGTGCAACTG ATTGGTTCGA GTTTGACTCT CAATTCAAAG
SEQ 34    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 36    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 37    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 39    CATT------ ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 41    GCGATGCCCT CCAGCATGCC T--------- ---------- -----CTCTT CCTCCGCCTC TCCTCTACAG AATGGATGGA AGATACCGAC ATCGGC-----
SEQ 43    CGGACGAGCA AGAATTTCAT C--------- ---------- -----CTCGG CATCAAAATT AACAGCGTCG AGTTCCAGGA GAAG------ ----------
SEQ 82    GTTATGCCTG AGGACATGCC C--------- ---------- -----TTGTT CACTCGCATC AGTGGAACTG ACTGGCTGGA GAACAACCCT GAG-------
SEQ 84    GAATTCCCCA ACAAGGGT-- ---------- ---------- -----CTCTG GGTGCGCGTC AGCTCCACCG ACTGGGCCGA CCAAGCGCAC CAA-------
```




1801 1811 1821 1831 1841 1851 1861 1871 1881 1891
SEQ 1 -----AAGCT GCTGGTTGCC GCCGTGGGTG CCATCACC-- ---------- ---------- ---------- ---------- ------AACG GCAAGCAGGC
SEQ 2 -----AAGCT GCTGGTTGCC GCCGTGGGTG CCATCACC-- ---------- ---------- ---------- ---------- ------AACG GCAAGCAGGC
SEQ 4 -----AAACT CGCAGTGGCA TCAGTGGGTA TGATTGCC-- ---------- ---------- ---------- ---------- ------AGCG CGCATTTGGC
SEQ 5 -----AAACT CGCAGTGGCA TCAGTGGGTA TGATTGCC-- ---------- ---------- ---------- ---------- ------AGCG CGCATTTGGC
SEQ 7 -----GCTGG CGCGTCGACT CTTGTGGGTG CTGTAGGTCT GATCACCGAT TCGGAACAGG CGAGGGGACT AGTTCAGGGA GCGGACGAGG CGACTGCAGC
SEQ 9 -----AAGCT CCTTGTTGCG ACGGTGGGCA CGATCACG-- ---------- ---------- ---------- ---------- ------AACG GTAAGCAGGC
SEQ 11 -----AAGTT ATTGGTCAGT TGCGTTGGTG GGCTTGAA-- ---------- ---------- ---------- ---------- ---------A AAGATCCTGA
SEQ 13 -----CGATG TTTGATCGCA TGCAGTGGAG GATTAGAT-- ---------- ---------- ---------- ---------- ---------C GAGACATATT
SEQ 15 GCAAGCAGCT CCTCGTCGGT GCCGTCGGCT TGGTCACC-- --------TCG GCTGAGATCG CCAAGGAGAC CGTCCAGGAG AAGGAGGATG GCAGAGTCAC
SEQ 17 TCCCCAAGCT TCCTCTCATG GTCACCGGCG GCTTCCGC-- ---------- ---------- ---------- ---------- ------ACTC GTCAGGGCAT
SEQ 18 TCCCCAAGCT TCCTCTCATG GTCACCGGCG GCTTCCGC-- ---------- ---------- ---------- ---------- ------ACTC GTCAGGGCAT
SEQ 20 -----AGGTT GCTCATAGGC GCGGTCGGCA ACATCAAC-- ---------- ---------- ---------- ---------- ------ACGG CTGACATTGC
SEQ 21 -----AGGTT GCTCATAGGC GCGGTCGGCA ACATCAAC-- ---------- ---------- ---------- ---------- ------ACGG CTGACATTGC
SEQ 23 --------AT ACTACTTGGC GCTGTCGGAA TGATCAGG-- ---------- ---------- ---------- ---------- ------GATG GTCTTACGGC
SEQ 25 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 26 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 28 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 29 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------A CTGGACATCT
SEQ 32 -----AGTGT ACTTGTTTCA GCAGTAGGTG GAATCAAG-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 36 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 37 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 39 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 41 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---GTGGGCG CCATGGTCGA
SEQ 43 -----ATGGT GGTCTACACC ACCGGCGGCT TCAAGACG-- ---------- ---------- ---------- ---------- ------ATAG GTACCCTTGC
SEQ 82 -----AAGAT GTTGATCAGC ACTGTTGGTA GCATCAAG-- ---------- ---------- ---------- ---------- ----CCGTGG GAATGATGGA
SEQ 84 --ATCGAACC CGACGCGTCC AAACGCATGC TCGTCGGGG- ---------- ---------- ---------- ---------- ----------
1901 1911 1921 1931 1941 1951 1961 1971 1981 1991
SEQ 1 GAATCAG--- ---ATTCTAG AGGAGCAG-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 2 GAATCAG--- ---ATTCTAG AGGAGCAG-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 4 CAATTCC--- ---TTGTTGG AGAAGGAC-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 5 CAATTCC--- ---TTGTTGG AGAAGGAC-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 7 CGAGGCAATG CTGTCGGGAC CTGAACCC-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 9 GAACAAG--- ---CTGCTTG AGGAGGAG-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 11 ATTGCTCAAC AAATATTTAG AAGAAGGA-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 13 TAAACTCGAT GAGTTTATTG CTAATGGT-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 15 CATCCAGCGC GAGAACGGCG CCAAGACT-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 17 GGAGGCC--- ---GCTTTGG AATCCGAT-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 18 GGAGGCC--- ---GCTTTGG AATCCGAT-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 20 GCGCGATGTC GTGGATGAGC AGGGCGCCGA GAAGGTGGCC GAGGCCAAGC AGACGCATGA CACCATCGAG GTCGTGAGCG AATCACATGG CGGCAAGACC
SEQ 21 GCGCGATGTC GTGGATGAGC AGGGCGCCGA GAAGGTGGCC GAGGCCAAGC AGACGCATGA CACCATCGAG GTCGTGAGCG AATCACATGG CGGCAAGACC
SEQ 23 GAATGAAATC CTAGAAAGTG GAAAAGCT-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 25 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 26 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 28 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 29 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 32 TGCTGAA--- ---GAGGTTT TGCAATCT-- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 36 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 37 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 39 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 41 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43 CGCGCTGCAG GGCGTCGATG GG-------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 82 GGAGGAG--- ---ATCATCG CTGGAGGAGA GGACGATACC ---------- ---------- ---------- ---------- ---------- ----------
SEQ 84 AGGTTCC--- ---TACGATT CGCCCAAC-- ---------- ---------- ---------- ---------- ---------- ----------
2001 2011 2021 2031 2041 2051 2061 2071 2081 2091
SEQ 1 GATATCGACG TTGCGCTGGT TGGCCGTGGG TTCCAGAAGG ATCCCGGTCT GGCCTGGACG TTTGCTCAGC ACCTCGGCGT C---------- ----------
SEQ 2 GATATCGACG TTGCGCTGGT TGGCCGTGGG TTCCAGAAGG ATCCCGGTCT GGCCTGGACG TTTGCTCAGC ACCTCGGCGT C---------- ----------
SEQ 4 GGACTGGACC TTGTGCTGGT TGGACGTGGC TTCCAGAAGA ACCCGGGGCT GGTGTGGGCG TGGGCCGACG AGCTGAATGT A---------- ----------
SEQ 5 GGACTGGACC TTGTGCTGGT TGGACGTGGC TTCCAGAAGA ACCCGGGGCT GGTGTGGGCG TGGGCCGACG AGCTGAATGT A---------- ----------
SEQ 7 AAGGCGGATG CCATTCTGAT AGCCCGTCAG TTCCTGCGCG AGCCAGAATG GGTGTTTTCC ACGGCGAGAA AGTTGGGCGT G---------- ----------
SEQ 9 GGATTGGATG TTGCGCTTGT GGGACGTGGT TTCCAGAAGG ATCCCGGTCT GGCGTGGACT TTCGCGCAGC ATCTTGATGT T---------- ----------
SEQ 11 ACATTTGATC TTGCTTTGAT CGGTAGAGGA TTTTTAAGAA ATCCAGGTTT GGTATGGGAG TTTGCCGATA AACTTGGTGT T---------- ----------
SEQ 13 GACTTTGATA TAGCATTGAT AGGTAAAGGA TTTCTCAAAA ACACTGGATT GATCAGCCGT ATTGCTGACC AATTGCAAGC A---------- ----------
SEQ 15 CGTGCCGATA TGGTCCTTGT TGCCAGGCAG TTCTTGAAGG AGCCCGAGTT CGTCCTCACT GTCGCCGACG AGTTGGGTGT T---------- ----------
SEQ 17 GATTGCGACA TGATCGGTAT CGGACGCCCG GCCATCATCA ACCCTTCGCT TCCCGCCAAC TTGATCCTCA ACCCGGAGGT G---------- ----------
SEQ 18 GATTGCGACA TGATCGGTAT CGGACGCCCG GCCATCATCA ACCCTTCGCT TCCCGCCAAC TTGATCCTCA ACCCGGAGGT C---------- ----------
SEQ 20 AAGGCGGATC TGGTCCTCAT TGCTCGCCAG TTCCTGCGCG AGCCTGAGTT TGTGCTGAGG ACGGCGCATA ACCTTGGGGT C---------- ----------
SEQ 21 AAGGCGGATC TGGTCCTCAT TGCTCGCCAG TTCCTGCGCG AGCCTGAGTT TGTGCTGAGG ACGGCGCATA ACCTTGGGGT C---------- ----------
SEQ 23 ------GATG TTACTTTTGT CGCAAGGGAG TTCTTAAGGA ACCCGTCGTT GGTGCTAGAC AGCGCGAACC AGTTGGGTGA A---------- ----------
SEQ 25 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 26 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 28 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 29 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 32 GGTATCGACA TTGTGAGGGC TGGACGTTGG TTCCAACAGA ATCCTGGTCT GGTTCGAGCT TTTGCTAACG AGCTTGGCGT G---------- ----------
SEQ 34 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 36 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 37 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 39 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 41 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43 ---------- --ATAGGCAT CGGGCGCGCA GCCGGTTCGG AGCCGGACCT CGCCAAGGAC ATCATCGCGG GCAAGGTGTC CAGCATTATC AAATACGCCA
SEQ 82 CCCTTGGATC TTGTGGCTTC AGGCCGTCTG TTCCAGAAGA ACACTGGACT TGTTTGGTCA TGGGCTGACG ATCTGAACAC T---------- ----------
SEQ 84 GGCCAAGACC GCAGCCAGAT TGGCAAGTTG GCCGAGCAGT CGATTCAGAG CGGAGAGTGT GATGCGGTAC TGTTGGCACG T---------- ---GGATTGA

```
          2101       2111       2121       2131       2141       2151       2161       2171       2181       2191
          ---------- ---------- ---------- ---------- --11------ ---------- ---------- ---------- ---------- ----------
          ---------- ---------- ---------- --********* ********** ***------- ---------- ---------- ---------- ----------
SEQ 1     ---------- ---------- ------GAAA TCTCCATGGC CAACCAGATC CGCTGGGGCT TCACCCGGCG TGGAGGCACC CCGTACATTG ATCCTTCGGT
SEQ 2     ---------- ---------- ------GAAA TCTCCATGGC CAACCAGATC CGCTGGGGCT TCACCCGGCG TGGAGGCACC CCGTACATTG ATCCTTCGGT
SEQ 4     ---------- ---------- ------GAGA TCTCCATGGC TAATCAGATC CGATGGGGTT TCTCGCGGCG CGGTGCTGGT CCTTACCTCA GGAAGAAACT
SEQ 5     ---------- ---------- ------GAGA TCTCCATGGC TAATCAGATC CGATGGGGTT TCTCGCGGCG CGGTGCTGGT CCTTACCTCA GGAAGAAACT
SEQ 7     ---------- ---------- ------CCGG TGACTGTCCC GGTGCAGTTT GGCAGGGCCA TTTAG----- ---------- ---------- ----------
SEQ 9     ---------- ---------- ------GAGA TTGCGATGGC GAGTCAGATT CGGTGGGGAT TCACAAGGCG CGGGGGCACG CCTTATATCG ACCCCAAAGC
SEQ 11    ---------- ---------- ------AGAC TCCACCAGGC CTTGCAGTTA GGTTGGGGTT TCTGGCCCAA CAAACAACAA ATTGTTGATT TGATTGAAAG
SEQ 13    ---------- ---------- ------CAAT TCAGAACAGC ACCTCAATAT AAGTTGGCCT TATCATAA-- ---------- ---------- ----------
SEQ 15    ---------- ---------- ------GATG TCAAGGCCCC TGTTCAGTAC CTCCGTGGTC CTCTTAGCAG CAGGCCCAAG AAGTTGACCA CTGTTCCTTA
SEQ 17    ---------- ---------- ------CCGG ATGCGGATGC CCGCTTGTTC GACAAGAAGA GGGCTGAGCC GCACTGGATC GTTGAGAAGT TGGGCATGAA
SEQ 18    ---------- ---------- ------CCGG ATGCGGATGC CCGCTTGTTC GACAAGAAGA GGGCTGAGCC GCACTGGATC GTTGAGAAGT TGGGCATGAA
SEQ 20    ---------- ---------- ------AATG TGCAGTGGCC TCACCAATAC CACAGAGCAG TGTGGCGCAA GGGTGCAAGG ATTTGA----- ----------
SEQ 21    ---------- ---------- ------AATG TGCAGTGGCC TCACCAATAC CACAGAGCAG TGTGGCGCAA GGGTGCAAGG ATTTGA----- ----------
SEQ 23    ---------- ---------- ------AATG TTGCATGGCC AGTTCAGTAT GACTATGCAG TTAAGGGACA CAGAAAGTTA CGTTGA----- ----------
SEQ 25    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 26    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 28    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 29    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 32    ---------- ---------- ------GAGG TCAAGATGGC GAACCAGATT GATTGGAGCT TCAAGGGACG TGGAAAGAAA GTGAACAAGA GTTCTTTATA
SEQ 34    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 36    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 37    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 39    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 41    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43    TGGGGGAGGA CGAGTTTGTG CTGCAGTTGA CTGCCTGCTC GGCGCAAATA AGGCTGATGG CCAAGGGCGA GGAGCCGTTT GAC------- ----------
SEQ 82    ---------- ---------- -------TCTA TCCAGATCGC TCATCAGATC GCATGGGGTT TCGGTGGCAG AGCTAAGAAG AACGCTCCCA AGCTTGTCTT
SEQ 84    TGTCCTACCC AAGCTGGACC GAGGATGCTA GTGTAGCGCT GATGGGTACC AGGGCAGCTG GCAACCCGCA GTACCATCGC GTTCACGTGG CTAAGAAGTG

          2201       2211       2221       2231       2241       2251       2261       2271       2281       2291
          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 1     GTACAAGCAG TCTATTTTCG ATGTATAG-- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 2     GTACAAGCAG TCTATTTTCG ATGTATAG-- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 4     CGAGAAGATA TAA------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 5     CGAGAAGATA TAA------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 7     ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 9     TTATAAGGAG AGCATCTTTG AGTAA----- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 11    AACATCTAAA TTAGAAGTAA ATTAG----- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 13    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 15    A--------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 17    GTCCATTGTT GGTGCTGGTG TTGAGGTGGT ACGTCACGTT CCAACCCCAT TTGCTTCATT GTGTTTCCGA GTATGTCATG CTGACTTGGT TCTTTTCTAG
SEQ 18    GTCCATTGTT GGTGCTGGTG TTGAGGTG-- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 20    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 21    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 23    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 25    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 26    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 28    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 29    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 32    G--------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 36    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 37    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 39    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 41    ---------- ---------- ---------- ---------- ---------- -----ATCTC AAACGCCGAC GAGGTGGCGC GGGTGACGCA GTTGATGGCG
SEQ 43    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 82    A--------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 84    A--------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------

          2301       2311       2321       2331       2341       2351       2361       2371       2381       2391
          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
          ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 1     AGTATAGATA GAGTTGAAGA TGATACCTCA TAGACGATCA ATGGACCCTT GCATATTATT TCTCGTCTCC TGCGTATGTT CAAGGTATTC ACAGTAGCTG
SEQ 2     AGTATAGATA GAGTTGAAGA TGATACCTCA TAGACGATCA ATGGACCCTT GCATATTATT T--------- ---------- ---------- ----------
SEQ 4     ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 5     ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 7     ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 9     ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 11    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 13    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 15    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 17    ACGTGGTATG TGAGCGAGCT CAAGAAGCTG GCCAAGTTTT AG-------- ---------- ---------- ---------- ----------
SEQ 18    ACGTGGTATG TGAGCGAGCT CAAGAAGCTG GCCAAGTTTT AG-------- ---------- ---------- ---------- ----------
SEQ 20    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 21    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 23    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 25    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 26    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 28    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 29    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 32    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 34    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 36    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 37    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 39    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 41    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 43    GAGGGCAAGG TG-------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 82    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SEQ 84    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
```



Figure 2. A multiple alignments of the 2031 OR nucleic acid sequence from *A. fumigatus* (SEQ 1,2) along with related 2031 ORs from other fungi and bacteria (see also Example 4). Regions 1-11, marked with * or #, refer to regions conserved at the amino acid level between Ors but not OYEs.

Fungal 2031 ORs are given by SEQ ID No.: SEQ ID Nos. 1, 2, 4, 5, and 7, *A. fumigatus*; SEQ ID No. 9, *A.nidulans*; SEQ ID Nos. 11 and 13, *C. albicans*; SEQ ID Nos. 15, 17 and 18, *N. crassa*; SEQ ID Nos. 20, 21 and 43, *M. grisea*; SEQ ID No. 23 (NP_595868), *S. pombe*; SEQ ID Nos. 25 and 26, *C. trifolii*; SEQ ID Nos. 28, 29, 31, 32 and 34, *F. sporotrichioides*; SEQ ID Nos. 36, 37 and 82, *F. graminearum*; SEQ ID Nos. 39 and 41, *M. graminicola*; SEQ ID No. 84, *U. maydis*.



Figure 3. Recombinant 2031 OR. (A) Time course of recombinant 2031 OR induction over 24 hours after the addition of IPTG (samples without IPTG are also shown). The gel was stained with coomassie; A prominent band of the correct molecular weight (marked with an arrow) is seen. (B) Coomassie stained gel showing purified recombinant 2031.



Figure 4. Phylogenetic tree showing relationships between *A. fumigatus* 2031 OR and similar proteins. This demonstrates a 2031 OR clade, which can be distinguished from the OYE proteins.



Figure 5: NADPH dehydrogenase activity of recombinant 2031 OR with cyclohexenone (CHX), N-ethylmaleimide (NEM), menadione (MEN) or duroquinone (DQ) as substrates. Final concentrations in the assay were as follows: 500 μM substrate, 120 μM NADPH, 1 μg/200 μL 2031 OR.



Figure 6: Inhibition of 2031 OR function by two inhibitors (shown in A and B) identified by high-throughput screening.